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Background
Kidney transplantation greatly improves the quality of life of patients with end-stage renal 
disease (ESRD) and reduces their mortality risk, even of elderly transplant recipients 1,2. 
In addition, a successful kidney transplantation increases the psychosocial well-being of 
children. Finally, kidney transplantation is also the preferred treatment for ESRD from an 
economical perspective 3,4. The short-term results of kidney transplantation have improved 
considerably over the last decades and 1-year graft survival (censored for death) is now 
95% in most transplant centers 5. One of the main factors responsible for the huge suc-
cess of kidney transplantation has been the development of potent immunosuppressive 
(combination) drug therapy to prevent acute rejection.
There are several mechanisms by which kidney allografts can be rejected. In the classic 
model of rejection, activated cells from the innate immune system, such as dendritic cells 
(DCs) or macrophages, trigger the cells from the adaptive immune response, such as T 
and B cells. They can present donor-derived Human Leucocyte Antigen (HLA) molecules to 
naïve T cells of the transplant recipient. When T cells specifically recognize allo-antigens by 
their T cell receptor (TCR), this leads to clonal expansion and migration of these alloreac-
tive cells from secondary lymphoid organs to the graft where they cause the classic acute 
T cell-mediated rejection response 6. Three general pathways of allograft recognition exist: 
direct, indirect and cross-dressing 7. In the direct pathway, donor-derived antigen present-
ing cells (APCs) present donor HLA molecules to T cells from the recipient. In the indirect 
pathway, donor-derived antigens are processed by the recipient’s own APCs and presented 
to the cells of the adaptive immune system of the recipient. The third form of allograft 
recognition, cross-dressing, includes the fusion of a recipient APC with a donor-derived 
HLA molecule followed by activation of the T cells of the recipient.
Acute rejection can occur in the first few days after transplantation. Ischemia-reperfusion 
injury (IRI) is a process which augments acute rejection and is inevitable as a result of the 
necessary surgical procedure. Ischemic damage occurs when the blood flow in the trans-
planted kidney is interrupted during explantation and storage of the organ. Reperfusion 
of the already damaged ischemic tissue causes microvascular injury which is associated 
with hypoxia and generation of reactive oxygen species, due to the oxidative damage and 
resupply of oxygen 8. Eventually, these processes will lead to an inflammatory response. IRI 
is an unavoidable consequence of transplantation and is a risk factor for acute rejection 
and also affects long-term graft survival 9.
The first responders to IRI-induced tissue injury are cells of the innate immune system, 
such as DCs, neutrophils, natural killer (NK) cells, monocytes and macrophages. These 
cells recognize so called damage-associated molecular patterns (DAMPS) (Figure 1) 10-12. 
DAMPS are biomolecules released by injured cells and function as danger signals. Recogni-
tion of DAMPS leads to the activation of toll-like receptors (TLRs) on the surface of cells of 
the innate immune system and a full-blown inflammatory response, which is characterized 
by an inflammatory cell infiltrate, the production of cytokines and the activation of the 
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complement system. In the end, the injured cells will be monitored and removed by the 
innate immune system.
In addition, antibody-mediated rejection (ABMR) is now recognized as an important 
mechanism of allograft rejection. B cells, with help from T cells, turn into alloantibody-pro-
ducing plasmablasts and plasma cells. These allo-antibodies are mostly directed against 
the HLA antigens of the donor (so-called donor-specific anti-HLA antibodies or DSA) but 
can also be directed against non-HLA antigens. Three types of ABMR are recognized clini-
cally, i.e. hyperacute ABMR, acute ABMR and chronic ABMR. Acute ABMR is a relatively rare 
phenomenon but chronic ABMR is now considered to be the most important cause of late 
allograft loss 13. Chronic ABMR often occurs years after transplantation and no established 
treatment is available for this type of rejection 6,14,15.
Without suppression of the above-described anti-donor responses, transplanted organs 
will reject and will ultimately fail. Fortunately, a number of immunosuppressive drugs that 
inhibit these responses are available. The drugs are mostly used as combination therapy in 
solid organ transplant (SOT) recipients to ensure maximum efficacy and limit toxicity of the 
individual agents. Currently, the most widely used immunosuppressive drug combination 
therapy after kidney transplantation consist of tacrolimus in combination with mycophe-
Figure 1. Myeloid cell differentiation. Multipotent hematopoietic stem cells develop into various types of cells, 
such as t cells, B cells (belonging to the adaptive immune system), natural killer cells and monocytes (belong-
ing to the innate immune system). Upon activation, monocytes can differentiate into macrophages, which are 
phagocytes that can also present antigens to t cells.
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nolic acid (MPA) and glucocorticoids 16. Better diagnostic approaches and the develop-
ment of potent and more specific immunosuppressive drug therapy have improved the 
clinical outcome after SOT 17,18. However, tacrolimus, which is nowadays the cornerstone 
immunosuppressant, has several side effects, such as nephrotoxicity, neurotoxicity and 
diabetes mellitus. Furthermore, immunosuppression in general increases the chance of 
developing malignancy and infection 19. In addition, the therapeutic window of tacrolimus 
is narrow, meaning that the dosage range for safe and effective treatment is small. The 
use of tacrolimus is also complicated by its high inter- and intra-patient variability 20. An 
important problem is nonadherence of transplantation recipients to their immunosup-
pressive agents. Nonadherence is a cause of fluctuating drug concentrations and increases 
the chance of developing rejection. Nonadherence has been shown to increase when a 
drug is dosed more frequently and when therapy is chronic 21. For this reason, treatment 
with tacrolimus, like many other immunosuppressants, is monitored by means of measur-
ing (whole blood) drug concentrations, a practice known as therapeutic drug monitoring 
(TDM). By performing TDM, the time a patient is exposed to supra- or sub-therapeutic drug 
concentrations is limited. However, there is another problem with the TDM of tacrolimus, 
next to the high intra-patient variability. The tacrolimus pre-dose concentration has an 
imperfect correlation (rs ≈ 0.7) with the total exposure to tacrolimus during a dosing 
interval as measured by the area-under the concentration versus time-curve (AUC), and, 
as a consequence, the occurrence of acute rejection or side effects could not accurately 
predicted 22-24. One way for solving these problems associated with TDM of tacrolimus is to 
focus on the biological effects of immunosuppressive drugs on T cells and other immune 
cells after transplantation 25,26.
T cell activation
T cells are arguably the most important players in acute rejection of SOT transplants. For 
a T cell response three signals are required: 1) antigenic stimulation of the T cell recep-
tor (TCR) by the HLA – alloantigen complex on an APC, 2) a co-stimulatory signal and, 3) 
amplification of the T cell activation through the production and binding of cytokines to 
their corresponding receptors on T cells (Figure 2) 27,28. The most extensively studied co-
stimulatory signal is the interaction between CD28 molecules on the T cell surface and the 
CD80/86 molecules on APCs, such as macrophages and dendritic cells. Once activated, 
intracellular signaling pathways are triggered, such as the calcineurin, Mitogen-Activated 
Protein Kinase (MAPK) and PI3K pathways that control transcription factor activity (e.g. 
NFκB and CREB) and gene transcription (Figure 3). As a consequence, cytokines are 
produced (e.g. interleukin (IL)-2, interferon (IFN)-γ and tumor necrosis factor (TNF)-α) that 
cause the proliferation and differentiation of T cells.
The third signal, needed for T cell differentiation, consists of a positive feedback loop 
driven by cytokines that are produced by activated T cells after receiving signal 1 and 2. 
Examples of cytokines needed for the third signal are IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 
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that bind to the IL-2 receptor family on the cell membrane of T cells. This interaction will 
activate the JAK/STAT (Janus activated kinase/Signal transducer and activator of transcrip-
tion) signaling pathways intracellular of a T cell which then induces T cell differentiation 29.
Different T cell subsets exist, the main distinction being that between CD4+ and CD8+ 
T cells. CD4+ T cells can be subdivided into naïve and memory T cells. Memory T cells 
are antigen-experienced cells and control a rapid and lifelong immune protection after 
responding to an antigen that they have previously encountered. Differentiated memory 
T cells can be further divided into T-helper (Th)1, Th2, Th9, Th17, Th22 and follicular Th 
cells 30. In general, these cells provide help to CD8+ T cells, B cells and cells of the innate 
immune system. CD8+ T cells can cause the apoptosis (cell death) of a target cell in differ-
ent ways. The first way is by the production of the cytokines perforin and granzyme that 
initiate the forming of pores in the membrane and induce the caspase cascade (consisting 
of cleaving enzymes) inside the target cell. Other ways to destroy their target cell is via the 
production of the cytokines TNF-α and IFN-γ, and via the interaction between the ligand 
FasL on the T cell and Fas receptor on the target cell. This will also activate the caspase 
cascade needed for apoptosis. In addition to alloreactive T cells, there also exist regulatory 
T cell (Treg) subsets that suppress the alloimmune response and may even be responsible 
for clinical tolerance 31,32.
The expression of the costimulatory molecule CD28 distinguishes several functionally 
different T cell subsets. The CD28 molecule provides, among others, co-stimulatory signals 
Figure 2. Overview of signals needed for T cell activation. t cells become activated upon receiving three 
separate signals: 1) antigenic stimulation of the t cell receptor (tCr) by the hLa–alloantigen complex on an apC; 
2) co-stimulation, of which the interaction between CD28 molecules on t cells and CD80/86 molecules on the 
apC is one of the best studied pathways, and 3) binding of cytokines, such as IL-2 that can enhance the t cell 
response.
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required for T cell activation and survival by acting as a receptor for the B7-molecules CD80 
and CD86 which are present on APCs. Upon activation, CD28 triggers T cell intracellular 
signaling pathways that are needed for T cell activation and proliferation, including the 
NFAT, MAPK, NFκB and PI3K pathways (Figure 3). The same ligands that control CD28 
activity can also bind with a greater affinity to the CTLA-4 molecule, also known as CD152, 
on T cells. This interaction will cause the inhibition of a T cell and induces the regulatory 
function of a T cell.
CD28+ T cells are naïve T cells which only become activated after encountering signal 1 
and a costimulatory signal via CD28. In contrast, CD28- T cells are terminally-differentiated 
memory T cells, which do not require signaling via CD28 in order to become activated. 
Upon antigenic re-stimulation, CD28- T cells produce high levels of effector cytokines 33,34. 
In addition, CD28- T cells are highly antigen-experienced and can react faster and stronger 
to antigen presentation than their positive counterpart 35. An important and clinically rel-
evant problem is that CD28- T cells are not susceptible to the immunosuppressive effects of 
the drug belatacept, which blocks the interaction between CD28 and CD80/CD86 and acts 
as CTLA-4 immunoglobulin (Ig) 36-38.
Monocyte activation
The role of monocytes in IRI and acute or chronic rejection is increasingly recognized 39-42. 
For example, the occurrence of ABMR is characterized by the accumulation of monocytes 
and macrophages and these cells are also present in renal biopsies taken during acute cel-
lular rejection 43,44. In general, upon activation, monocytes differentiate into macrophages 
or DCs, after which they process and present alloantigen to the immune system of the 
recipient. They also play a role in tissue repair processes, providing co-stimulation signals 
and producing pro-inflammatory cytokines, such as TNF-α, IL-1 and IL-6 45. In IRI, mono-
cytes are attracted to the site of injury by the binding of monocyte chemotactic protein 1 
(MCP-1) to their CCR2 receptor, after which they differentiate into DCs or macrophages 46. 
In ABMR, monocytes contribute to cell injury via the activation of their Fcγ-receptor (FcγRI 
or CD64) by allo-antibodies 47. The signal received by the Fcγ-receptor will block apoptosis 
and cause the accumulation of monocytes at the site of rejection where they produce pro-
inflammatory cytokines. Monocytes can be divided into three phenotypically and function-
ally distinct subsets, based on their expression of CD14 and CD16: CD14++CD16− (classical), 
CD14++CD16+ (intermediate), and CD14+CD16++ (non-classical) monocytes 48. Infiltrating 
monocytes can differentiate into classically and alternatively activated macrophages, 
generally called M1 and M2 macrophages, that are now recognized as two ends in a wide 
functional spectrum 49.
Although the knowledge about the role of monocytes in the alloimmune response in 
transplant patients is increasing, the impact of immunosuppressive drugs on monocyte/
macrophage functions has hardly been studied 50-52. It is, therefore, necessary to learn 
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more about the effects of currently prescribed immunosuppressive drugs on monocyte 
activation and function, in order to improve patient outcome after transplantation and to 
develop better strategies for patient treatment.
Immunosuppressive drug therapy
To prevent and overcome rejection responses, SOT recipients are treated with immunosup-
pressive drugs. The most frequently prescribed immunosuppressive drug therapy consists 
of the combination of a calcineurin inhibitor (CNI; either cyclosporine or tacrolimus), MPA 
(either mycophenolate mofetil (MMF) or mycophenolate sodium) and glucocorticoids with 
or without induction therapy, consisting of T cell-depleting antibody therapy or the IL-2 
receptor blocker basiliximab 16,28. After intake of the pro-drug MMF, this agent is converted 
to the active metabolite MPA, which inhibits the function of inosine monophosphate dehy-
drogenase (IMPDH). As a consequence, the production of guanosine nucleotides, required 
for DNA synthesis, is blocked and T and B cell proliferation is inhibited 53. Glucocorticoids 
bind to the glucocorticoid receptor, intracellular of T cells, but can also bind to this receptor 
in many other cells that regulate the immune response. After translocation to the nucleus, 
glucocorticoids interact with the glucocorticoid response elements that interfere with the 
promotors of different genes, such as tyrosine aminotransferase and NFκB. Glucocorti-
coids, such as prednisolone, have a wide biological effect and inhibit the gene expression 
of numerous cytokines and chemokines, such as IL-2, IL-6, INF–γ and TNF–α 18.
CNIs inhibit intracellular T cell activation by blocking the calcineurin pathway (Figure 2). 
This results in a reduction of cytokine production, including IL-2 54. The therapeutic window 
of tacrolimus is small, meaning that the range between an effective dose and the dose 
causing (nephro)toxicity or other drug-related side effects is narrow 55. The most recent 
immunosuppressive drug to be approved for the prevention of acute rejection after kidney 
transplantation by the US Food and Drug Administration and the European Medicines 
Agency is belatacept. Belatacept is non-nephrotoxic and inhibits T cell responses more 
selectively than tacrolimus. Belatacept is a fusion protein consisting of the extracellular 
domain of the human cytotoxic T-lymphocyte antigen (CTLA)-4 linked to a Fc-fragment of 
immunoglobulin G1 56. It binds to the CD80/CD86 molecule on APCs, thereby blocking the 
second signal needed for T cell activation. Belatacept is more selective in inhibiting the T 
cell response after transplantation than other immunosuppressive drugs, due to its high 
affinity for the CD80/CD86 molecules. The co-stimulatory interaction between CD80/CD86 
and CD28 is largely limited to APCs and T cells, which explains the low rate of side effects 
after belatacept treatment.
Altogether, the above-described immunosuppressive drugs mainly target the activation, 
proliferation and differentiation of T cells, while the knowledge of their effects on mono-
cytes is limited. For example, in vitro studies have shown that tacrolimus and MPA affect 
cytokine production by isolated monocytes but their effect on monocytes in whole-blood 
samples of transplant recipients is unknown 57,58. Therefore, research is needed to establish 
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the effect of immunosuppressive drugs on monocyte functions in vivo after transplanta-
tion.
Therapeutic drug monitoring: Pharmacokinetics versus pharmacodynamics
Problems arising from the small therapeutic window of tacrolimus can be limited by TDM, 
whereby tacrolimus blood concentrations are routinely monitored to adjust dosages. 
Currently, TDM of tacrolimus is based on pharmacokinetic (PK) approaches, of which the 
whole-blood pre-dose concentration (C0) is the parameter of choice since it correlates well 
with total exposure to tacrolimus during a dosing interval 59. However, the tacrolimus C0 
has a limited predictive power with regard to the occurrence of acute rejection episodes or 
the long-term outcome after transplantation 55,60. In contrast, tacrolimus C0 have a better 
correlation with the total tacrolimus exposure, measured as the AUC (rs ≈ 0.7), which is 
however more labor-intensive to measure 22.
A better or complementary way for TDM of immunosuppressive drugs may be to mea-
sure their biological effects directly. This is called pharmacodynamic (PD) monitoring 61-63. 
Essential for PD monitoring is the knowledge about the pharmacological mechanism of 
action of a drug in order to develop a specific assay. Tacrolimus is known to inhibit the sig-
naling molecule calcineurin within T cells, which controls the activation and translocation 
of nuclear factor of activated T-cells (NFAT) to the nucleus (Figure 3) 64. Once in the nucleus, 
NFAT activation leads to transcription of several genes playing a role in T cell activation, 
differentiation and the production of cytokines. Other signaling pathways important for 
T cell activation are the Mitogen-Activated Protein Kinase (MAPK) and PI3K pathways 65. 
Activation of these pathways is characterized by the phosphorylation of specific signaling 
molecules, such as p38MAPK, Extracellular signal-Regulated Kinases 1 and 2 (ERK1/2) and 
AKT8 virus oncogene cellular homolog (Akt).
Improving transplantation diagnostics: Novel concepts for TDM
Most studies focusing on the PD effects of immunosuppressive drugs performed to date 
failed to find a strong correlation with clinical outcomes or with PK parameters 66,67. These 
studies include the measurement of calcineurin phosphatase activity, cytokine production 
by T cells, and the expression of NFAT-regulated genes 68,69. So far, none of these techniques 
has found its way into routine clinical practice. Apart from their imperfect correlation with 
clinical outcomes, problems with these assays are the fact that they are time-consuming, 
costly, and importantly, measure the effect of a single immunosuppressive agent rather 
than the combined effect of several drugs 70. Other reasons for the failure of these assays 
for routine clinical practice are the long turnaround time and the difficulties that arise in 
reproducing the results 71.
Phospho-specific flow cytometry is a relatively novel and potential clinically useful 
approach to directly measure and monitor PD drug effects in whole blood samples of 
transplant recipients 62,72-74. This technique allows measurement and quantification of the 
19
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phosphorylation of intracellular signaling molecules in a rapid, sensitive way at the single-
cell level. Previous studies using this technique have shown a dose-dependent response 
of tacrolimus on the inhibition of p38MAPK phosphorylation in T cells and have also dem-
onstrated the strength of TDM by means of phospho-specific flow cytometry in the field of 
rheumatoid arthritis and oncology 75-77. These studies indicate that phospho-specific flow 
cytometry could be a powerful technique tool to measure cell activation markers for PD 
TDM.
Aim and outline of the thesis
Despite intensive PK monitoring of immunosuppressive drugs after transplantation, a large 
number of patients suffer from a lack of efficacy or toxicity, due to the small therapeutic 
window of tacrolimus and the high intra-patient variability. A better way to control drug 
exposure might be PD monitoring. The aim of this thesis was to assess techniques for PD 
TDM of immunosuppressive drug effects after kidney transplantation. The work described 
in this thesis focused on two cell types involved in the immune response after transplanta-
tion. The first part of the thesis focusses on the effects of immunosuppressive drugs on 
monocyte activation; the second part aims to describe the effects of tacrolimus, belatacept 
and MPA on signaling transduction pathways in T cells and several T cell subsets. In more 
detail, this thesis will assess the following:
•	 To	 assess	 the	 role	 of	monocytes	 in	 transplantation	 and	 the	 effects	 of	 currently	 pre-
scribed immunosuppressive drugs on these cells (Chapter 2)
•	 To	investigate	the	individual	PD	effects	of	tacrolimus	and	MPA	on	monocytes	of	healthy	
volunteers (Chapter 3)
•	 To	determine	the	combined	effects	of	immunosuppressive	drug	therapy	on	monocytes	
after kidney transplantation (Chapter 4)
•	 To	 assess	 the	 PD	monitoring	 of	 tacrolimus	 and	 other	 immunosuppressive	 drugs	 by	
measuring the inducible isoform of NFAT in T cells (Chapter 5)
•	 To	determine	whether	measuring	p38MAPK	phosphorylation	can	be	a	promising	tool	
for monitoring the effects of conversion from the twice-daily tacrolimus formulation to 
the once-daily, prolonged-release tacrolimus formulation (Chapter 6)
•	 To	study	differences	 in	the	PD	drug	effects	of	tacrolimus-based	therapy	compared	to	
belatacept-based therapy (Chapter 7)
•	 To	review	the	use	of	the	JAK	inhibitor	tofacitinib	in	kidney	transplantation	and	to	assess	
why the clinical trials of this drug were relatively unsuccessful (Chapter 8)
Chapter 9 and 10 summarize the findings of the studies described above and place them 
into a larger perspective.
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Abstract
There is an unmet clinical need for immunotherapeutic strategies which specifically target 
the active immune cells participating in the process of rejection after solid organ trans-
plantation. The monocyte-macrophage cell lineage is increasingly recognized as a major 
player in acute and chronic allograft immunopathology. The dominant presence of cells of 
this lineage in rejecting allograft tissue is associated with worse graft function and survival. 
Monocytes and macrophages contribute to alloimmunity via diverse pathways: antigen 
processing and presentation, co-stimulation, pro-inflammatory cytokine production and 
tissue repair. Cross talk with other recipient immune competent cells and donor endothe-
lial cells leads to amplification of inflammation and a cytolytic response in the graft.
Surprisingly little is known about therapeutic manipulation of the function of cells of 
the monocyte-macrophage lineage in transplantation by immunosuppressive agents. 
Although not primarily designed to target monocyte-macrophage lineage cells, multiple 
categories of currently prescribed immunosuppressive drugs, such as mycophenolate 
mofetil, mTOR inhibitors and calcineurin inhibitors, do have limited inhibitory effects. 
These effects include diminishing the degree of cytokine production, blocking co-stimu-
lation and inhibiting the migration of monocytes to the site of rejection. Outside the field 
of transplantation, some clinical studies have shown that the monoclonal antibodies 
canakinumab, tocilizumab and infliximab are effective in inhibiting monocyte functions. 
Indirect effects have also been shown for simvastatin, a lipid lowering drug, and BET 
(Bromodomain and Extra-Terminal motif) inhibitors that reduce the cytokine production 
by monocytes-macrophages in patients with diabetes mellitus and rheumatoid arthritis.
To date, detailed knowledge concerning the origin, the developmental requirements 
and functions of diverse specialized monocyte-macrophage subsets justifies research for 
therapeutic manipulation. Here, we will discuss the effects of currently prescribed immu-
nosuppressive drugs on monocytes/macrophages features and the future challenges.
29
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
Ch
ap
te
r 2
Introduction
Solid organ transplantation (SOT) is the preferred method to treat organ failure. Over the 
past decades, transplantation has become the preferred approach to treat solid organ 
failure. Striking improvement in short-term allograft survival, in particular of kidney al-
lograft, has been achieved while long-term survival has lagged behind 1. Intriguingly, this 
improvement is seen mainly in recipients who have never experienced a rejection episode, 
emphasizing the recipient’s alloimmunity; in particular chronic antibody mediated rejec-
tion (cABMR) as a major determinant of overall transplant outcome 2,3. At present, there is 
an unmet clinical need to apply immunotherapeutic strategies to specifically target the 
active immune cells crucially participating in the process of rejection after SOT.
However, treatment with immunosuppressive drugs has exchanged the morbidity and 
mortality of organ failure for the risks of infection, cancer and increased mortality from 
cardiovascular disease. Although acute and chronic rejection, regardless of the type and 
the time of occurrence, are still major contributors leading to graft failure 1,4,5, cABMR is 
the main concern for the long term graft survival. Chronic antibody mediated rejection 
arises, at least in part, because immunosuppressive strategies do not completely inhibit 
rejection-related alloimmune responses specifically, resulting in slow progressive deterio-
ration of graft function.
The monocyte-macrophage cell lineage is increasingly recognized as a major player in 
acute and chronic allograft immunopathology 6,7. The clinically used immunosuppressive 
drugs are not specifically directed against monocyte-macrophage lineage cells but still 
have some inhibitory effects. These cells contribute to alloimmunity via diverse pathways; 
antigen processing and antigen presentation, co-stimulation, pro-inflammatory cytokine 
production and tissue repair. Cross talk with other recipient immune competent cells and 
donor endothelial cells underlies amplification of inflammation at the graft site 8-10. Inter-
estingly, acute and chronic antibody mediated rejection are characterized amongst others 
by accumulation of monocyte-macrophage cells. Kidney graft infiltrating macrophages 
have been described to be a predictor of death-censored graft failure 11-21. Macrophages 
are present in both acute antibody mediated rejection (ABMR) and acute cellular rejection 
(ACR) of solid organ transplants 19,22. In rejecting cardiac tissue, interstitial and intraluminal 
macrophage density correlates with effector alloantibodies and clinical antibody mediated 
rejection 22. Even more, histopathological staining’s for macrophages have been found to 
be positive prior to the onset of graft dysfunction indicating that macrophages can serve 
as potential diagnostic markers for transplant rejection 18. Intravascular macrophages in 
the capillaries of endomyocardial tissue are shown to be a distinguishing feature of ABMR 
and are considered as one of the important histopathological diagnostic criteria in cardiac 
transplantation 22,23.
A recent study showed that the severity of macrophage infiltration during ACR with arte-
ritis is associated with impaired kidney function as measured by creatinine values up to 36 
months post transplantation 19. Importantly, Oberbarnscheidt et al. showed that monocyte 
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recognition of allogeneic non-self persists over time, long after acute surgical inflammation 
has been subsided, indicating the important role of monocytes in the principle of long-
term graft failure 24. Recently, the presence of smooth muscle like-precursor cells within 
the non-classical monocyte subset has been described in kidney transplant patients. Char-
acterization of non-classical monocytes in peripheral blood of kidney transplant patients 
undergoing chronic transplant dysfunction showed lower numbers compared to patients 
without chronic transplant dysfunction. Within the total living cell percentages of CD14+ 
monocytes there was no change observed, suggesting a shift within different subsets. 
Non-classical monocytes being reduced in transplant recipients with chronic transplant 
dysfunction may indicate a vital role in interstitial and vascular remodelling 25.
In stable kidney transplant recipients, a skewed balance towards pro-inflammatory 
CD16+ monocytes was shown at the time of kidney transplantation and during the first 
6 months post-transplant. These monocytes were able to produce IFNγ, which acts as an 
important bridge between innate and adaptive immunity 26,27.
In summary, the currently available knowledge concerning the immunobiology of spe-
cialized monocyte–macrophage subsets, their pathogenic role in rejection, and the still 
unmet clinical need to specifically prevent alloimmunity justify research on strategies for 
monocyte-macrophage directed therapeutics. In this review, we aim to discuss the relevant 
knowledge on monocyte-macrophage immunobiology. Briefly, to elaborate on the effects 
of currently available immunosuppressive drugs in relation to monocyte/macrophage 
lineage cells mainly focussed within, but also outside of the SOT field (Table I and Figure 
1), and eventually touch upon the future challenges and developments.
Monocyte immunobiology
Monocytes and macrophages are mononuclear phagocytes with crucial and distinct roles 
in transplant immunity. Monocytes display a remarkable plasticity in response to signals 
from the microenvironment, enabling them to differentiate into various cell types. Several 
pro-inflammatory, metabolic and immune stimuli all increase the attraction of monocytes 
towards tissue 7. Based on the expression of CD14 (LPS co-receptor) and CD16 (Fcγ receptor 
III), three phenotypically and functionally distinct human monocyte subsets: CD14++CD16- 
(classical), CD14++CD16+ (intermediate), and CD14+CD16++ (non-classical) monocytes 
can be defined 28-31. Monocytes arise from myeloid precursor cells in primary and second-
ary lymphoid organs, such as liver and bone marrow. In humans, monocytes represent 
respectively 10% of the nucleated cells in peripheral blood, with 2 major reservoirs: the 
spleen and lungs that can mobilize monocytes on demand 32,33. Classical monocytes are 
able to start proliferating in the bone marrow in response to infection or tissue damage, 
and subsequently be released into the circulation in a CCR2 dependent manner (Figure 
2) 34. Intermediate and non-classical monocytes are thought to be descendants of classical 
monocytes that have been under control of transcription factor Nur77 (NR4A1) returned 
to the bone marrow 35. Non-classical monocytes show a patrolling, distinct motility and 
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crawling pattern 36. Interestingly, intermediate monocytes show higher expression of major 
histocompatibility (MHC) class II molecules and thereby more related to non-classical 
monocytes 37,38. CD14+ monocytes can be recruited to the site of inflammation or areas 
of tissue injury where they can differentiate into macrophages and dendritic cells 39. In 
steady state, circulating monocytes have minimal contribution to the maintenance of 
tissue resident macrophages 40,41. Depending on the microenvironment, activation stimuli 
and cross talk with other immunological effector cells, activation of macrophages alters 
their cytokine profile and co-stimulatory molecule expression. Monocyte differentiation 
to tissue macrophages is Colony Stimulating Factor 1 Receptor (CSF1R) dependent. Most 
tissue macrophages are seeded before birth in embryonic state, with varying contributions 
of primitive-derived and definitive-derived cells. Monocytic input to tissue macrophage 
compartments seems to be restricted to inflammatory settings, such as infection and 
acute graft rejection 39. Monocyte chemotactic peptide-1 (MCP-1) is an important regulator 
of macrophage recruitment and was shown to be highly expressed in the kidney allograft, 
supporting the concept of recruitment of monocytes from the circulation 42.
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Figure 1. Monocyte and macrophage lineage cells and the effect of immunosuppressive drugs. the effect of 
currently prescribed immunosuppressive drugs with several inhibition spots on and in monocyte/macrophage 
lineage cells.
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Table I. Immunosuppressive drugs and the monocyte/macrophage lineage
Drug type Effects on monocytes/macrophages Key references
Basiliximab & 
ATG
•	 	Basliximab	targets	the	CD25	molecule	(the	IL-2	receptor)	on	activated	
T	cells
•	 	ATG	binds	to	multiple	T-cell	specific	antigens	and	causes	cell	death	via	
complement	mediated	cytotoxicity
•	 	Reduced	number	of 	monocytes	in vivo
•	 	Upregulation	of 	the	anti-inflammatory	M2	macrophage	subset	CD14+	
CD163+	in vivo
Sekerkova	et	al,	2014
Alemtuzumab •	 	Targets	CD52	on	B	cells,	T	cells,	NK	cells,	dendritic	cells	and	monocytes
•	 	Less	effective	in	depleting	monocytes	than	depleting	T	cells
•	 	Leads	to	a	relative	high	expression	of 	co-stimulatory	molecules,	IL-6	
and	NFκB	
Hale	et	al,	1990
Kirk	et	al,	2003
Fabian	et	al,	1993
Rao	et	al,	2012
Calcineurin 
inhibitors
(tacrolimus & 
cyclosporin)
•	 	No	inhibitory	effect	on	p38MAPK	phosphorylation,	but	reduce	
cytokine	production	via	ERK	phosphorylation
•	 	Downregulate	production	of 	IL-6	and	TNF-α	after	TLR	stimulation	in 
vitro
•	 	Impaired	phagocytosis	function	and	promotion	of 	infection	(CsA)	
Escolano	et	al,	2014
Howell	et	al,	2013
Tourneur	et	al,	2013
Mycophenolate 
mofetil
•	 	Diminished	the	production	of 	IL-1β,	IL-10	and	TNF-α	and	decreased	
expression	of 	TNF-receptor	1	on	monocytes
•	 	Reduced	monocyte	migration	through	lower	expression	of 	adhesion	
molecules
Alisson	et	al,	2000
Weimer	et	al,	2003
Glucocorticoids •	 	Lower	CD14+CD16++monocyte	counts
•	 	Lower	expression	of 	B7	molecules	leading	to	disturbed	co-stimulation
•	 	Induction	of 	anti-inflammatory	response	via	increased	IL-10	
production
•	 	Impaired	phagocytosis	function	
Rogacev	et	al,	2015
Girndt	et	al,	1998
Hodge	et	al,	2005
Blotta	et	al,	1997
Rinehart	et	al,	1974
mTor inhibitors •	 	Decreased	chemokine	and	cytokine	production
•	 	Combination	therapy	with	steroids	increased	pro-inflammatory	cytokine	
production
Lin	et	al,	2014
Oliveira	et	al,	2002
Weichhart	et	al,	2011
Belatacept/
abatacept
•	 	Block	CD80/86	molecules	on	antigen-presenting	cells	and	inhibit	co-
stimulatory	function
•	 	Lower	migration	and	adhesion	capacity
•	 	Decreased	expression	of 	the	pro-inflammatory	cytokines	IL-12	and	
TNF-α
Latek	et	al,	2009
Bonelli	et	al,	2013
Wenink	et	al,	2011
Experimental 
drugs
•	 	Canakinumab	inhibits	IL-1β	production	by	monocytes
•	 	Sinomenine	is	associated	with	less	monocyte	migration,	differentiation	
and	maturation
•	 	15-deoxyspergualin	decreases	monocyte	proliferation,	TNF-α	
production,	phagocytosis	and	antigen	presentation
•	 	Simvastatin	and	salsalate	are	associated	with	less	monocyte	activation	
and	inhibition	of 	IL-6	and	IL-8	production	in	diabetes	patients
•	 	Tocilizumab	inhibits	IL-6	production	by	monocytes
•	 	BET	inhibitors	are	involved	in	epigenetic	control	of 	monocytes	thereby	
preventing	inflammation
•	 	Fish	oils	are	associated	with	lower	numbers	of 	macrophages	in	obesitas	
patients	and	a	reduced	secretion	of 	TNF-α	in vitro
Hoffman	et	al,	1993
Ou	Y	et	al,	2009
Wang	et	al,	2011
Perenyei	et	al,	2014
Donath	et	al,	2011
McCarty	et	al,	2010
Tono	et	al,	2015
Chan	et	al,	2015
Spencer	et	al,	2013
Zhao	et	al,	2013
Jialal	et	al.	2007
ATG anti-thymocyte globulin; IL interleukin; NFκB nuclear factor kappa-light-chain-enhancer of activated B 
cells; MAPK; mitogen-activated protein kinases; ERK extracellular signal–regulated kinase; CsA Cyclosporin a; 
TNF tumor necrosis factor; BET bromodomain and extra-terminal motif
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Macrophages can be subdivided in ‘classically activated’ or ‘alternatively activated’. Clas-
sically activated macrophages are described as M1 macrophages, which are developed 
upon response to IFNγ, LPS or TNF-α. M1 macrophages express surface markers: MHCII, 
CD40, CD80, CD86 and CD11b. They can produce inflammatory cytokines such as: TNF-α, 
IL-1, IL-6, IL-8, IL-12, CCL2, CXCL9 and CXCL10. M1 macrophages are linked to the Th1 
response and are mainly considered as pro-inflammatory macrophages whereas M2 are 
considered as mainly anti-inflammatory. M2 macrophages can be subdivided in M2a, M2b 
and M2c. M2a macrophages are generated on response to IL-4 and IL-13. Immune com-
plexes and TLR/IL-1R ligands activate M2b macrophages whereas M2c macrophages are 
activated by IL-10, TGF-β and glucocorticoids. M2 macrophages express surface markers: 
CD163, CD206 and CD209. M2 macrophages produce IL-10 and TGF-β mainly leading to 
tissue repair and scar formation. M2 macrophages are linked to Th2 response and show 
immune-modulatory functions 7,39,43. Human regulatory macrophages (Mregs) are in a spe-
cific state of differentiation with a robust phenotype and potent T-cell suppressor function. 
These Mregs arise from CD14+ peripheral blood monocytes during 7-day culture exposed 
to M-CSF and activation by IFNγ 44. Mregs express several molecules such as MHCII, FCγR, 
IFNγR, TLR-4 and PD-L1 as shown in Figure 2 45. Shifting the balance between regulatory 
macrophages and/or monocytes on the one hand, and the effector macrophages and 
proinflammatory monocytes on the other hand could theoretically result in dampening 
the immune response against the graft and the immunological tolerance, or to aggravation 
of graft rejection. To date, two clinical trials investigated the feasibility of regulatory macro-
phages in promoting allograft acceptance with promising results 46,47. Moreover, recently, a 
new homogeneous monocyte subpopulation of human G-CSF induced CD34+ monocytes 
with powerful immunosuppressive properties upon human allogeneic T-cell activation 
was described. Such tolerogenic monocytes could be used for novel immune-regulatory 
or cellular therapy development 48.
Recently, an adaptive feature of innate immunity has been described as “trained im-
munity”. Trained immunity is defined as a nonspecific immunological memory resulting 
from rewiring the epigenetic program and the functional state of the innate immunity 49. 
Twenty naïve patients were vaccinated for bacille Calmette-Guérin (BCG) to investigate 
mechanisms of the enhanced immune function. Interestingly, these authors identified 
trained monocytes in the circulation of BCG-vaccinated individuals for at least 3 months 
suggesting that reprogramming takes place at the level of progenitor cells in the bone mar-
row 50. Recent evidence emerged to indicate that innate immune memory could be trans-
ferred via hematopoietic stem and progenitor cells. In vitro studies showed effects lasting 
for days 51,52, whereas other reports showed memory effects for weeks 53. These interesting 
observations might be explained by alterations in epigenetic (de)methylation profiles 
after antigenic stimulation. Altering the epigenetic program by pharmacological means 
leading to behavioral changes of monocytes could be a promising method to restore or 
modify the healthy gene/protein expression in the pro-inflammatory microenvironment. 
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The phenomenon of trained immunity in alloreactivity and transplantation may be a very 
interesting area of future research: i.e. innate memory towards donor antigens resulting 
from cross-reactivity with other microbial and/or viral agents.
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Figure 2. Monocyte immunobiology. Monocytes arise from myeloid precursor cells in primary lymphoid or-
gans, including liver and bone marrow. In the peripheral blood, monocytes can be subdivided in three distinct 
subsets according to their CD14 and CD16 expression profile. Monocytes can undergo transendothelial migra-
tion through α4β1 integrin interaction with VCaM-1. activation of monocytes is followed by the polarization of 
macrophages to acquire proinflammatory phenotype (M1), anti-inflammatory phenotype (M2) or the regulatory 
phenotype (Mreg). the secretion of distinct pro- or anti-inflammatory cytokines, next to expression patterns of 
surface molecules characterizes each phenotype.
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rATG and basiliximab and monocyte/macrophage cell lineage
Rabbit Anti-thymocyte globulin (rATG) is a polyclonal antibody with mainly T cell deplet-
ing capacities. rATG can also induce B cell apoptosis, and stimulates Treg and NKT cell 
generation 54. After rATG treatment, cytokine dependent homeostatic proliferation of T cells 
is initiated 55. Basiliximab (anti CD25 monoclonal antibody) blocks the CD25 receptor on 
the surface of activated T cells. Studies on the effects of basiliximab or rATG on monocytes/
macrophages are scarce. However, one report showed a reduction in the percentage of 
CD14+CD16+ monocytes when PBMC were cultured in vitro in the presence of rATG 56. In 
contrast, this cell type was not affected by basiliximab, although low expression levels of 
CD25 on stimulated monocytes and macrophages are described 57,58. These authors also 
reported a reduction of circulating CD14+CD16+ monocytes in kidney transplant patients 
treated with rATG during the first week after transplantation, while this was not seen for 
basiliximab induction therapy. Another part of the same study showed an upregulation of 
the percentage of CD14+CD163+ monocytes in either basiliximab or rATG -treated kidney 
transplant recipients, which could be detected for a longer time period in the circulation 
than in patients without induction therapy. CD14+CD163+ monocytes are precursors for 
M2 macrophages and these cells are well known for their anti-inflammatory effect, sug-
gesting that the upregulation of CD14+CD163+ cells may contribute to a better outcome 
after transplantation. However, this study only described the changes in the CD14+CD16+ 
monocyte subset after rATG or basiliximab therapy, while the effect on other subsets such as 
the classical CD14++CD16- monocytes remains unknown. Therefore, it is unclear whether 
the pro-inflammatory immune response by monocytes is changed in the presence of rATG 
or basiliximab.
Alemtuzumab and monocyte/macrophage cell lineage
The humanized monoclonal antibody alemtuzumab targets the CD52 molecule which is 
expressed at different levels on B cells, T cells, NK cells, dendritic cells and monocytes. 
The CD52 molecule, also known as CAMPATH-1 antigen, is a glycoprotein of which the 
precise function is unclear, although it might be involved in T-cell migration and co-
stimulation 59. However, monocytes are known to be less sensitive for the depleting effects 
of alemtuzumab than lymphocytes, despite their high CD52 expression 60-63. For example, 
in acute cellular rejection dominated by monocytes, alemtuzumab treatment did not show 
depletion of monocytes in tissue, confirming the low sensitivity of monocytes to alemtu-
zumab treatment 64. An explanation for this low susceptibility could be the high expression 
levels of complement inhibitory proteins, which protect monocytes from complement 
mediated lysis 63. Another study showed repopulation of monocytes within 3 months after 
alemtuzumab therapy, while the recovery of T and B cells takes usually more than 1 year. 
Consequently, the low susceptibility of monocytes for alemtuzumab is thought to be one 
of the reasons for renal graft dysfunction after induction therapy with alemtuzumab, such 
as reperfusion and rejection 65. So far, this low susceptibility of monocytes to alemtuzumab 
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therapy could be partially explained by the high expression of complementary inhibitory 
proteins that protect monocytes from getting lysed after alemtuzumab treatment 63. After 
alemtuzumab treatment, tissue monocytes in the rejecting graft showed an increased 
expression of the co-stimulatory molecules CD80 and CD86, a higher intracellular expres-
sion of NFκB and stronger production of IL-6 compared to patients without alemtuzumab 
therapy 61. Moreover, this pro-inflammatory cytokine production could facilitate kidney 
allograft rejection after alemtuzumab therapy, although other cell types, such as NK cells, 
could also contribute to rejection processes after alemtuzumab therapy 66.
Calcineurin inhibitors and monocyte/macrophage cell lineage
Tacrolimus and cyclosporine A inhibit the calcineurin pathway in T cells, which is also pres-
ent in other cell types. As a consequence, the activation of the Nuclear Factor of Activated 
T cells (NFAT) is blocked, leading to a reduced production of IL-2 and IFN-γ by T cells 67,68. 
Calcineurin inhibitors (CNI) also have an effect on the MAPK signalling pathway via the in-
hibition of p38MAPK phosphorylation and consequently, reduced production of cytokines, 
such as IL-2, IL-10, TNF-α and IFN-γ 69. The calcineurin and MAPK pathway are also present 
in macrophages, although the inhibitory effects of CNIs on T cells and macrophages are 
different 70. In more detail, tacrolimus was found to have no inhibitory effect on p38MAPK 
phosphorylation at low (5 ng/ml) and high (50 ng/ml) concentrations in LPS-activated 
monocytic THP-1 leukaemia cells 71. However, another member of the MAPK pathway, 
ERK, did show less phosphorylation in the presence of a high concentration (50 ng/ml) of 
tacrolimus in monocytes as measured by western blotting, leading to a lower production 
of TNF-α. Kang et al. reported that monocyte signalling pathways were activated instead of 
inhibited by CNI via the inhibition of the calcineurin pathway and, as a consequence, the 
activation of the NFκB signalling pathway 70. However, the concentrations of CNIs used in 
this study were supratherapeutic. Therefore, the observed induction in cytokine produc-
tion, shown in this study, could also be explained by toxic lysis of the monocytes 72. Overall, 
these studies suggest that CNIs cannot supress the activation of monocytes to the same 
degree as in T-cells.
Recognition of damage-associated molecular patterns (DAMP’s) by toll like receptors 
(TLR) on the surface of monocytes leads to the activation of these cells and plays an im-
portant pathogenic role during transplant rejection 73-75. Both tacrolimus and cyclosporine 
can inhibit TLR signaling of PBMC in liver transplant patients, as shown by decreased 
production of IL-6 and TNF-α after TLR stimulation 72. CNIs act differently in suppressing the 
cytokine production upon TLR activation. For example, cyclosporine inhibits the produc-
tion of TNF-α mediated by TLR7/8 and the production of IL-6 mediated by TLR2 and TLR7/8 
signalling significantly more than tacrolimus 72. Moreover, monocytes from renal transplant 
recipients treated with tacrolimus showed an increased production of IL-1β, TNF-α, IL-6, 
IL-10 after stimulation with LPS, in comparison to cyclosporine treated patients 76. Thus, 
the effect of CNIs on monocytes differs between tacrolimus and cyclosporine.
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The different outcomes of tacrolimus and cyclosporine on cytokine production concerns 
only one of the monocyte/macrophage functions. Bacterial infections can have a signifi-
cant impact on the graft after transplantation. Cyclosporine inhibits the phagocytosis of 
bacteria by macrophages via the alteration of NOD-1 expression. The NOD-1 expression 
depends on the activation of the transcription factor NFAT, which is the main target of 
CNI 77. Thus, cyclosporine can promote bacterial infections after transplantation by altering 
phagocytic capacity of macrophages more rigorously.
Mycophenolate mofetil and monocyte/macrophage cell lineage
Mycophenolate mofetil (MMF) has led to significantly reduced rejection rate as compared 
to its counterpart azathioprine 78-80. The active metabolite mycophenolic acid (MPA) re-
duces the synthesis of guanosine nucleotides via the inhibition of inosine monophosphate 
dehydrogenase, which is a more specific metabolic pathway for T and B cells than for other 
cell types 81,82 .
Circulating monocytes of kidney transplant recipients suffering from chronic rejection 
who were treated with MMF showed a decreased capacity to produce IL-1β, IL-10 and TNF-α 
as compared to circulating monocytes of chronic rejection patients who were not treated 
with MMF. Cytokine production capacity was measured by flow cytometry and confirmed 
by PCR on gene expression level 83. Moreover, the expression of the TNF-receptor 1 was 
decreased in the MMF treated group, suggesting a favourable effect in patients with chronic 
rejection 83. Furthermore, MMF reduced the expression of the adhesion molecules; intercel-
lular adhesion molecule (ICAM)-1 and MHC II on isolated human monocytes 84.
Glucocorticoids and monocyte/macrophage cell lineage
The immunosuppressive and anti-inflammatory effects of glucocorticoids are redundant 
and cover different stages of alloreactivity triggered by activation of donor-specific T cells 
after transplantation. Steroids can bind via passive diffusion to the intracellular gluco-
corticoid receptor. After translocation to the nucleus, steroids bind to the glucocorticoid 
response elements (GRE’s) that have a connection with promotors of different genes. The 
anti-inflammatory effect of glucocorticoids is based on the transrepression of inflamma-
tory gene transcription, such as the inhibition of the transcription factors AP-1 and NFκB, 
and the transactivation of anti-inflammatory genes, including tyrosine aminotransferase 
(TAT) and the induction of IκB 85-88. In this way, glucocorticoids control antigen presenta-
tion, cytokine production and proliferation of lymphocytes.
In monocytes, glucocorticoids specially affect the heterogeneity of monocyte sub-
sets 89-91. Flow cytometric analysis revealed that steroid treatment of stable kidney trans-
plant patients for more than 12 months is associated with an increased absolute number 
of CD14++CD16- and CD14++CD16+ monocyte subsets compared to patients without 
steroid intake. As a consequence, the counts for the non-classical CD14+CD16++ monocyte 
subset, were significantly lower 89. Furthermore, glucocorticoids inhibit the upregulation of 
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B7 molecules on the surface of human monocytes, which can negatively affect the antigen 
presenting function of the cell 92,93. The B7 family consists of many peripheral membrane 
proteins, including CD80 and CD86, which are all involved in the co-stimulatory signal 
needed for T cell activation. This suggests that glucocorticoid therapy in combination with 
belatacept therapy (blocking CD80/CD86) could theoretically block the immune response 
by T cells induced via antigen presenting monocytes after transplantation.
The production of the anti-inflammatory cytokine IL-10 by monocytes is increased 
under treatment with methylprednisolone while the production of the pro-inflammatory 
cytokines IL-12, IL-1 and TNF-α are down-regulated in the presence of glucocorticoids 94,95. 
Addition of 16 μg/ml of glucocorticoids in vitro leads to a decreased uptake of bacteria 
by monocytes, indicating that the phagocytosis of bacteria by monocytes is downregu-
lated  96. Glucocorticoids are also known to drive the polarization of macrophages to a 
M2 phenotype 43,97. This indicates that glucocorticoids drive the cytokine production by 
monocyte to a more anti-inflammatory phenotype and inhibits the phagocytic function 
of monocytes. Glucocorticoids enhance the uptake of apoptotic cells by macrophages 
trough the induction of Mer-Tk (MER proto-oncogene tyrosine kinase), thereby inducing 
macrophage reprogramming toward a regulatory phenotype, also called Meff, for macro-
phages performing efferocytosis 98-100. This approach has been evaluated in the treatment 
of collagen-induced arthritis (Bonnefoy F et al., Arthritis Res Ther. 2016 Aug 11;18(1):184), 
as well as acute graft rejection (Wang Z et al., Am J Transplant. 2006 Jun;6(6):1297-311.) 
justifying further exploration in the field of transplantation.
Inhibitors of the mammalian target of rapamycin (mTOR) and monocyte/macrophage 
cell lineage
The mammalian target of rapamycin (mTOR) signalling pathway is involved in the activa-
tion, proliferation, differentiation and translocation of T cells. Inhibitors of mTOR, such 
as everolimus and sirolimus, are therefore very useful after transplantation 101. The same 
mTOR inhibitors do also have an inhibitory effect on human monocytes by suppressing the 
production of the chemokines MCP-1, RANTES, IL-8, MIP-1α and MIP-1β 102. Furthermore, 
the downstream effects of rapamycin therapy are characterized by a decreased production 
of the monocyte-derived cytokine IL-6 and an increase of TGF-beta production in compari-
son to MMF, as it was shown by fine-needle biopsy cultures from kidney transplant patients 
treated with either a cyclosporine-rapamycin-prednisone or a cyclosporine-MMF-predni-
sone therapy one week after transplantation 103. This resulted in a more tolerogenic effect 
of the monocytes and less graft rejection during the first 6 months after transplantation in 
comparison to a MMF based drug therapy. Moreover, combined therapy of mTOR inhibitors 
and glucocorticoid therapy increased the production of the pro-inflammatory cytokines 
IL-12, TNF-α and IL-1β 104. Altogether, mTOR inhibitors can inhibit cytokine production by 
monocytes shortly after transplantation, although a combination therapy with prednisone 
should be regarded with caution.
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Belatacept and monocyte/macrophage cell lineage
Belatacept, a fusion-protein consisting of the extracellular domain of the human cytotoxic 
T-lymphocyte antigen (CTLA)-4 antigen linked to a Fc-fragment of immunoglobulin G1 
(IgG1), inhibits the co-stimulatory signal between the CD80/CD86 molecules on antigen 
presenting cells and the CD28 molecule on T cells, thereby preventing T cell activation 105. 
Monocytes express CD80/CD86 molecules and, as a consequence, the antigen presenting 
function of monocytes is blocked by belatacept 106-108. This suggests that belatacept inhibits 
the antigen presenting function of monocytes/macrophages. In one case of acute rejection 
within 3 months after transplantation, the blockade of CD80/CD86 was incomplete under 
belatacept treatment, suggesting the importance of higher belatacept tissue concentra-
tions needed to completely block monocyte antigen presentation function 106. Thus belata-
cept, in controlled dosages, blocks the expression of CD80/CD86 on monocytes, thereby 
inhibiting their antigen presenting function and activation of T cells.
The older variant of belatacept, abatacept (CTLA-4Ig), is frequently used in the treat-
ment of patients with rheumatoid arthritis (RA) 109. After treatment with abatacept, the 
number of circulating monocytes was increased, and the phenotype of these cells was 
significantly changed, due to down regulation of actin fibers. For example, the capability of 
monocyte migration was negatively changed even as the number of adhesion molecules 
in vitro. Data were verified with monocytes from healthy controls. The reduced number of 
adhesion molecules and migration capacity could be a reason for the increased number of 
monocytes in the peripheral blood that cannot pass endothelial barriers, whereby it is no 
longer possible for the monocyte to contribute in inflammation.
Binding of abatacept to the CD80/CD86 receptor on macrophages from healthy blood do-
nors is associated with decreased production of the pro-inflammatory cytokines IL-12 and 
TNF-α, suggesting again a role for abatacept/belatacept in changing the pro-inflammatory 
environment via macrophages after transplantation 110.
Other experimental drugs and monocyte/macrophage cell lineage
Although no monocyte specific drugs as such exist now, multiple experimental and less 
known drugs do influence monocyte functions. Looking outside the box of currently used 
immunosuppressive drugs in solid organ transplantation, there are a few compounds with 
immune-inhibitory effects, which theoretically could be interesting in combating alloim-
munity. For example, the human monoclonal antibody canakinumab, originally designed 
as an interleukin-beta (IL-1β) inhibitor for the repression of inflammation in autoimmune 
diseases, can also inhibit the IL-1β production by monocytes 111. A high expression of IL-1β 
is noticed in the most severe liver transplant rejection episodes and at the time of kidney 
transplantation, suggesting the importance of blocking its production by monocytes 112,113. 
However, treatment of kidney transplant recipients with canakinumab can inhibit IL-1β 
secretion in many other cell types, leading to undesirable side effects 114.
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
40
Infliximab, originally used in the treatment of autoimmune diseases, is another mono-
clonal antibody targeting monocyte TNF-α production. Monocytes and macrophages are 
main producers of TNF-α, suggesting the importance of infliximab for targeting mono-
cytes 115. Beside the effect on TNF-α production, monocytes from Crohn’s disease patients 
treated with therapeutic concentrations of infliximab showed also increased apoptosis via 
the activation of caspase-3, 8 and 9 116.
Furthermore, the herbal medicine sinomenine was found to reduce migration of acti-
vated human monocyte cells and inhibits human monocytes-derived DC differentiation 
and maturation 71,117. In addition, peripheral blood monocytes from healthy donors cul-
tured for 60 hours in the presence of different concentrations of sinomenine showed an 
enhanced production of IL-6 and a decreased expression of IL-8, which is important for cell 
migration 118. This would suggest a positive effect of sinomenine on monocyte infiltration 
and migration, although there is still an increased production of pro-inflammatory cyto-
kines. However, this research was performed using monocytic THP-1 cell-line, and isolated 
peripheral blood monocytes from healthy donors, so that possible effects with regard to 
transplantation are still unknown.
15-deoxyspergualin or gusperimus is a relatively long known immunosuppressive drug 
with an inhibitory effect on monocyte proliferation, TNF-α production and phagocytotic 
functions of monocytes. More recently, it was been suggested that gusperimus can also 
be effective in suppressing the antigen presentation function of monocytes in transplanta-
tion 119. Another member of the spergualin family is LF15-0195. This drug is known for its 
inhibitory effect on monocyte accumulation in the tubulo-interstitial compartment of rat 
kidneys and was shown to have beneficial effects in the treatment of glomerulonephritis 120.
In diabetes mellitus, macrophage accumulation and activation play a central role in 
disease progression. Research on simvastatin, a drug to lower elevated lipid levels, has 
been shown to effectively lower IL-6, IL-8, TNF cytokine and superoxide anion production 
by monocytes isolated from human blood samples of patients with diabetes mellitus type 
1 121. In addition, simvastatin reduces the NFκB activity in monocytes with approximately 
60%, which causes the inhibition of IL-6 and IL-8 production. Treatment of IgA nephropathy 
with the drug atorvastatin showed a reduction of monocyte proliferation 122. In diabetes 
mellitus type 2 patients this drug lowers the TNF-alpha production by monocytes 123. Other 
studies in diabetes mellitus patients have shown potential effects of salsalate on macro-
phages activation. Salsalate, a prodrug of salicylic acid, is also known for the inhibition of 
the NFκB pathway in macrophages 124,125. This suggests a working mechanism for salsalate 
that is similar to simvastatin. Both drugs can be promising compounds to inhibit monocyte 
and macrophage activation.
In RA, research on therapeutic drugs to target monocytes and macrophages is more 
common because of the important role of monocytes in developing this disease. In ad-
dition, TNF-α is a key player known to cause inflammation in RA and is mainly produced 
by monocytes 126. Some of the drugs used to suppress inflammation in RA could also 
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have a potential in transplantation. For example, a decreased number of CD14+ CD16+ 
monocytes was found after treatment of RA patients with tocilizumab, an IL-6 receptor 
blocker 127. In addition, production of IL-6 by monocytes from healthy donors was reduced 
when tocilizumab was added in vitro. The drug also induces the apoptosis of SEB (staphy-
lococcal enterotoxin B)-activated monocytes 128. These results suggest that tocilizumab 
could theoretically impair the monocyte responses after transplantation. Furthermore, 
bromodomain and extra terminal (BET) inhibitors are developed to control the intracel-
lular chromatin regulation responsible for the activation of monocytes, thereby inhibiting 
inflammation processes induced by monocytes. In more detail, CD14+ monocytes were 
isolated from blood samples of healthy volunteers and cultured in the presence of BET 
inhibitors and IFN-β, IFN-γ, IL-4 and IL-10 stimuli, where after the intracellular activation 
cytokine response were suppressed 129. In RA patients this epigenetic control by BET inhibi-
tors could suppress the production of pro-inflammatory cytokines and chemokines such 
as CXCL10. This would indicate that BET inhibitors could also inhibit monocyte activation 
after transplantation, although this is very speculative and require more research.
Fish oil based drugs, such as lovaza, are used to lower triglyceride levels in obesity. 
These fish oil compounds demonstrated a reduction in the number of macrophages and 
reduced MCP-1 blood levels 130. Eicosapentaenoic acid, one of the major fatty acids in fish 
oil, reduces the secretion of TNF-α by human monocytic THP-1 cells, via the inhibition of 
the intracellular NFκB activation 131. This suggests also a suppressing role for fatty acids in 
monocyte activation that could have a potential effect in transplantation as well.
Future challenges and developments
Therapies targeting monocytes and macrophages in (SOT) could intervene at different 
points with monocyte actions and their subsequent functions (Figure 3). First, the activa-
tion and function of the cells can be inhibited at multiple stages: Signaling pathway activa-
tion, antigen presentation and cytokine production. Blockade of the intracellular signaling 
pathways inhibits the activation of monocytes and macrophages. For example, the use of 
specific MAPK inhibitors, such as SB203580, blocks the activation of monocytes 132. How-
ever, these drugs will also block the activation of many other cell types. Targeting antigen 
presentation is even more difficult than targeting signaling pathways. It is known that the 
Fcγ-receptor on monocytes is involved in the recognition and processing of donor antigen 
specific antibodies 133,134. Blocking this receptor with specific antibodies could inhibit the 
antigen presentation function of monocytes. Furthermore, already existing drugs that re-
duce the cytokine production by monocytes and macrophages, for example canakinumab, 
infliximab and tocilizumab, mainly target the inhibition of one single cytokine. To be more 
effective, monocyte specific drugs should be developed to inhibit the production or the 
effects of multiple cytokines at once, thereby reducing side effects.
Second, delivering any potential new drug to the target cell, in this case, monocytes and 
macrophages, is a major point of intervention, which could lower the side effects. One can 
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envision a delivery system using the phagocytosis function of the monocyte/macrophage, 
whereby macrophages can ingest immunosuppressive drug loaded-inactivated bacteria 
or liposomes carrying the potential new drug 135. However, the monocyte is not the only 
cell type with a phagocytic system. Therefore the surface of these bacteria or liposomes 
should be modified to facilitate the specific recognition by the monocyte/macrophage in 
order to overcome side eff ects. Another approach to target monocytes and macrophages 
via their phagocytotic function is to use apoptotic cells through a process that is known as 
eff erocytosis 99,100. Phagocytosis of these apoptotic cells by monocytes and macrophages 
will induce an anti-inflammatory response at the tissue level and may induce immunologi-
cal tolerance. Furthermore, ex vivo experiments showed a decrease in CD11b expression 
on macrophages 136, suggesting that treatment with apoptotic cells induces the generation 
of Mregs. As mentioned above (paragraph “Glucocorticoids and monocyte/macrophage 
cell lineage”), the uptake of apoptotic cells can be enhanced by treatment with glucocor-
ticoids 100.
The third point of therapeutic eff icacy would be the manipulation of the nature of these 
cells. The future of in vivo manipulation of macrophages is intriguing; phenotypes could 
be changed by transfection with adenovirus, modulation of nuclear transcription factor 
NR4A1 (Nur77) or by modulation of local microenvironment with cytokines to polarize 
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Figure 3. Future challenges and developments: Strategies to target monocytes/macrophages. New thera-
pies targeting monocytes and macrophages could intervene at three levels with monocyte actions and their 
subsequent functions as depicted, and described in manuscript body.
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macrophages to reparative phenotype 35. Targeting all monocytes and macrophages in-
discriminately could also be a disadvantage as regulatory and effector macrophages also 
have beneficial effects including the control of infections and the induction of regulatory 
cells 137.
Moreover, inhibition of all macrophages will also affect the number of Mregs, which are 
important for inducing tolerance after transplantation 138. Too much inhibition of effector 
macrophages or Mregs could lead to graft rejection or complications, such as atheroscle-
rosis and cardiovascular diseases. Furthermore, currently pre-scribed immunosuppres-
sive drugs might miss the power to upregulate Mregs efficiently. In experimental mouse 
models, Mregs have demonstrated anti-inflammatory and T-cell suppressing effects (Other 
beneficial effects of Mregs are described in the paragraph “Monocyte immunobiology”) 
139,140. A more specific upregulation of these cells could be an approach to beneficially 
shift the balance towards macrophages controlling immune responses including those in 
organ transplant patients. Ideally, after SOT, the balance of macrophage subsets should 
be in favour of macrophages that control the anti-donor response, while the accumula-
tion of macrophages with pro-inflammatory and antigen presentation characteristics 
should be decreased 141,142. For example reduced function of the detrimental functions of 
macrophages involved in alloreactivity might be a useful therapy, although more research 
is needed to find a specific approach. Another way to differentiate between effector and 
controlling functions of macrophages could be by polarizing cells into M1 and M2 subsets. 
Targeting specific signaling pathways involved in this polarization process like the Notch 
signaling pathway could change the nature of these cells to an more anti-inflammatory 
phenotype  143. NFκB signaling, controlled by the Notch pathway, is associated with pro-
inflammatory macrophage responses, while a more anti-inflammatory phenotype is 
induced via the ERK pathway 143,144. Targeting these pathways with specific stimuli may 
change the phenotype of macrophages. Stimuli that induce macrophage polarization 
towards a M1 phenotype are GM-CSF, IFN-γ and LPS, while IL-4, IL-13 and IL-10 enhance a 
M2 macrophage phenotype 145. Future insight and research are necessary to investigate the 
effect of these manipulated macrophages on healthy and diseased tissue.
Ideally, a potential new drug inhibiting monocytes-macrophages at these three levels 
would change the spectrum of not only rejection treatment or prevention after (SOT) but 
also the course of many autoimmune mediated diseases. Either alone or in combination 
with other existing immunosuppressive drugs, this field constitutes a challenging area of 
future therapeutic research.
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
44
References
 1. Koo EH, Jang HR, Lee JE, et al. The impact of early and late acute rejection on graft survival in 
renal transplantation. Kidney Res Clin Pract 2015;34:160-4.
 2. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant fail-
ure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 
2012;12:388-99.
 3. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause 
of late kidney transplant failure. Am J Transplant 2009;9:2520-31.
 4. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft 
survival despite a marked decrease in acute rejection rates over the most recent era. Am J 
Transplant 2004;4:378-83.
 5. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010;363:1451-62.
 6. Mannon RB. Macrophages: Contributors to Allograft Dysfunction, Repair or Innocent Bystand-
ers? Curr Opin Organ Transplant 2012;17:20-5.
 7. Rowshani AT, Vereyken EJF. The Role of Macrophage Lineage Cells in Kidney Graft Rejection 
and Survival. Transplantation 2012;94:309-18.
 8. Girlanda R, Kleiner DE, Duan Z, et al. Monocyte Infiltration and Kidney Allograft Dysfunction 
During Acute Rejection. Am J Transplant 2008;8:600.
 9. van Kooten C, Daha MR. Cytokine cross-talk between tubular epithelial cells and interstitial 
immunocompetent cells. Curr Opin Nephrol Hypertens 2001;10:55-9.
 10. Moreau A, Varey E, Anegon I, Cuturi MC. Effector Mechanisms of Rejection. Cold Spring Harb 
Perspect Med 2013;3.
 11. Toki D, Zhang W, Hor KLM, et al. The Role of Macrophages in the Development of Human 
Renal Allograft Fibrosis in the First Year After Transplantation. Am J Transplant 2014;14:2126-
36.
 12. Sentís A, Kers J, Yapici U, et al. The prognostic significance of glomerular infiltrating leuko-
cytes during acute renal allograft rejection. Transpl Immunol 2015;33:168-75.
 13. Kwan T, Wu H, Chadban SJ. Macrophages in renal transplantation: Roles and therapeutic 
implications. Cell Immunol 2014;291:58-64.
 14. Kozakowski N, Böhmig GA, Exner M, et al. Monocytes/macrophages in kidney allograft intimal 
arteritis: no association with markers of humoral rejection or with inferior outcome. Nephrol 
Dial Transplant 2009;24:1979-86.
 15. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute 
renal allograft rejection independent of C4d status. Kidney Int 2005;68:1866-74.
 16. Fahim T, Böhmig GA, Exner M, et al. The Cellular Lesion of Humoral Rejection: Predominant 
Recruitment of Monocytes to Peritubular and Glomerular Capillaries. Am J Transplant 
2007;7:385-93.
 17. Özdemir BH, Demirhan B, Güngen Y. The Presence and Prognostic Importance of Glomerular 
Macrophage Infiltration in Renal Allografts. Nephron 2002;90:442-6.
45
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
Ch
ap
te
r 2
 18. Grimm PC, McKenna R, Nickerson P, et al. Clinical Rejection Is Distinguished from Subclinical 
Rejection by Increased Infiltration by a Population of Activated Macrophages. Clin J Am Soc 
Nephrol 1999;10:1582-9.
 19. Bergler T, Jung B, Bourier F, et al. Infiltration of Macrophages Correlates with Severity of Allograft 
Rejection and Outcome in Human Kidney Transplantation. PLoS One 2016;11:e0156900.
 20. Om A BA, Raja R, Kim P, Bannett AD. The prognostic significance of the presence of monocytes 
in glomeruli of renal transplant allografts. Transplant Proc 1987;19:1618-22.
 21. Copin MC, Noel C, Hazzan M, et al. Diagnostic and predictive value of an immunohistochemi-
cal profile in asymptomatic acute rejection of renal allografts. Transpl Immunol 1995;3:229-
39.
 22. Xu L, Collins J, Drachenberg C, KuKuruga D, Burke A. Increased macrophage density of cardiac 
allograft biopsies is associated with antibody-mediated rejection and alloantibodies to HLA 
antigens. Clin Transplant 2014;28:554-60.
 23. Fishbein GA, Fishbein MC. Morphologic and immunohistochemical findings in antibody-
mediated rejection of the cardiac allograft. Hum Immunol 2012;73:1213-7.
 24. Oberbarnscheidt MH, Zeng Q, Li Q, et al. Non-self recognition by monocytes initiates allograft 
rejection. J Clin Invest 2014;124:3579-89.
 25. Boersema M, van den Born JC, van Ark J, et al. CD16+ monocytes with smooth muscle cell 
characteristics are reduced in human renal chronic transplant dysfunction. Immunobiology 
2015.
 26. Vereyken EJF, Kraaij MD, Baan CC, et al. A Shift towards Pro-Inflammatory CD16+ Monocyte 
Subsets with Preserved Cytokine Production Potential after Kidney Transplantation. PLoS 
One 2013;8:e70152.
 27. Kraaij MD, Vereyken EJF, Leenen PJM, et al. Human monocytes produce interferon-gamma 
upon stimulation with LPS. Cytokine 2014;67:7-12.
 28. Ziegler-Heitbrock L. Blood monocytes and their subsets: established features and open ques-
tions. Front Immunol 2015;6.
 29. Ziegler-Heitbrock L. Monocyte subsets in man and other species. Cell Immunol 2014;289:135-
9.
 30. Ziegler-Heitbrock L, Hofer TP. Toward a refined definition of monocyte subsets. Front Immu-
nol 2013;4:23.
 31. Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: 
implications for health and disease. Immunol Res 2012;53:41-57.
 32. van Furth R, Sluiter W. Distribution of blood monocytes between a marginating and a circu-
lating pool. J Exp Med 1986;163:474-9.
 33. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of Splenic Reservoir Monocytes and 
Their Deployment to Inflammatory Sites. Science 2009;325:612-6.
 34. Terry RL, Miller SD. Molecular control of monocyte development. Cell Immunol 2014;291:16-
21.
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
46
 35. Hanna RN, Carlin LM, Hubbeling HG, et al. The transcription factor NR4A1 (Nur77) controls 
bone marrow differentiation and the survival of Ly6C- monocytes. Nat Immunol 2011;12:778-
85.
 36. Ghattas A, Griffiths HR, Devitt A, Lip GYH, Shantsila E. Monocytes in Coronary Artery Disease 
and Atherosclerosis: Where Are We Now? J Am Coll Cardiol 2013;62:1541-51.
 37. Frankenberger M, Hofer TPJ, Marei A, et al. Transcript profiling of CD16-positive monocytes 
reveals a unique molecular fingerprint. Eur J Immunol 2012;42:957-74.
 38. Brooks CF, Moore M. Differential MHC class II expression on human peripheral blood mono-
cytes and dendritic cells. Immunology 1988;63:303-11.
 39. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue ho-
meostasis. Nat Rev Immunol 2014;14:392-404.
 40. Yona S, Kim K-W, Wolf Y, et al. Fate Mapping Reveals Origins and Dynamics of Monocytes and 
Tissue Macrophages under Homeostasis. Immunity 2013;38:79-91.
 41. Hashimoto D, Chow A, Noizat C, et al. Tissue-Resident Macrophages Self-Maintain Lo-
cally throughout Adult Life with Minimal Contribution from Circulating Monocytes. Immunity 
2013;38:792-804.
 42. W. Prodjosudjadi MRD, J. S. J. Gerritsma, K. W. Florijn, J. N. M. Barendregt , J. A.Bruijn, F.J. 
van der Woude and L.A. van Es. Increased urinary excretion of monocyte ehemoattractant 
protein-1 during acute renal allograft rejection. Nephrol Dial Transplant 1996;11:7.
 43. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reas-
sessment. F1000Prime Rep 2014;6:13.
 44. Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting Edge: Immunological Consequences and 
Trafficking of Human Regulatory Macrophages Administered to Renal Transplant Recipients. 
J Immunol 2011;187:2072-8.
 45. Fleming BD, Mosser DM. Regulatory macrophages: Setting the Threshold for Therapy. Eur J 
Immunol 2011;41:2498-502.
 46. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptance-inducing cells as an 
immune-conditioning therapy in renal transplantation. Transpl Int 2008;21:728-41.
 47. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization 
of immunosuppression in renal transplantation. Transpl Int 2008;21:742-54.
 48. D’Aveni M, Rossignol J, Coman T, et al. G-CSF mobilizes CD34+ regulatory monocytes that 
inhibit graft-versus-host disease. Sci Transl Med 2015;7:281ra42-ra42.
 49. Netea MG, Joosten LAB, Latz E, et al. Trained immunity: A program of innate immune memory 
in health and disease. Science 2016;352.
 50. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guérin induces NOD2-dependent 
nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc 
Natl Acad Sci U S A 2012;109:17537-42.
 51. Ostuni R, Piccolo V, Barozzi I, et al. Latent Enhancers Activated by Stimulation in Differenti-
ated Cells. Cell 2013;152:157-71.
47
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
Ch
ap
te
r 2
 52. Quintin J, Saeed S, Martens Joost  HA, et al. Candida albicans Infection Affords Protection 
against Reinfection via Functional Reprogramming of Monocytes. Cell Host & Microbe 
2012;12:223-32.
 53. Yoshida K, Ishii S. Innate immune memory via ATF7-dependent epigenetic changes. Cell Cycle 
2016;15:3-4.
 54. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. 
Leukemia 2007;21:1387-94.
 55. Bouvy AP, Kho MM, Klepper M, et al. Kinetics of homeostatic proliferation and thymopoiesis 
after rATG induction therapy in kidney transplant patients. Transplantation 2013;96:904-13.
 56. Sekerkova A, Krepsova E, Brabcova E, et al. CD14+CD16+ and CD14+CD163+ monocyte sub-
populations in kidney allograft transplantation. BMC Immunol 2014;15:4-.
 57. Bosco MC, Espinoza-Delgado I, Schwabe M, et al. Regulation by interleukin-2 (IL-2) and in-
terferon gamma of IL-2 receptor gamma chain gene expression in human monocytes. Blood 
1994;83:2995.
 58. Valitutti S, Carbone A, Castellino F, et al. The expression of functional IL-2 receptor on acti-
vated macrophages depends on the stimulus applied. Immunology 1989;67:44-50.
 59. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in 
a human CD52 transgenic mouse model. Immunology 2009;128:260-70.
 60. Hale G, Xia M-Q, Tighe HP, Dyer MJS, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue 
Antigens 1990;35:118-27.
 61. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial 
evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). 
Transplantation 2003;76:120-9.
 62. Fabian I, Flidel O, Gadish M, Kletter Y, Slavin S, Nagler A. Effects of CAMPATH-1 antibodies 
on the functional activity of monocytes and polymorphonuclear neutrophils. Exp Hematol 
1993;21:1522-7.
 63. Rao SP, Sancho J, Campos-Rivera J, et al. Human Peripheral Blood Mononuclear Cells Exhibit 
Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab 
Mediated Cytolysis. PLoS One 2012;7:e39416.
 64. Zhang PL, Malek SK, Prichard JW, et al. Acute cellular rejection predominated by monocytes 
is a severe form of rejection in human renal recipients with or without Campath-1H (alemtu-
zumab) induction therapy. Am J Transplant 2005;5:604-7.
 65. Bloom D, Chang Z, Pauly K, et al. BAFF Is Increased in Renal Transplant Patients Following 
Treatment with Alemtuzumab. Am J Transplant 2009;9:1835-45.
 66. Lenihan CR, Tan JC, Kambham N. Acute transplant glomerulopathy with monocyte rich 
infiltrate. Transpl Immunol 2013;29:114-7.
 67. Liu J, Farmer JD, Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common 
target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-15.
 68. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lympho-
cytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A 1992;89:3686-90.
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
48
 69. Vafadari R, Hesselink DA, Cadogan MM, Weimar W, Baan CC. Inhibitory effect of tacrolimus on 
p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by 
whole-blood phosphospecific flow cytometry. Transplantation 2012;93:1245-51.
 70. Kang YJ, Kusler B, Otsuka M, et al. Calcineurin Negatively Regulates TLR-Mediated Activation 
Pathways. J Immunol 2007;179:4598-607.
 71. Ou Y-q, Chen L-h, Li X-j, Lin Z-b, Li W-d. Sinomenine influences capacity for invasion and 
migration in activated human monocytic THP-1 cells by inhibiting the expression of MMP-2, 
MMP-9, and CD147. Acta Pharmacol Sin 2009;30:435-41.
 72. Howell J, Sawhney R, Testro A, et al. Cyclosporine and tacrolimus have inhibitory effects on 
toll-like receptor signaling after liver transplantation. Liver Transpl 2013;19:1099-107.
 73. Zhuang Q, Lakkis FG. Dendritic cells and innate immunity in kidney transplantation. Kidney 
Int 2015;87:712-8.
 74. Rao DA, Pober JS. Endothelial injury, alarmins, and allograft rejection. Crit Rev Immunol 
2008;28:229-48.
 75. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 
2008;8:279-89.
 76. Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G. Switch from cyclosporine A to 
tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Hum 
Immunol 2000;61:884-97.
 77. Tourneur E, Ben Mkaddem S, Chassin C, et al. Cyclosporine A Impairs Nucleotide Binding 
Oligomerization Domain (Nod1)-Mediated Innate Antibacterial Renal Defenses in Mice and 
Human Transplant Recipients. PLoS Pathog 2013;9:e1003152.
 78. Zuckermann A, Klepetko W, Birsan T, et al. Comparison between mycophenolate mofetil- and 
azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung 
Transplant 1999;18:432-40.
 79. Rigotti P, Cadrobbi R, Baldan N, et al. Mycophenolate mofetil (MMF) versus azathioprine (AZA) 
in pancreas transplantation: a single-center experience. Clin Nephrol 2000;53:suppl 52-4.
 80. van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int 2015;28:508-15.
 81. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharma-
cology 2000;47:85-118.
 82. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an 
ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28.
 83. Weimer RM, Joannis; Feustel, Andreas; Preiss, Astrid; Daniel, Volker; Grimm, Helmut; Wiesel, 
Manfred; Opelz, Gerhard. Mycophenolate mofetil-based immunosuppression and cytokine 
genotypes: effects on monokine secretion and antigen presentation in long-term renal trans-
plant recipients. Transplantation 2003;75:2090-9.
 84. Glomsda BA, Blaheta RA, Hailer NP. Inhibition of monocyte//endothelial cell interactions 
and monocyte adhesion molecule expression by the immunosuppressant mycophenolate 
mofetil. Spinal Cord 2003;41:610-9.
49
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
Ch
ap
te
r 2
 85. Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce 
for the glucocorticoid receptor? Mol Pharmacol 2007;72:799-809.
 86. Jantzen HM, Strahle U, Gloss B, et al. Cooperativity of glucocorticoid response elements 
located far upstream of the tyrosine aminotransferase gene. Cell 1987;49:29-38.
 87. Rigaud G, Roux J, Pictet R, Grange T. In vivo footprinting of rat TAT gene: dynamic interplay 
between the glucocorticoid receptor and a liver-specific factor. Cell 1991;67:977-86.
 88. Cato AC, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. 
Bioessays 1996;18:371-8.
 89. Rogacev KS, Zawada AM, Hundsdorfer J, et al. Immunosuppression and monocyte subsets. 
Nephrol Dial Transplant 2015;30:143-53.
 90. Orii M, Imanishi T, Teraguchi I, et al. Circulating CD14++CD16+ Monocyte Subsets as a Sur-
rogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac 
Sarcoidosis. Circ J 2015;79:1585-92.
 91. Sumegi A, Antal-Szalmas P, Aleksza M, et al. Glucocorticosteroid therapy decreases CD14-
expression and CD14-mediated LPS-binding and activation of monocytes in patients suffer-
ing from systemic lupus erythematosus. Clin Immunol 2005;117:271-9.
 92. Girndt M, Sester U, Kaul H, Hünger F, Köhler H. Glucocorticoids inhibit activation-dependent 
expression of costimulatory molecule B7-1 in human monocytes. Transplantation 
1998;66:370-5.
 93. Jirapongsananuruk O, Leung DY. The modulation of B7.2 and B7.1 on B cells by immunosup-
pressive agents. Clin Exp Immunol 1999;118:1-8.
 94. Hodge G, Hodge S, Reynolds PN, Holmes M. Up-regulation of Interleukin-8, Interleukin-10, 
Monocyte Chemotactic Protein-1, and Monocyte Chemotactic Protein-3 in Peripheral Blood 
Monocytes in Stable Lung Transplant Recipients: Are Immunosuppression Regimens Work-
ing? Transplantation 2005;79:387-91.
 95. Blotta MH, DeKruyff RH, Umetsu DT. Corticosteroids inhibit IL-12 production in human mono-
cytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 
1997;158:5589-95.
 96. Rinehart JJ, Balcerzak SP, Sagone AL, LoBuglio AF. Effects of corticosteroids on human mono-
cyte function. J Clin Invest 1974;54:1337-43.
 97. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional 
Differentiation. Front Immunol 2014;5:514.
 98. Schif-Zuck S, Gross N, Assi S, Rostoker R, Serhan CN, Ariel A. Saturated-efferocytosis generates 
pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J 
Immunol 2011;41:366-79.
 99. Saas P, Daguindau E, Perruche S. Concise Review: Apoptotic Cell-Based Therapies-Rationale, 
Preclinical Results and Future Clinical Developments. Stem Cells 2016;34:1464-73.
 100. Poon IK, Lucas CD, Rossi AG, Ravichandran KS. Apoptotic cell clearance: basic biology and 
therapeutic potential. Nat Rev Immunol 2014;14:166-80.
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
50
 101. Shipkova M, Hesselink DA, Holt DW, et al. Therapeutic Drug Monitoring of Everolimus: A Con-
sensus Report. Ther Drug Monit 2016;38:143-69.
 102. Lin HY-H, Chang K-T, Hung C-C, et al. Effects of the mTOR inhibitor Rapamycin on Monocyte-
Secreted Chemokines. BMC Immunol 2014;15:1-9.
 103. Oliveira JGG, Xavier P, Sampaio SM, et al. Compared to mycophenolate mofetil, rapamycin 
induces significant changes on growth factors and growth factor receptors in the early days 
postkidney transplantation1. Transplantation 2002;73:915-20.
 104. Weichhart T, Haidinger M, Katholnig K, et al. Inhibition of mTOR blocks the anti-inflammatory 
effects of glucocorticoids in myeloid immune cells. Blood 2011;117:4273-83.
 105. Graav GNd, Bergan S, Baan CC, Weimar W, van Gelder T, Hesselink DA. Therapeutic Drug 
Monitoring of Belatacept in Kidney Transplantation. Ther Drug Monit 2015;37:560-7.
 106. Graav GNd, Hesselink DA, Dieterich M, et al. An Acute Cellular Rejection With Detrimental Out-
come Occurring Under Belatacept-Based Immunosuppressive Therapy: An Immunological 
Analysis. Transplantation 2015;Online First.
 107. Latek R, Fleener C, Lamian V, et al. Assessment of Belatacept-Mediated Costimulation Block-
ade Through Evaluation of CD80/86-Receptor Saturation. Transplantation 2009;87:926-33.
 108. Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: transplantation and 
autoimmunity. Nat Rev Nephrol 2014;10:14-24.
 109. Bonelli M, Ferner E, Goschl L, et al. Abatacept (CTLA-4IG) treatment reduces the migratory 
capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum 2013;65:599-
607.
 110. Wenink MH, Santegoets KCM, Platt AM, et al. Abatacept modulates proinflammatory mac-
rophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation. 
Ann Rheum Dis 2011.
 111. Dhimolea E. Canakinumab. mAbs 2010;2:3-13.
 112. Hoffmann MW, Wonigeit K, Steinhoff G, Herzbeck H, Flad HD, Pichlmayr R. Production of cyto-
kines (TNF-alpha, IL-1-beta) and endothelial cell activation in human liver allograft rejection. 
Transplantation 1993;55:329-35.
 113. Vereyken EJ, Kraaij MD, Baan CC, et al. A shift towards pro-inflammatory CD16+ monocyte 
subsets with preserved cytokine production potential after kidney transplantation. PLoS One 
2013;8:e70152.
 114. Wanderer AA. Rationale and timeliness for IL-1β-targeted therapy to reduce allogeneic organ 
injury at procurement and to diminish risk of rejection after transplantation. Clin Transplant 
2010;24:307-11.
 115. Ebert EC. Infliximab and the TNF-α system. Am J Physiol Gastrointest Liver Physiol 
2009;296:G612-G20.
 116. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces 
apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-
dependent pathway. Gastroenterology 2001;121:1145-57.
51
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
Ch
ap
te
r 2
 117. Wang Q, Li X-K. Immunosuppressive and anti-inflammatory activities of sinomenine. Int Im-
munopharmacol 2011;11:373-6.
 118. Shenghao T, Yonghong H, Fu’er L. Effect of sinomenine on IL-8, IL-6, IL-2 produced by periph-
eral blood mononuclear cells. J Tongji Med Univ 1999;19:257-9.
 119. Perenyei M, Jayne DR, Flossmann O. Gusperimus: immunological mechanism and clinical 
applications. Rheumatology 2014;53:1732-41.
 120. Tesch GH, Hill PA, Wei M, Nikolic-Paterson DJ, Dutartre P, Atkins RC. LF15-0195 prevents the 
induction and inhibits the progression of rat anti-GBM disease. Kidney Int 2001;60:1354-65.
 121. Jialal I, Miguelino E, Griffen SC, Devaraj S. Concomitant reduction of low-density lipoprotein-
cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients 
with type 1 diabetes. J Clin Endocrinol Metab 2007;92:3136-40.
 122. Lundberg S, Lundahl J, Gunnarsson I, Jacobson SH. Atorvastatin-induced modulation of 
monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory 
kidney disease. Clin Nephrol 2010;73:221-8.
 123. Mandosi E, Fallarino M, Gatti A, et al. Atorvastatin downregulates monocyte CD36 expression, 
nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb 2010;17:539-
45.
 124. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 
2011;11:98-107.
 125. McCarty MF. Salsalate may have broad utility in the prevention and treatment of vascular 
disorders and the metabolic syndrome. Med Hypotheses 2010;75:276-81.
 126. Davignon J-L, Hayder M, Baron M, et al. Targeting monocytes/macrophages in the treatment 
of rheumatoid arthritis. Rheumatology 2012.
 127. Kikuchi J, Hashizume M, Kaneko Y, Yoshimoto K, Nishina N, Takeuchi T. Peripheral blood 
CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab 
treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with 
clinical response. Arthritis Res Ther 2015;17:10.
 128. Tono T, Aihara S, Hoshiyama T, Arinuma Y, Nagai T, Hirohata S. Effects of anti-IL-6 receptor 
antibody on human monocytes. Mod Rheumatol 2015;25:79-84.
 129. Chan CH, Fang C, Qiao Y, Yarilina A, Prinjha RK, Ivashkiv LB. BET bromodomain inhibition sup-
presses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner 
in human monocytes. Eur J Immunol 2015;45:287-97.
 130. Spencer M, Finlin BS, Unal R, et al. Omega-3 fatty acids reduce adipose tissue macrophages 
in human subjects with insulin resistance. Diabetes 2013;62:1709-17.
 131. Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS-induced TNF-
alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 2004;23:71-8.
 132. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-
-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005;1754:253-
62.
Chapter 2  |  tarGetinG Monocyte-MacrophaGe lineaGe in transplantation
52
 133. Gosselin J, Flamand L, D’Addario M, et al. Modulatory effects of Epstein-Barr, herpes simplex, 
and human herpes-6 viral infections and coinfections on cytokine synthesis. A comparative 
study. J Immunol 1992;149:181-7.
 134. Castro-Dopico T, Clatworthy MR. Fcγ Receptors in Solid Organ Transplantation. Curr Trans-
plant Rep 2016:1-10.
 135. Kelly C, Jefferies C, Cryan S-A. Targeted Liposomal Drug Delivery to Monocytes and Macro-
phages. J Drug Deliv 2011;2011:11.
 136. Pashover-Schallinger E, Aswad M, Schif-Zuck S, Shapiro H, Singer P, Ariel A. The atypical 
chemokine receptor D6 controls macrophage efferocytosis and cytokine secretion during the 
resolution of inflammation. Faseb J 2012;26:3891-900.
 137. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev 
Immunol 2011;11:723-37.
 138. Zhang C, Wang S, Yang C, Rong R. The Crosstalk between Myeloid Derived Suppressor Cells 
and Immune Cells: To Establish Immune Tolerance in Transplantation. J Immunol Res 
2016;2016:4986797.
 139. Brem-Exner BG, Sattler C, Hutchinson JA, et al. Macrophages driven to a novel state of activa-
tion have anti-inflammatory properties in mice. J Immunol 2008;180:335-49.
 140. Kraaij MD, van der Kooij SW, Reinders ME, et al. Dexamethasone increases ROS production and 
T cell suppressive capacity by anti-inflammatory macrophages. Mol Immunol 2011;49:549-
57.
 141. Conde P, Rodriguez M, van der Touw W, et al. DC-SIGN(+) Macrophages Control the Induction 
of Transplantation Tolerance. Immunity 2015;42:1143-58.
 142. Scalea JR, Tomita Y, Lindholm CR, Burlingham W. Transplantation Tolerance Induction: Cell 
Therapies and Their Mechanisms. Front Immunol 2016;7:87.
 143. Quillard T, Charreau B. Impact of notch signaling on inflammatory responses in cardiovascu-
lar disorders. Int J Mol Sci 2013;14:6863-88.
 144. Zhang Q, Wang C, Liu Z, et al. Notch signal suppresses Toll-like receptor-triggered inflamma-
tory responses in macrophages by inhibiting extracellular signal-regulated kinase 1/2-medi-
ated nuclear factor kappaB activation. J Biol Chem 2012;287:6208-17.
 145. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polar-
ization balance. Front Immunol 2014;5:614.


 3
The Effect of Tacrolimus and Mycophenolic Acid on CD14+ 
Monocyte Activation and Function
Nynke M. Kannegieter1, Dennis a. hesselink1, Marjolein Dieterich1, rens Kraaijeveld1, 
ajda t. rowshani1, pieter J.M. Leenen2, Carla C. Baan1
1 Department of Internal Medicine, Section of Transplantation and Nephrology, Erasmus 
MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
2 Department of Immunology, Erasmus MC, University Medical Center Rotterdam, 
Rotterdam, the Netherlands
PLoS One. 2017;12(1):e0170806.
Chapter 3  |  effect of tacroliMus and Mycophenolic acid on Monocyte functions
56
Abstract
Monocytes and macrophages play key roles in many disease states, including cellular 
and humoral rejection after solid organ transplantation (SOT). To suppress alloimmunity 
after SOT, immunosuppressive drug therapy is necessary. However, little is known about 
the effects of the immunosuppressive drugs tacrolimus and mycophenolic acid (MPA) 
on monocyte activation and function. Here, the effect of these immunosuppressants on 
monocytes was investigated by measuring phosphorylation of three intracellular signal-
ing proteins which all have a major role in monocyte function: p38MAPK, ERK and Akt. 
In addition, biological functions downstream of these signaling pathways were studied, 
including cytokine production, phagocytosis and differentiation into macrophages. To this 
end, blood samples from healthy volunteers were spiked with diverse concentrations of 
tacrolimus and MPA.
Tacrolimus (200 ng/ml) inhibited phosphorylation of p38MAPK by 30% (mean) in CD14+ 
monocytes which was significantly less than in activated CD3+ T cells (max 60%; p < 0.05). 
This immunosuppressive agent also partly inhibited p-Akt (14%). MPA, at a therapeutic 
concentration showed the strongest effect on p-Akt (27% inhibition). p-ERK was inhibited 
with a maximum of 15% after spiking with either tacrolimus or MPA. The production of IL-1β 
and phagocytosis by monocytes were not affected by tacrolimus concentrations, whereas 
MPA did inhibit IL-1β production by 50%. Monocyte/macrophage polarization was shifted 
to an M2-like phenotype in the presence of tacrolimus, while MPA increased the expression 
of M2 surface markers, including CD163 and CD200R, on M1 macrophages.
These results show that tacrolimus and MPA do not strongly affect monocyte function, 
apart from a change in macrophage polarization, to a clinically relevant degree.
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Introduction
Monocytes have numerous biologic functions that make them key players in solid organ 
transplantation (SOT)-related conditions, including ischemia-reperfusion injury and 
its repair, as well as regulation of allograft rejection 1-5. After SOT, cells of the monocyte/
macrophage lineage, process and present alloantigen to the recipients’ immune system, 
induce inflammation and contribute to allograft rejection, through the secretion of pro-
inflammatory cytokines and by providing help to alloreactive T- and B-cells. For example, 
after ischemia and reperfusion injury, monocytes infiltrate the allograft where, after dif-
ferentiation into macrophages, they produce inflammatory cytokines, can present donor 
antigen and also contribute to tissue injury and repair processes 6. Furthermore, immu-
nohistochemistry of acute rejection kidney specimens demonstrated massive infiltration 
of the transplanted organ by CD68+ monocyte/macrophages 3,7. In antibody-mediated 
rejection, monocytes control and induce cell injury via the activation of their Fcγ-receptor 
by allo-antibodies 8,9.
In tissue, monocytes differentiate into different macrophages subsets depending on the 
environmental cues the cells encounter. In general, classically and alternatively activated mac-
rophages, termed M1 and M2 macrophages, respectively, represent the ends of a spectrum and 
can be distinguished by a unique set of cell surface markers 10-12. Typically, M1 macrophages 
have a pro-inflammatory function and secrete large amounts of IL-12 and low levels of IL-10, 
while M2 macrophages can be divided into functionally different subsets. M2a macrophages 
are involved in T-helper type 2 (Th2) immune responses and have pro-fibrotic properties. M2b 
macrophages are considered immunoregulatory because they secrete large amounts of IL-10 
in combination with TNF-α, IL-1 and IL-6 13. Just like the M2a cells, M2b macrophages are also 
involved in Th2 immune responses 14. M2c macrophages are anti-inflammatory and character-
ized by their capacity to produce large amounts of TGF-ß and IL-10 14,15.
Despite their clinical importance, surprisingly little is known about the effects of immunosup-
pressive drugs on monocyte/macrophage differentiation and function. Currently, most kidney 
transplant recipients, as well as the majority of recipients of other solid organ transplants 
receive combination immunosuppressive therapy consisting of tacrolimus and mycophenolic 
acid (MPA; either in the form of mycophenolate mofetil or mycophenolate-sodium) 16-24. In addi-
tion, tacrolimus has also shown to be effective in the treatment of patients with ulcerative colitis 
and atopic dermatitis 25-28 while MPA is used for the treatment of auto-immune disease such as 
systemic lupus erythematosus 29. The limited number of studies on the effect of tacrolimus on 
monocyte functions have been mostly performed in animal models, immortalized cell lines 
and cord blood cells. These studies report that tacrolimus can suppress the production of IL-1β, 
IL-10 and TNF-α by polyclonally activated monocytes 26,30,31.
A limited number of studies report on the effects of MPA on macrophage functions. The 
study by Weimer et al. showed that MPA can suppress the production of IL-1β and IL-6 by 
staphylococcal superantigens activated monocytes, while the effects of MPA on phagocy-
tosis and monocyte differentiation are unknown 32.
Chapter 3  |  effect of tacroliMus and Mycophenolic acid on Monocyte functions
58
Monocyte/macrophage responses to environmental triggers are controlled by the 
activation of multiple intracellular signaling pathways, in which p38 mitogen-activated 
protein kinases (p38MAPK), extracellular signal-regulated kinases (ERK) and Akt play 
important roles (Figure 1) 33-36. Activation of these pathways initiates a complex cascade 
leading to binding of transcription factors to DNA followed by cytokine gene expression 
and production, phagocytosis and other functions. Previous studies in T-lymphocytes 
have demonstrated that tacrolimus does not only inhibit the calcineurin pathway, but also 
affects the MAPK pathway, while the effects of MPA are unknown 37. It is unknown if im-
munosuppressive drugs also inhibit these same pathways in monocytes, and affect related 
biological functions.
Given the important role of monocytes in immune responses after SOT, the effects on 
monocyte function of the two most commonly prescribed immunosuppressive agents, 
tacrolimus and MPA, have been studied. Monocytes have been studied in peripheral blood 
samples of healthy volunteers that were incubated with tacrolimus or MPA and subse-
quently their activation, signal transduction, phenotypic differentiation, phagocytic capac-
ity and cytokine production upon PMA/ionomycin stimulation were investigated.
Figure 1. Simplified overview of intracellular signaling pathways involved in monocyte activation. after 
toll like receptor (tLr) or FC-γ receptor activation the MapK, akt and NFat pathways are activated upstream. 
the phosphorylation of the intracellular signaling proteins leads to the activation of transcription factors, such 
as CreB and NF-ΚB p65, which after activation leads to gene transcription. this process determines the function 
of monocytes including phenotypic differentiation, cytokine production and phagocytosis.
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Materials and Methods
In vitro phosphorylation study and whole-blood phospho-specific flowcytometry
To measure the effect of tacrolimus and MPA on signaling molecules, heparinized blood 
samples were drawn from healthy volunteers (n = 5). The study protocol was approved by 
the local ethics committee of the Erasmus medical center and written informed consent 
was obtained from each individual after receiving detailed information about the aims of 
the study. Samples were incubated for one hour at 37 °C with either vehicle, tacrolimus 
(10, 50 or 200 ng/ml; Prograf ®, Astellas Pharma Inc., Tokyo, Japan), MPA (10 μg/ml; Sigma-
Aldrich, Steinheim, Germany) or the p38MAPK inhibitor SB203580 (20 μM; Invivogen, San 
Diego, CA). The vehicle used was IMDM medium (Gibco BRL, Carlsbad, CA) supplemented 
with 10% heat-inactivated fetal bovine serum (BioWhittaker, Verviers, Belgium). Phos-
phorylation of p38MAPK, ERK and Akt was measured according to the manufacturer’s 
instructions for phosphoprotein analysis (BD Biosciences, San Jose, CA). In brief, 200 μl 
heparinized blood was stained with Brilliant Violet (BV)510-labelled mouse anti-human 
CD3 (Biolegend, San Diego, CA) and Fluorescein Isothiocyanate (FITC)-labelled mouse 
anti-human CD14 (Serotec, Oxford, UK) for 30 minutes at 37˚C. After 15 minutes, blood 
samples were activated with PMA/ionomycin (25 μg per ml/500 μg per ml for p38MAPK 
and Akt; 5 μg per ml/100 μg per ml for ERK, Sigma-Aldrich, Steinheim, Germany) for 15 
minutes. To compare phosphorylation of p38MAPK in CD3+ T-cells and CD14+ monocytes, 
samples were also stimulated for 30 minutes with PMA/ionomycin. Then cells were fixed 
for 10 minutes with Lyse/Fix buffer (BD Biosciences) and permeabilized with 90% methanol 
at -20˚C for 30 minutes. Samples were stained intracellular with fluorchrome conjugated 
mAb phycoerythrin (PE)-labelled mouse anti-p38MAPK (clone pT180/pY182), PE-labelled 
mouse anti-pAkt (clone pS473) or AlexaFluor647 (AF647)-labelled mouse anti-pERK1/2 
(pT202/pY204) (all from BD Biosciences) for 30 minutes at room temperature and analyzed 
on a FACS Canto II flowcytometer (BD Biosciences). Unstimulated samples were used 
as negative controls. Isotype controls; mouse IgG1-PE (p38, Akt Biolegend) and mouse 
IgG1-AF647 (ERK; Biolegend); were included in separated tubes. Interday-variability of the 
flowcytometer was corrected by using Cytocalbeads (Thermo Scientific, Fremont, CA) ac-
cording to the manufacturer’s instructions.
Cytokine production
Heparinized blood samples from healthy volunteers were incubated for 1 hour at 37°C 
with either vehicle, tacrolimus (10 ng/ml and 50 ng/ml), MPA (10 μg/ml) and activated 
with PMA/ionomycin (25 μg per ml/400 μg per ml) for four hours at 37°C. Golgiplug (BD 
Biosciences) was added during the incubation phase to accumulate cytokines intracel-
lularly. Subsequently, EDTA was added for 15 minutes to stop activation. Cells were then 
stained with BV510-labelled mouse anti-human CD3 (Biolegend) and FITC-labelled mouse 
anti-human CD14 (Serotec) for 30 minutes at 37 °C, fixed for 10 minutes with FACS lysing 
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solution (BD Biosciences) and treated with permeabilization buffer II (BD Biosciences) for 
10 min. AF647-labelled anti-IL-1β (detecting the bioactive form of IL-1β, 17.3 kD, clone 
JK1B-1, BD Biosciences) was used for intracellular cytokine staining for 30 minutes at 4°C.
Phagocytosis
To assess phagocytosis by monocytes, whole-blood samples of healthy volunteers were 
incubated for 1 hour at 37°C with either vehicle, tacrolimus (10, 50 and 200 ng/ml) or MPA 
(10 μg/ml). Then 100 µl of spiked blood per sample was tested for phagocytosis according 
to the manufacturer’s instructions of the Phagotest (Glycotope Biotechnology, Heidelberg, 
Germany), which used FITC- labelled E. coli-bacteria.
Macrophage phenotypic differentiation
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples 
by density-gradient centrifugation using Ficoll-paque (GE Healthcare, Uppsala, Sweden). 
Subsequently, monocytes were isolated by MACS magnetic cell separation (Miltenyi Biotec, 
Bergisch Gladbach, Germany) using anti-human CD14 magnetic microbeads (Miltenyi). 
Then, monocytes were cultured in a 12 wells plate at a concentration of 75 x104 cells/ml in 
RPMI 1640 culture medium with glutaMAX and 25 mM HEPES (Gibco, Life technologies, Pais-
ley, UK), supplemented with 10% heat inactivated fetal bovine serum (FBS, BioWhittaker, 
Verviers, Belgium) and M-CSF (macrophage colony-stimulating factor; 5ng/ml, Bioconnect, 
Huissen, the Netherlands). As positive controls, cells were polarized with recombinant hu-
man IFN-γ, IL-10 and IL-4 (all 50 ng/ml, Bioconnect) according to Ambarus et al. 38. Effects of 
immunosuppressive drugs on monocyte differentiation were examined by culturing mono-
cytes in the presence of either vehicle, tacrolimus (10 ng/ml and 50 ng/ml) or MPA (10 μg/
ml). At baseline (day 0) and after 4 days of differentiation, monocytes were tested for their 
polarization profile after incubation on ice for 1 h by using the following markers 38: BV421-
labelled mouse anti-human CD80 (Biolegend), FITC-labelled mouse anti-human CD163 
(Serotec), allophycocyanin (APC)-H7-labelled mouse anti-human CD14 (BD Biosciences), 
BV510-labelled mouse anti-human CD64 (BD Biosciences), PE-Cyanine7 (PE-Cy7)-labelled 
mouse anti-human CD16 (BD Biosciences), peridinin-chlorophyll-protein (PERCP)-labelled 
mouse anti-human CD200R (eBioscience, Vienna, Austria) and APC-labelled rat anti-mouse/
human CD11b (Biolegend). Unstained samples were used as a negative control. Background 
fluorescence levels of isotype controls were used as negative reference.
Data analysis and statistics
The phosphorylation of p38MAPK, Akt and ERK was measured as the Median Fluorescence 
Intensity (MFI) and normalized using Cytocalbeads (Thermo Scientific). MFI values of the 
unstimulated samples were subtracted from the stimulated MFI values. Data and statistical 
analysis was performed with Diva-version 6.0 software (BD Biosciences) and Graph Pad 
Prism 5.0 (Graph Pad Software Inc., La Jolla, CA) by using paired t-tests (for the in vitro 
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phosphorylation study after performing log transformation and after finding a p-value 
>0.05 with an F-test). A two-sided p-value < 0.05 was considered statistically significant.
Results
Inhibitory effect of tacrolimus and MPA in monocyte signaling pathway activation
A typical example of monocytes (CD14+) and T-cells (CD3+) gating strategies is depicted in 
Figure 2A. In line with previous observations, activation of whole blood samples by PMA/
ionomycin significantly increased the expression of phosphorylated p38MAPK in CD3+ T-cells 
compared to the ex vivo (unstimulated) whole blood level and isotype controls 37 (Figures 
2B and 2C). In CD14+ monocytes, an increase in phosphorylation levels after stimulation was 
observed for p38MAPK, ERK and Akt compared to the isotype controls and ex vivo samples 
(Figures 2D and 2E). Again, this increase is in line with previous studies 39-41.
To study the effect of tacrolimus on CD3+ T-cells and CD14+ monocytes, cells were 
incubated with tacrolimus in a dose dependent manner. In this study, T-cell p38MAPK 
phosphorylation levels served as controls. At a high concentration (200 ng/mL), tacrolimus 
inhibited p-p38MAPK in T-cells with a mean of 60%, which was significantly higher than the 
percentage of inhibition in monocytes (30%, p < 0.05) (Figure 3). For the monocytes this 
was not different over time.
Next, the effect of tacrolimus and MPA on the phosphorylation of each signaling protein 
in CD14+ monocytes was measured and compared to the phosphorylation in the samples 
without drugs. The p38MAPK inhibitor SB203580, used as a control, showed the maximal 
inhibitory effect on p38MAPK phosphorylation (inhibition 48%; p < 0.001, Figures 4A and 
4B). Apart from the effect on p38MAPK, SB203580 also suppressed the phosphorylation of 
ERK (mean inhibition 13%; p < 0.05), and Akt (mean inhibition 59%; p < 0.001).
In the presence of high tacrolimus concentrations (50 ng/ml, 200 ng/ml), phospho-
p38MAPK was significantly lower expressed (p < 0.05 and p < 0.01, respectively) than in 
the samples without tacrolimus Figure 4A). This decrease was not seen in the presence 
of a therapeutic tacrolimus concentration (10 ng/ml). The mean maximal p38MAPK phos-
phorylation inhibition in monocytes was 30% and 33% at 50 and 200 ng/ml tacrolimus, 
respectively (Figure 4B). Furthermore, in the presence of 200 ng/ml tacrolimus the PMA/
iono activated phosphorylation of both ERK and Akt were suppressed, although with small 
percentages (mean 7% and 14%, respectively, p < 0.05, Figure 4) On the other hand, MPA 
(10 μg/ml) downregulated p-ERK and p-Akt (mean inhibition 14% and 27%, respectively, p 
< 0.01), but not phospho-p38MAPK (p = 0.51, Figure 4).
Taken together, these experiments demonstrate that tacrolimus at high concentrations 
inhibits phosphorylation of p38MAPK more than Akt and ERK, while at therapeutic con-
centrations, tacrolimus did not affect the activation of these molecules. In addition, MPA 
suppresses the phosphorylation of Akt more than the phosphorylation of ERK or p38MAPK.
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Figure 2. Gating strategy for the selection of monocytes and T-cells, and the measurement of p38MAPK, 
ERK and Akt phosphorylation. (a) Scatter dot plots to define the monocyte population in blood samples from 
healthy controls. Cells were selected in whole blood samples for each healthy control and then gated for their 
expression of either CD3 or CD14. then, CD3+ and CD14+ cells were combined in one dotplot, to make sure that 
there were no double positive cells in the analysis. (B) an example of p38MapK phosphorylation in CD3+ t cells, 
measured as the median fluorescence intensity (MFI) prior to (ex vivo) or after stimulation with pMa/ionomycin 
(in vitro) compared to the isotype control. (C) p38MapK phosphorylation in CD3+ t-cells was increased after stim-
ulation with pMa/ionomycin compared to isotype controls and ex vivo (unstimulated) samples. (D) examples of 
the phosphorylation of p38MapK, akt and erK in CD14+ monocytes of isotype controls, ex vivo (unstimulated) 
and pMa/Ionomycin stimulated (in vitro) samples. (e) phosphorylation (MFI) of p38MapK, akt and erK in CD14+ 
monocytes is increased after pMa/ionomycin stimulation compared to isotype controls and ex vivo samples and 
showed the maximum phosphorylation capacity for each protein. FSC, forward scatter; SSC, side scatter; MFI, 
median fluorescence intensity.(Data are plotted as the mean ±SeM; n=5)
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IL-1β production decreased in the presence of MPA but not after tacrolimus spiking
The percentage of IL-1β-producing cells was studied to determine whether the significant 
alterations in phosphorylation of the MAPK pathway members p38 and ERK by tacrolimus 
has an effect on cytokine production by monocytes. Again, whole blood samples were 
stimulated with PMA/ionomycin after which IL-1β protein expression was measured (Fig-
ure 5A). After stimulation, more than 10% of the monocytes expressed the 17.3 kD form of 
IL-1β, which is the active IL-1β protein (in contrast to the 31kD precursor protein which is 
not biologically active). No significant change in IL-1β protein expression was found when 
blood samples were spiked with tacrolimus at either a therapeutic concentration (10 ng/
ml, p = 0.28) or a concentration of 50 ng/ml or 200 ng/ml (p = 0.36 and p = 6758, respec-
tively) (Figure 5B). A significantly lower percentage of IL-1β-producing cells was found in 
the presence of 10 µg/ml MPA (about 50% inhibition; p < 0.05).
Effects of tacrolimus and MPA on phagocytosis by monocytes
Subsequently, phagocytosis, one of the primary biological functions of monocytes, was 
studied in the presence and absence of immunosuppressive drugs. The percentage of 
monocytes that phagocytized labeled bacteria after incubation at 37°C, was more than 
90% (Figure 6). This percentage was not influenced by tacrolimus at therapeutic (10 ng/
ml, p = 0.44) or high (50 ng/ml, p = 0.29 and 200 ng/ml, p = 0.33) concentrations nor by a 
high concentration of MPA (10 μg/ml, p = 0.45).
Figure 3. p38MAPK phosphorylation is inhibited more in T-cells than in monocytes. Blood samples from 
healthy volunteers were spiked with either vehicle, 10 ng/ml tacrolimus, 50 ng/ml tacrolimus or 200 ng/ml ta-
crolimus. thereafter, the phosphorylation of p38MapK was determined in t-cells and monocytes after 15 or 30 
min. of stimulation with pMa/ionomycin. after 30 min. stimulation, t-cells were significantly more inhibited than 
monocytes. (Data are plotted as the mean ±SeM; n=3) *) p < 0.05; **) p < 0.01; ***) p < 0.001
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Figure 4. Tacrolimus and MPA can inhibit signaling pathway activation in whole-blood samples. (a) phospho-
p38MapK (upper left panel), p-erK (upper right panel) and p-akt (lower panel) phosphorylation in monocytes was 
measured as MFI level. Blood samples from healthy volunteers were spiked with vehicle, 10 ng/ml tacrolimus, 50 
ng/ml tacrolimus, 200 ng/ml tacrolimus, 10 μg/ml Mpa or 20 µM of the MapK inhibitor SB203580. the effect of 
tacrolimus and Mpa was based on the stimulated samples without the addition of drugs. the MapK inhibitor was 
used as a positive control. Gating was performed according to figure 2. tacrolimus was found to have an effect on 
p38MapK, erK and akt phosphorylation. akt and erK phosphorylation was decreased in the presence of Mpa. (B) 
percentages of inhibition for the phosphorylation of p38MapK (upper left panel), erK (upper right panel) and akt 
(lower panel). Data are normalized for the MFI values of the stimulated samples without the addition of immuno-
suppressive drugs (Data are plotted as the mean ±SeM; n = 5) *) p < 0.05; **) p < 0.01; ***) p < 0.001
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Phenotypic macrophage differentiation is influenced by tacrolimus and MPA
After stimulation with M-CSF, freshly isolated monocytes differentiate into M1 or M2 subsets 
when additionally treated with the appropriate triggers (a schematic flow diagram of these 
experiments is given in Supplementary Figure 1A). In line with previously published data, 
M1 macrophages had a higher expression of CD80 and CD64, M2a macrophages had a 
lower expression of CD14 and a higher expression of CD200R, and M2c macrophages had a 
higher expression of CD163 and CD16 on their surface compared to macrophages cultured 
without the addition of cytokines (Supplementary Figure 1B) 38.
Figure 5. IL-1β production by monocytes of healthy controls is suppressed in the presence of MPA but not 
in the presence of tacrolimus. (a) Dot plots showing IL-β production with or without stimulation in monocytes. 
Cells were gated of whole blood samples according to figure 2a. Isotype controls were used as negative controls 
and were used to set the gate for the positive IL-1β expression. results are shown as the percentage of IL-1β 
producing monocytes compared to the isotype control. Samples were stimulated with pMa/ionomycin for maxi-
mum production of IL-1β. (B) Mean percentages of IL-1β producing monocytes after spiking with vehicle, 10 ng/
ml tacrolimus, 50 ng/ml tacrolimus or 10 µg/ml Mpa. Samples were corrected for the unstimulated results and 
then normalized to the samples without drug exposure. IL-1β production in monocytes was significantly sup-
pressed by a concentration of 10 μg/ml Mpa. (Data are plotted as the mean ±SeM; n = 5) *) p < 0.05
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Differentiation of monocytes/macrophages can be divided into two processes: matura-
tion of the monocyte into a macrophage and the subsequent polarization of a macrophage 
into an M1 or M2 type. First, the effect of tacrolimus and MPA on monocyte maturation was 
studied. After maturation of monocytes under M-CSF culture conditions only, the expres-
sion of all six tested markers increased significantly (Figure 7). During maturation, tacroli-
mus (10 ng/ml), but not MPA, slightly increased the expression of CD200R and CD16 (both 
markers for M2 macrophages, p < 0.05 Figure 7), compared to the maturation without the 
presence of immunosuppressive drugs. A high concentration of tacrolimus (50 ng/ml) also 
increased the expression of CD16 (MFI increase: 5692 to 6607 p < 0.05). Second, the polar-
ization of these mature macrophages was determined. The addition of IFN-γ, IL-4 and IL-10 
was used as a positive control for the differentiation assays to compare the polarization 
Figure 6. The percentage of phagocytosis by monocytes from healthy controls was not changed in the 
presence of tacrolimus or MPA. (a) Monocytes were selected from the leukocyte population by a forward and 
side scatter. analysis was based on the phagocytosis of the FItC-labeled bacteria. Incubation with FItC-labeled 
bacteria on 37°C showed a high percentage of phagocytosing monocytes (positive control) compared to mono-
cytes on 0°C (negative control). (B) Mean percentage of phagocytosing monocytes after spiking with either ve-
hicle, 10 ng/ml tacrolimus, 50 ng/ml tacrolimus, 200 ng/ml tacrolimus or 10 µg/ml Mpa. Incubation at 37°C 
increased the percentage of phagocytosing monocytes by more than 90%. effects of tacrolimus and Mpa on 
phagocytosis were determined as the percentage of phagocytosing monocytes compared to the positive control 
without immunosuppressive drugs. (Data are plotted as the mean ±SeM; n=4 )
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of the macrophages after their maturation from monocytes. An increase of CD200R and 
CD16 expression on monocytes was seen after the addition of IL-4 and IL-10 to the culture 
medium, which are both stimuli to induce M2 macrophages (Supplementary Figure 1B). 
Thus, tacrolimus increased the expression of markers for M2 macrophages, while this was 
not seen for MPA.
Next, the influence of tacrolimus and MPA on the polarization of macrophage subsets 
was determined, by measuring the expression of M1- and M2-related surface markers. 
Monocytes were cultured for 4 days in the presence of M-CSF as a maturation stimulus 
supplemented with M1 (IFN-γ), M2a (IL-4), and M2c (IL-10) stimulants and different concen-
trations of tacrolimus or MPA.
 In the presence of IFN-γ, a stimulus for M1, the addition of tacrolimus (50 ng/ml and 
200 ng/ml) led to the increased expression of the M2 marker CD16 (p < 0.01 and p < 0.05, 
respectively) and a lower expression of CD14 (p < 0.05 and p < 0.01, respectively, Figure 8, 
left column). In addition, tacrolimus at a therapeutic concentration (10 ng/ml) also lowered 
CD14 expression (p < 0.05). MPA caused a significant increase of the other two M2 markers, 
CD200R and CD163 (p< 0.05) and, although not significant, seemed to lower the expression 
of the M1 markers CD80 and CD64.
In the presence of the M2a stimulus IL-4, high concentrations of tacrolimus (50 and 200 
ng/ml) increased the expression of CD163, although this difference was small (MFI: from 
3906 to 3958 and 3957, respectively, p < 0.05, Figure 8, middle column). MPA significantly 
decreased the expression of CD80 (M1 marker, p < 0.05).
Figure 7. Monocyte differentiation in the presence of tacrolimus and MPA causes a small shift in macro-
phages subsets. CD14+ monocytes were freshly isolated from whole blood samples of healthy volunteers (n = 5) 
and then cultured for 4 days with either vehicle, 10 ng/ml tacrolimus, 50 ng/ml tacrolimus, 200 ng/ml tacrolimus 
or 10 µg/ml Mpa. the addition of cytokines was used a positive control. Differentiated macrophages were gated 
based on their location on the forward sideward scatter. after 4 days of culturing, the expression of all tested 
surface markers was increased compared to freshly isolated monocytes. the addition of tacrolimus, but not 
Mpa, resulted in an increase of the expression of M2 markers (CD16 and CD200r). (Data are plotted as the mean 
±SeM; n = 5 *) p < 0.05; **) p < 0.01; ***) p < 0.001
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Figure 8. MPA and tacrolimus act differentially on the polarization of M1 and M2 macrophages. CD14+ iso-
lated monocytes were cultured for 4 days in the presence of either M-CSF and IFN-γ (left graphs), M-CSF and IL-4 
(middle graphs) or M-CSF and IL-10 (right graphs). In addition, vehicle, 10 ng/ml tacrolimus, 50 ng/ml tacrolimus, 
200 ng/ml tacrolimus or 10 µg/ml Mpa were added to each culture condition. tacrolimus changed the expres-
sion of M2 markers under a M1-driven condition and decreases the expression of M1 markers under M2 condi-
tions. Mpa reduced the expression of CD80 under a M2 inducing condition and increased M2 expression under 
IFN-γ stimulation. (Data are plotted as the mean ±SeM n = 3 *) p < 0.05; **) p < 0.01; ***) p < 0.001.
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Finally, tacrolimus, but only at a concentration of 200 ng/ml, decreased CD14 and CD80 
expression in the presence of IL-10 (M2c stimulus) (p < 0.05), while MPA decreased CD14 
expression (p < 0.05) and did not affect the other markers (Figure 8, right column). Thus, 
both tacrolimus and MPA increased the expression of M2 markers and decreased the ex-
pression of M1 markers in the presence of different M1 and M2 stimuli.
Discussion
Cells from both the adaptive and innate immune system play an important role in the im-
mune response after SOT but the effects of the immunosuppressants tacrolimus and MPA 
on human monocyte differentiation and functions have not been studied in-depth in previ-
ous studies. This study demonstrates that 1) these drugs partially inhibit phosphorylation 
of signaling molecules involved in CD14+ monocyte activation, i.e., p38MAPK, ERK and Akt 
kinases, but 2) have only limited effects on cytokine production, phagocytosis, phenotypic 
maturation, and polarization (an overview of de results is given in Supplementary Table I).
The inhibitory effect of tacrolimus on the calcineurin pathway and the effect of MPA on the 
reduction of guanosine nucleotide synthesis in T-cells are well-known 19,42. Tacrolimus also 
proved to inhibit p38MAPK phosphorylation in T-cells by more than 60%, which contrasts 
with the inhibition in monocytes 37. As demonstrated here, in monocytes the suppression of 
phosphorylation of intracellular signaling molecules was not more than 35%. Tacrolimus 
partly inhibited p38 phosphorylation, while MPA mainly inhibited Akt phosphorylation, 
although this inhibitory effect was also limited. Furthermore, phagocytosis and differentia-
tion were minimally influenced by tacrolimus and MPA, showing that monocytes could be 
functional in the presence of tacrolimus and MPA. This may imply that cells of the innate 
immune system are less susceptible for the immunosuppressive effects of tacrolimus or 
MPA in comparison to cells of the adaptive immune system. The difference in inhibition 
between the two immune responses could be explained by the working mechanism of the 
immunosuppressive drugs. For example, the main target of tacrolimus is the calcineurin 
pathway and it may be that this pathway plays a more important role in T-cell activation 
than in monocyte activation 43.
The limited effect of tacrolimus on p-ERK, a member of the MAPK pathway, may explain 
the incomplete inhibition of monocyte activity and function as demonstrated in this study 
44. P-ERK is involved in processes leading to IL-10 production (M2 macrophages), while 
phosphorylated p38MAPK is essential for IL-12 production, which is in agreement with the 
observed shift in macrophage polarization 45. These data are in contradiction with the find-
ings reported by Chang et al. who described an inhibitory effect of tacrolimus on p-ERK but 
not on p38MAPK phosphorylation 26. However, in contrast to the present study in which pri-
mary monocytes were investigated, the experiments by Chang et al. were performed with 
LPS-stimulated monocytic leukemia cells (THP-1) and phosphorylation was measured by 
means of Western blot. In the present study, phospho-specific flowcytometry was used to 
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quantify the biological effects of tacrolimus and MPA at the single-monocyte level, which is 
a more sensitive tool for pharmacodynamic monitoring of drug effects 46,47.
In contrast to tacrolimus, MPA (at a therapeutic concentration of 10 μg/ml) did not 
suppress the phosphorylation of p38MAPK, affected p-ERK to some degree, and had the 
largest effect on p-Akt. MPA inhibits inosine monophosphate dehydrogenase, an enzyme 
that is responsible for the de novo synthesis of guanosine nucleotides. As a consequence, 
the proliferation of B and T-cells is inhibited. The only described effect of MPA on monocyte 
function is the reduced production of IL-6 and IL-10, which are both downstream prod-
ucts of the Akt/mTOR pathway 42,48. It has also been reported that IL-1β is a downstream 
molecule of the Akt pathway 49,50. Here we found that MPA indeed partly inhibited IL-1β 
production, suggesting that, in combination with the preferred inhibition of p-Akt, MPA 
affects cytokine production via p-Akt.
The inhibition of signaling molecule phosphorylation by tacrolimus and MPA was smaller 
than by the positive control SB203580, showing the limited effects of both immunosup-
pressive drugs. However, the inhibition of phosphorylated p38MAPK by the positive control 
was also not more than 50%. SB203580 was designed as an inhibitor of the phosphoryla-
tion induced by p38MAPK on other molecules and on its own molecule, but cannot inhibit 
phosphorylation of p38MAPK by other kinases 51. Here, a significantly inhibitory effect of the 
MAPK inhibitor on phosphorylated p38MAPK was found, which can probably be ascribed 
to auto-phosphorylation in monocytes 52-54. This alternative, non-canonical pathway for 
p38MAPK phosphorylation could be another partial explanation for the incomplete inhibi-
tion of monocytes by tacrolimus and MPA, besides the unaffected ERK phosphorylation.
The residual phosphorylation of the signaling molecules after tacrolimus or MPA treat-
ment may imply that monocyte functions, such as phagocytosis, remain intact. After 
SOT, phagocytosis by monocytes/macrophages is one of the mechanisms to overcome 
infections. Here, phagocytosis of E.coli-bacteria by monocytes was not affected by either 
tacrolimus or MPA, suggesting that this monocyte function is still active during immuno-
suppressive drug treatment.
The present study reports for the first time on the change of human macrophage matura-
tion and polarization in the presence of tacrolimus or MPA. Only high concentrations of 
tacrolimus affect the maturation and change the polarization of macrophages to some 
extent. Addition of tacrolimus or MPA did not affect the expression of CD80/CD64 (M1). 
However, tacrolimus did stimulate the expression of CD16 and CD200R (M2). A similar 
change in polarization by tacrolimus was previously found in mouse studies 55. In addition, 
the effect of tacrolimus and MPA on macrophage polarization in the presence of specific 
stimuli was investigated. A shift to an M2 phenotype was noticed when monocytes were 
cultured with tacrolimus or MPA in combination with IFN-γ, a cytokine that induces the 
differentiation of monocytes into M1 macrophages. CD200R and CD163 (M2) expression 
was increased, although the expression in M1 markers did not change. However, in the 
presence of M2-driving cytokines (IL-4 or IL-10) the CD80 marker for M1 macrophages was 
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diminished by tacrolimus, again pointing to induction of M2 differentiation. Altogether, 
these findings suggest that tacrolimus and MPA have a limited effect on the function of 
monocytes by driving their differentiation towards an M2 phenotype.
In order to reveal the clinical relevance of the limited effect of tacrolimus and MPA on 
monocytes, the drug effects should be studied in a clinical setting. The role of monocytes 
in alloreactivity after SOT includes the recognition of non-self antigens during the cellular 
immune response and danger signals (PAMP’s) induced by ischemia-reperfusion injury 
56,57. The humoral immune response includes the activation of Fcγ-receptors on monocytes 
by allo-antibodies 8. This immune response plays an important role in chronic antibody-
mediated rejection which is the main reason for chronic graft loss 58. The residual mono-
cyte activity, a consequence of the limited effect of tacrolimus and MPA treatment, may 
partly explain why chronic antibody-mediated rejection occurs after SOT. Furthermore, our 
previous study on monocytes from kidney transplant patients showed a similarly limited 
functional effect of immunosuppressive drugs on monocytes, suggesting that these cells 
can still play a role in early post-transplant cellular immunity 59. As readout in a new study, 
signaling protein phosphorylation could be measured, thereby relating the results to the 
outcomes of the present paper. Here, we focused on the activation and function of CD14+ 
monocytes, without dividing them into CD16-positive and -negative subsets, which show 
differential responses in an inflammatory setting 60. Future studies can focus on these 
subsets to reveal the effects of immunosuppressive medication on these clinically relevant 
monocyte subsets. In addition, studies in patients can unveil the effect of combination 
therapy on monocyte activation and function, since the present study focused on the indi-
vidual immunosuppressive drug effects. It must also be considered that the role of macro-
phages may be different in different types of organ transplantation. For example, cardiac 
macrophages are involved in tissue remodeling and repair after myocardial infarction, 
while in the lungs their primary role is immune surveillance. In the liver, Kupffer cells are 
involved in the breakdown of erythrocytes and the response to infections, toxins, ischemia 
and other stress conditions 61,62. These cells are involved in allograft rejection and may also 
play an important role in the development of immune tolerance after transplantation, sug-
gesting that (partly) inhibition of these cells with tacrolimus and MPA may will cause nega-
tive effects on graft survival 62. In addition, macrophages are known for their heterogeneity 
and it is possible that the composition of macrophage subsets is different for different 
organs 63,64. For example, the polarization of tissue-resident macrophages is dependent on 
their local environment, suggesting high heterogeneity in macrophage subsets between 
different organs 65. Research is needed to show the functional effects of tacrolimus and 
MPA on these cells. However, each macrophage does have targets for tacrolimus and MPA 
(e.g. calcineurin pathway and inosine monophosphate dehydrogenase) suggesting that 
the difference in sensibility for these drugs between different macrophage subsets at the 
single cell level may be limited.
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In conclusion, tacrolimus and MPA hardly suppress monocyte signaling pathway activa-
tion. The residual phosphorylation of signaling proteins explains the limited effect of both 
immunosuppressive drugs on cytokine production and phagocytosis, apart from mono-
cyte differentiation. This suggests that innate immune responses induced by monocytes 
after SOT may still occur despite immunosuppressive therapy.
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Supplementary Figures and Tables
Supplementary Figure 1. Monocyte differentiation experiments. (a) Schematic overview of the monocyte 
differentiation experiments. For the first part of the differentiation study, monocytes were cultured in the pres-
ence of M-SCF to induce maturation into macrophages. Next, the expression of the surface markers for M1, M2a 
or M2c macrophages was determined after addition of tacrolimus or Mpa to the culture system. In the second 
part of the experiments, monocytes were induced to polarize into a specific macrophage subtype. addition of 
IFN-γ drives the monocytes to polarize into M1 macrophages, IL-4 induces M2a and IL-10 increases M2c macro-
phages. then, tacrolimus and Mpa were added to the cultured cells to determine the capability of both drugs 
to change the expression of surface markers on M1, M2a and M2c differentiated macrophages. (B) Validation of 
the differentiation assay. after addition of IFN-γ to the culture medium, monocytes are stimulated to differenti-
ate into M1 macrophages with a significantly higher expression of the CD80 (p < 0.001) and CD64 (p < 0.001) 
compared to monocytes cultured without the addition of extra cytokines. Culturing with IL-4 increased the ex-
pression of CD200r (p < 0.01), lowered CD14 expression (p < 0.01), and thus drove the differentiation into M2a 
macrophages. IL-10 stimulation induced the expression of CD163 (p < 0.01) and CD16 (p < 0.05) and resulted in 
M2c macrophage differentiation. (Data are plotted as the mean ±SeM; n = 5) *) p < 0.05; **) p < 0.01; ***) p < 0.001
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Supplementary Table I. Overview of the effects of tacrolimus and MPA on monocyte activation and 
function
Tacrolimus MPA Comments
Signaling pathways + + Maximum	of 	30%
Cytokine production - + 50%	inhibition	by	MPA
Phagocytosis - -
Differentiation +/- +/- Change	in	M2	expression	markers,	but	not	all	subset	markers
+) effect; +/-) small effect; -) no effect
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Abstract
Background
 Monocytes significantly contribute to ischemia reperfusion injury and allograft rejection 
after kidney transplantation. However, the knowledge about the effects of immunosup-
pressive drugs on monocyte activation is limited. Conventional pharmacokinetic methods 
for immunosuppressive drug monitoring are not cell type-specific. In this study, phos-
phorylation of three signaling proteins was measured to determine the pharmacodynamic 
effects of immunosuppression on monocyte activation in kidney transplant patients.
Methods
Blood samples from 20 kidney transplant recipients were monitored before and during the 
first year after transplantation. All patients received induction therapy with basiliximab, fol-
lowed by tacrolimus (TAC), mycophenolate mofetil (MMF), and prednisolone maintenance 
therapy. TAC whole-blood pre-dose concentrations were determined using an antibody-
conjugated magnetic immunoassay. Samples were stimulated with PMA/ionomycin 
and phosphorylation of p38MAPK, ERK, and Akt in CD14+ monocytes was quantified by 
phospho-specific flow cytometry.
Results
Phosphorylation of p38MAPK and Akt in monocytes of immunosuppressed recipients was 
lower after 360 days compared with before transplantation in the unstimulated samples 
(mean median fluorescence intensity (MFI) reduction 36%; range -28% to 77% for p-
p38MAPK and 20%; range -22% to 53% for p-Akt; p < 0.05). P-ERK was only decreased at 
day 4 after transplantation (mean inhibition 23%; range -52% to 73%; p < 0.05). At day 4, 
when the highest whole-blood pre-dose TAC concentrations were measured, p-p38MAPK 
and p-Akt, but not p-ERK, correlated inversely with TAC (rs = -0.65; p = 0.01 and rs = -0.58; p 
= 0.03, respectively).
Conclusions
Immunosuppressive drug combination therapy partially inhibits monocyte activation 
pathways after kidney transplantation. This inhibition can be determined by phospho-
specific flow cytometry, which enables the assessment of the pharmacodynamic effects of 
immunosuppressive drugs in a cell-type-specific manner.
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Introduction
Monocytes and macrophages contribute to the immune responses after kidney transplan-
tation, which include tissue repair after ischemia-reperfusion injury, as well as acute cellular 
and antibody-mediated allograft rejection 1-5. After ischemia-reperfusion injury, monocytes 
are activated, in particular via their Toll-like receptor (TLR)-4, and infiltrate the allograft 6,7. 
Directly after transplantation and during acute cellular rejection, recipient monocytes 
migrate to the site of tissue injury at the graft and differentiate into CD68+ macrophages, 
where the presence of these macrophages is associated with graft dysfunction 4,8. Infiltrat-
ing monocytes can differentiate locally into macrophages, which may be polarized into 
pro- or anti-inflammatory phenotypes. These have previously been indicated as M1 and 
M2 macrophages, respectively, and these are now recognized as extremes in a wide func-
tional spectrum 8-10. Macrophages are key players in the initiation of anti-donor responses 
through their antigen-presenting function and production of cytokines. In addition to 
their role in acute cellular rejection, these cells are also involved in antibody-mediated 
rejection. After binding of monocyte Fc-γ receptors to donor allo-antibodies, the signal will 
block apoptosis and cause the accumulation of monocytes at the site of inflammation, 
where they produce pro-inflammatory cytokines 11-14.
Activation of monocytes and macrophages is controlled, among others, by the three 
intracellular signaling molecules p38 Mitogen-Activated Protein Kinase (p38MAPK), Extra-
cellular signal-Regulated Kinases 1 and 2 (ERK1/2), and AKT8 virus oncogene cellular ho-
molog (Akt) 15-20. Phosphorylation of these molecules by upstream kinases in the signaling 
pathway causes them to act on transcription factors. Phosphorylation of the MAPK mem-
bers p38MAPK and ERK will lead to the activation of transcription factors (e.g., NFκB, CREB, 
ATF-1) that regulate the transcription and translation of several genes involved in cytokine 
production (e.g., TNF-α, IL-1β and IL-6). In the end, activation of the MAPK pathway will af-
fect many other monocyte functions, such as phagocytosis and differentiation into distinct 
macrophage activation stages 21-23. Similarly, Akt plays a central role in several pathways 
(PI3K, NFκB, and mTOR) involved in cytokine production, macrophage differentiation, and 
phagocytosis 24-26.
After kidney transplantation, most patients are treated with combination immuno-
suppressive drug therapy consisting of tacrolimus (TAC), mycophenolic acid (MPA), and 
glucocorticoids to prevent allograft rejection 27. The effects of these drugs on alloreactive 
T-cell function have been extensively characterized, but the knowledge of their effect on 
monocytes is limited 5. The few in vitro studies that have been conducted in this respect 
have indicated that TAC and MPA affect cytokine production by monocytes 28,29. Further-
more, TAC did not affect phagocytosis or production of IL-1β in vitro, whereas MPA did 
reduce the production of IL-1β 30.
Given the important role of monocyte/macrophages in the immune responses follow-
ing kidney transplantation, a deeper understanding of the effect of immunosuppressive 
drugs on their activation is important. Furthermore, there is an unmet need for laboratory 
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techniques that can reliably measure such effects to guide clinical immunosuppression. 
The conventional method of therapeutic drug monitoring (TDM) of immunosuppressive 
drugs is pharmacokinetic monitoring by determining the (pre-dose) concentration of these 
drugs in whole blood (in case of TAC) or plasma (in case of MPA). This, however, disregards 
putative differences in individual responsiveness to these agents. Possibly, cell-specific 
and pharmacodynamic monitoring of the effects of immunosuppressive drug therapy on 
monocyte signaling pathway activation may be a superior strategy for TDM 31-34.
To define a new method for monitoring the impact of immunosuppression on monocyte 
activation we monitored and quantified the phosphorylation of p38MAPK, ERK, and Akt by 
phospho-specific flow cytometry, in whole-blood samples of kidney transplant patients 
before and after transplantation during treatment with TAC, MPA, and glucocorticoids.
Materials and Methods
Kidney transplant patients
To determine the effect of immunosuppressive drugs on CD14+ monocyte activation, we 
studied 20 renal transplant patients who were followed during the first 12 months after 
transplantation. The present study was part of a clinical study that was approved by the 
Medical Ethical Committee of the Erasmus MC, University Medical Center (MEC number 
2012-421, EudraCT # 2012-003169-16) 35,36. All participants gave written consent for col-
lecting their blood samples. Patients were treated with 20 mg basiliximab intravenously 
(Simulect®, Novartis, Basel, Switzerland) on the day of transplantation and day 4 after 
transplantation. During the first three post-operative days, prednisolone was administered 
intravenously in a dosage of 100 mg/day. Subsequently, prednisolone was given orally 
in a dose of 20 mg and tapered to 5 mg/day by month 3. Mycophenolate mofetil (MMF; 
Cellcept®; Roche, Basel, Switzerland) was given in a starting dose of 2000 mg/day equally 
divided in two doses, and then adjusted to pre-dose concentrations (target concentration 
range: 1.5-3.0 μg/mL). Patients received TAC (Prograf ®, Astellas Pharma Inc., Tokyo, Japan) 
from the day of transplantation twice a day with a starting dose of 0.2 mg/kg/day. There-
after, TAC was adjusted to pre-dose concentrations: 10-15 ng/mL (week 1-2), 8-12 ng/mL 
(week 3-4), and 5-10 ng/mL (from week 5 onwards). Heparin blood samples were collected 
pre-transplantation and 4 days, 1 month, and 3, 6, and 12 months post-transplantation.
Absolute numbers of CD14+ monocytes were measured with BD multi-test 6-colour in 
BD TruCount Tubes (BD Biosciences, San Jose, CA). TAC whole-blood and MPA plasma 
pre-dose concentrations were determined in EDTA blood using the antibody-conjugated 
magnetic immunoassay on a Dimension Xpand analyzer (Siemens HealthCare Diagnostics 
Inc., Newark, DE) according to the manufacturer’s instructions. The lower and upper limits 
of quantification of TAC were 1.5 and 30 ng/mL and for MPA 0.5 μg/mL and 15 μg/mL, 
respectively. For TAC, the coefficients of variation (CV) were 15.0%, 8.9%, and 11.2% for the 
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low, middle, and high control samples, respectively. For MPA, the CV were 3.9% and 3.7%, 
for the low and high controls, respectively. Proficiency samples were obtained from the UK 
Quality Assessment Scheme (Analytical Services International Ltd, London, UK) and the 
laboratory successfully participates in this international proficiency testing scheme.
Whole-blood phospho-specific flow cytometry
Phosphorylation of p38MAPK, ERK, and Akt was measured in whole-blood samples ac-
cording to the manufacturer’s instructions for phosphoprotein analysis (BD Biosciences; 
CV: 5.6%) and as described previously 37,38. In short, 200 μL heparinized blood was stained 
for 30 minutes at 37ºC with Fluorescein Isothiocyanate (FITC)-labeled mouse anti-human 
CD14 (Serotec, Oxford, UK) and Brilliant Violet (BV) 510-labeled mouse anti-human CD3 
(Biolegend, San Diego, CA). After 15 minutes of staining, PMA/ionomycin (Sigma-Aldrich, 
Steinheim, Germany) was added for 15 minutes to activate the blood cells. Applied final 
concentrations of PMA/ionomycin were 500 ng per mL/5 μg per mL for samples stained 
for p38MAPK and Akt, and 100 ng per mL/1 μg per mL was used for ERK, based on prior 
titration for optimal detection of phosphorylated protein. Thereafter, cells were fixed for 10 
minutes with Lyse/Fix buffer (BD Biosciences). After permeabilization with 90% methanol at 
-20ºC for 30 minutes, intracellular staining was performed with phycoerythrin (PE)-labeled 
mouse anti-p-p38MAPK (clone pT180/pY182), PE-labeled mouse anti-p-Akt (clone pS473), 
or AlexaFluor647 (AF647)-labeled mouse anti-p-ERK1/2 (pT202/pY204) mAB (all from BD 
Biosciences) for 30 minutes at room temperature. Samples were analyzed on a FACS Canto 
II flow cytometer (BD Biosciences). Isotype controls; mouse IgG1-PE (p38MAPK and Akt, 
Biolegend) and mouse IgG1-AF647 (ERK; Biolegend); were included in separate tubes and 
served as negative controls. Interday-variability of the flow cytometer was corrected by 
using Cytocalbeads (Thermo Scientific, Fremont, CA) according to the manufacturer’s 
instructions.
Statistical analysis
The Median Fluorescence Intensity (MFI) was measured for the phosphorylation of p38MAPK, 
ERK, and Akt and data analysis was performed with Diva-version 6.0 software (BD Biosci-
ence). MFI values were normalized using Cytocalbeads (Thermo Scientific). Statistical analy-
sis was performed with Graph Pad Prism 5.0 (Graph Pad Software Inc., La Jolla, CA) by using 
paired and unpaired t-tests (after finding a p-value > 0.05 with the Kolmogorov-Smirnov 
test for normality for the study population). Correlations between drug concentrations and 
phosphorylation were calculated as the Spearman correlation coefficient. Associations 
between phosphorylation levels and covariates were tested by linear regression with IBM 
SPSS statistics software (version 21; IBM Analytics, Chicago, Illinois, USA). Bonferroni cor-
rection was used to correct for multiple testing. A two-sided p-value < 0.05 was considered 
statistically significant, and for the association calculations, a two-sided p value < 0.006 was 
considered statistically significant after Bonferroni correction.
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Results
Patient characteristics
Baseline characteristics of the kidney transplant patients at the time of transplantation 
are shown in Table I. Two patients suffered from an acute T-cell mediated rejection cor-
responding to an overall one-year acute rejection incidence of 10%. The rejections were 
classified as Banff type 1B and 2A and occurred on post-operative days 152 and 10, respec-
Table I: Patient demographics and baseline characteristics
Study population
(n	= 20)
Age	in	years	 55	(21-76)
Male/female 16	(80%)/4	(20%)
Ethnicity
•	 Caucasian 16	(80%)
•	 African 2	(10%)
•	 Asian 2	(10%)
Body	weight	(kg,	mean	and	range) 88.5	(51.4-120.0)
HLA	A	mismatch 1.4	(±	0.5)
HLA	B	mismatch	 1.5	(±	0.5)
HLA	DR	mismatch 1.3	(±	0.4)
Current	PRA	(%)	(mean	and	range) 2.5	(0-17)
Peak	PRA	(%)	(mean	and	range) 4.2	(0-21)
Donor	age	in	years	 51	(22-80)
Living-related/living-unrelated	donor	 5	(25%)/15	(75%)
Cause	of 	end-stage	renal	disease	
•	 Diabetes	mellitus 7	(35%)
•	 Hypertension 5	(25%)
•	 IgA	nephropathy 3	(15%)
•	 Polycystic	kidney	disease 3	(15%)
•	 Obstructive	nephropathy 1	(5%)
•	 Unknown 0	(0%)
•	 Other 1	(5%)
Renal	replacement	therapy	prior	to	transplantation
•	 None	(pre-emptive) 12	(60%)
•	 Hemodialysis 6	(30%)
•	 Peritoneal	dialysis 2	(10%)
Time	on	dialysis	(days)	(mean	and	range) 783	(465-1519)
Continuous variables are presented as means (± SD) or medians (range) and categorical variables as numbers 
(plus percentages), unless otherwise specified.
all patients received their first kidney transplant.
hLa, human leukocyte antigen; pra, panel reactive antibodies (current = pra at time of transplantation, peak = 
historically highest measured pra); SD, standard deviation.
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tively 39,40. Samples from these patients were excluded for further analysis after the rejection 
time point. Absolute monocyte counts before and after transplantation were measured. 
An increase in the absolute monocyte count was measured at day 4 after transplantation 
(mean increase of 224 monocytes/μL whole blood; p < 0.01), which can be due to the 
surgical procedure (Figure 1A and Supplementary Table I). At months 1 and 3, the ab-
solute counts were decreased in comparison to the baseline value (p < 0.01 and p < 0.001, 
respectively), while at months 6 and 12 the monocyte numbers recovered to the baseline 
level. As expected, the TAC pre-dose concentrations were higher at day 4 than at the later 
time points (p < 0.001) with a median concentration of 15.3 ng/mL (9.1 to 28.4) at day 4 vs. 
6.8 ng/mL (4.4 to 13.3) at day 360 (Figure 1B and Supplementary Table I). In contrast to 
TAC, the MPA pre-dose concentrations did not significantly change over time, which reflects 
TDM and the intention to keep MPA exposure constant (Supplementary Table I).
Figure 1. Absolute monocyte numbers and 
TAC pre-dose concentrations before and 
after transplantation. a) absolute mono-
cyte count in patients before and after trans-
plantation measured as the number of CD14+ 
monocytes/μL whole blood. B) taC blood pre-
dose concentrations within the first year after 
transplantation. Data are plotted as box and 
whiskers indicating total range. target ranges 
for both drugs are indicated in light grey in the 
background. (n = 20) *) p < 0.05, **) p < 0.01, ***) 
p < 0.001
Chapter 4  |  pharMacodynaMic MonitorinG of iMMunosuppression in Monocytes
88
Phosphorylation of p38MAPK, ERK, and Akt in kidney transplant patients
To assess the effects of immunosuppression on the potential of monocytes to become 
activated, the phosphorylation levels of p38MAPK, ERK, and Akt were measured in whole-
blood samples from kidney transplant patients either directly or after stimulation with 
PMA/ionomycin. (Supplementary Figure 1A and B)
In the unstimulated samples (directly analyzed in fresh blood), the baseline phosphory-
lation levels of p38MAPK, ERK, and Akt were higher before transplantation than for the 
isotype control (p < 0.001 for all tested proteins) (Figure 2). The phosphorylation level 
of p38MAPK in these samples was significantly lower compared to pre-transplant levels 
at all test days through day 360 (p < 0.01), except at day 90 (Figure 2A). In contrast, the 
Figure 2. Unstimulated phosphorylation of in-
tracellular signaling molecules before and after 
transplantation in CD14+ monocytes. Unstimulated 
phosphorylation of p38MapK (a), erK (B), and akt (C) 
in kidney transplant patients before and within 1 year 
after transplantation compared to isotype controls. 
Within 1 month after transplantation, phosphoryla-
tion of p38MapK, erK, and akt was decreased. after 1 
month, only p-p38MapK and p-akt showed a decrease 
compared to the samples before transplantation. (n = 
20 patients) *) p < 0.05, **) p < 0.01, ***) p < 0.001
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other MAPK member, ERK, showed only an inhibited phosphorylation at day 4 and day 
30 (p < 0.05 and p < 0.001, respectively) and a constant phosphorylation pattern between 
day 90 and day 360 (Figure 2B). The MFI values were comparable with the levels before 
transplantation. The third signaling protein, Akt, showed a decrease in phosphorylation 
levels at all time points compared with baseline (pre-transplantation; p < 0.05) (Figure 2C). 
The strongest reduction was measured at day 30 (p < 0.01).
To determine the effects of immunosuppression on the maximum phosphorylation 
capacity of each tested signaling protein, whole-blood samples were stimulated with PMA/
ionomycin for 15 minutes. In these stimulated whole-blood samples, the baseline phos-
phorylation levels of p38MAPK, ERK, and Akt were higher before transplantation than for the 
Figure 3. PMA/ionomycin-stimulated phosphory-
lation of signaling molecules in CD14+ monocytes 
before and within 1 year after transplantation. 
Blood samples were stimulated with pMa/ionomycin 
to determine the maximum phosphorylation capacity 
for each signaling protein in monocytes. phosphoryla-
tion of p38MapK (a), erK (B), and akt (C) was higher 
compared to the isotype controls. During 1 year after 
transplantation, p-p38MapK and p-akt, but not p-
erK, were decreased, which is in comparison with the 
unstimulated results. (n = 20 patients) *) p < 0.05, **) p 
< 0.01, ***) p < 0.001
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isotype control (Figure 3). Again, phosphorylation of p38MAPK and Akt was decreased after 
transplantation compared to pre-transplant phosphorylation (Figures 3A and 3B), which 
was comparable with the results obtained with the directly measured samples. However, 
p-ERK expression showed only a decrease at day 4 (Figure 3C), which was in contrast to the 
significant decrease observed at both day 4 and day 30 in the unstimulated samples.
One patient, who was diagnosed with acute rejection on day 152, also showed an in-
crease in p-ERK expression over time after stimulation with PMA/ionomycin, while this was 
not seen for the expression of p-p38MAPK or p-Akt (Supplementary Figure 2).
We also calculated the percentage of phosphorylation reduction (Table II). In line with 
the absolute data, the decrease of p-p38MAPK was highest at day 360 (36% (SD ±31%) 
and 34% (SD ±28%) for the unstimulated and PMA/ionomycin stimulated samples, respec-
tively). At the other time points tested, the decrease was 31% at most. Finally, p-Akt was 
reduced, with a maximum of 27%, and showed the smallest decrease at day 90 and 180.
Correlations of monocyte signaling protein phosphorylation with patient treatment and 
demographics
To determine a putative association between phosphorylation for all tested signaling 
proteins and the given immunosuppressive therapy, correlations between immunosup-
pressive drug pre-dose concentrations and MFI levels at day 4 (n = 14) and 360 (n = 19) in 
the unstimulated samples were calculated (Table III). Both p-p38MAPK and p-AKT, but not 
p-ERK, showed an inverse correlation with TAC at day 4 (rs = -0.65; p < 0.05 and rs = -0.58; p 
< 0.05, respectively) (Supplementary Figure 3). At day 360, none of the tested signaling 
proteins was correlated with TAC pre-dose concentrations.
To define whether the demographic parameters were confounding variables in this study, 
linear regression analysis was performed (Supplementary Table II). After correction for 
multiple testing, no association between the demographic characteristics of patients and 
the level of phosphorylation of p38MAPK, ERK, and Akt was found before transplantation 
or 4 and 360 days after transplantation, indicating that these parameters did not confound 
the results (Supplementary Table II).
Table II: Reduction of signaling molecule phosphorylation
%	inhibition	
(mean	±	SD)
p38MAPK ERK Akt
Unstim PMA/iono Unstim PMA/iono Unstim PMA/iono
Day 4 30%	(±26%)	** 24%	(±14%)	** 23%	(±34%)	* 18%	(±25%)	* 16%	(±20%)	* 27%	(±18%)	***
Day 30 24%	(±24%)	** 16%	(±24%)	** 39%	(±22%)	*** 12%	(±37%) 20%	(±17%)	** 21%	(±22%)	*
Day 90 13%	(±49%) 17%	(±31%)	 19%	(±51%) 7%	(±31%) 17%	(±21%)	* 21%	(±18%)	**
Day 180 31%	(±16%)	** 27%	(±27%)	** 16%	(±49%) -5%	(±38%) 13%	(±26%)	* 25%	(±27%)	**
Day 360 36%	(±31%)	** 34%	(±28%)	** 16%	(±61%) -28%	(±60%) 20%	(±23%)	* 27%	(±25%)	**
Unstim) unstimulated samples; PMA/iono) pMa/ionomycin stimulated samples
Significant difference with baseline phosphorylation: *) p < 0.05; **) p < 0.01; ***) p < 0.001
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Discussion
Monocytes and macrophages are crucial cells in the innate immune response and are in-
volved in the adaptive immune response via antigen presentation after kidney transplanta-
tion 3,4. In this pilot study, phospho-specific flow cytometry was used to monitor the effects 
of immunosuppressive drugs on CD14+ monocyte activation by measuring phosphoryla-
tion of three major signaling molecules: p38MAPK, ERK, and Akt.
Phospho-specific flow cytometry is a relatively novel technique useful for studying the 
pharmacodynamic effects of immunosuppressive drug combination therapy in whole-
blood samples of kidney transplant patients at the single-cell level 41-43. In most transplant 
centers, TDM is performed by measuring immunosuppressive drug blood concentrations. 
However, this method is not cell type-specific and does not completely reflect the phar-
macodynamic effects of immunosuppressants on monocytes and other immune cells 44. 
Furthermore, classic, pharmacokinetic TDM of TAC in general is based on pre-dose concen-
trations that have an imperfect correlation with the area under the concentration vs. time 
curve and do not accurately predict acute rejection 45,46.
In recent years, several methods for pharmacodynamic TDM have been investigated, 
including the measurement of calcineurin phosphatase activity, cytokine production, and 
the expression of NFAT-regulated genes 47-50. However, until now these methods have not 
found their way into routine clinical practice, because of poor correlation with clinical out-
comes, controversial data on the correlation with pharmacokinetic parameters, and high 
interindividual variability, respectively 44. Furthermore, these pharmacodynamic assays 
were developed to study the effect on T-cells and it is unknown whether these methods 
can also be used for studying the effect of immunosuppressants on monocytes.
A correlation between reduction of p-p38MAPK levels in T-cells and TAC blood concentra-
tions after kidney transplantation was previously found with phospho-specific flow cytom-
etry 37,51. In the present study, CD14+ monocytes from kidney transplant patients showed 
a decrease in p-p38MAPK and p-Akt with a maximum of 36% and 20%, respectively, as 
compared to pre-transplant levels. These results are in line with previous in vitro findings: 
healthy control blood samples spiked with TAC showed a maximum p-p38MAPK and p-Akt 
inhibition in monocytes of 33% and 14%, respectively 30. In the in vitro study, spiking with 
TAC did not affect the production of IL-1β or the phagocytosis by monocytes. Only a slight 
change in monocyte differentiation toward an M2-like phenotype was measured in the 
Table III: Correlation between signaling molecule phosphorylation (unstimulated) and immuno-
suppressive drug trough blood concentrations at day 4 and day 360 after transplantation
Correlation
p-p38MAPK p-ERK p-Akt
rs p	value rs p	value rs p	value	
day 4 Tacrolimus -0.65 0.012 -0.15 0.615 -0.58 0.030
day 360 Tacrolimus -0.21 0.512 0.20 0.563 -0.10 0.780
rs = Spearman’s rank Correlation Coefficient
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presence of high TAC concentrations 30. In contrast to the reduction of p-p38MAPK and 
p-Akt, phosphorylation of the other MAPK member, ERK, was only significantly reduced 
within the first month after transplantation. The maximum decrease at day 4 and day 30 
was 39%, indicating a stronger reduction of p-ERK than for p-p38MAPK and p-Akt. Of note, 
the expression of p-ERK after stimulation increased with time after transplantation in the 
one patient suffering from an acute rejection, indicating a potential role for this signaling 
molecule in acute rejection.
The decreased phosphorylation found for the signaling molecules indicates that the 
innate immune response of monocytes is not completely inhibited after kidney transplan-
tation. The incomplete inhibition causes a residual monocyte activity that may contribute 
to immune responses after kidney transplantation, such as chronic antibody-mediated 
rejection. The residual monocyte activity is reflected in the retained ability of monocytes 
to produce pro- and anti-inflammatory cytokines after transplantation 52. Moreover, the 
PI3K/Akt pathway is the main regulator of cell survival in human monocytes and decreased 
activation of this pathway is associated with immunological quiescence after kidney 
transplantation 53,54. It has also been suggested that p-Akt inhibition causes impairment in 
IL-10 production and upregulation of p-p38MAPK and p-ERK1/2 after transplantation 16,55. 
Furthermore, MAPK pathways are involved in monocyte adhesion (ERK) and chemotaxis 
(p38MAPK) 56,57. p-ERK controls the differentiation, survival, and homeostasis of monocytes 
when the cells are stimulated with a growth or survival factor, such as M-CSF (macrophage 
colony-stimulating factor), while inhibition of p-ERK causes cell apoptosis 58,59. Altogether, 
this shows that monitoring of signaling pathway activation is important to control mono-
cyte-mediated immune responses after transplantation.
Multiple factors can influence signaling protein phosphorylation, including immuno-
suppressive drugs. TAC showed a significant negative correlation with phosphorylation 
intensity of p38MAPK and Akt, suggesting that the inhibition of p-p38MAPK and p-Akt is TAC 
concentration dependent. However, these correlations were only observed at day 4, when 
TAC pre-dose concentrations were highest, and are in line with the findings of the previous 
in vitro study 30. No other associations were observed between patient demographics and 
signaling protein phosphorylation, indicating that phospho-specific flow cytometry is a 
promising tool to detect TAC effects after transplantation.
These data also indicate that TAC has the most important role in the inhibition of in-
tracellular signaling pathways in monocytes within 4 days after transplantation, while the 
inhibition at later time points may be due to the presence of prednisolone in the blood 
samples. In mouse peritoneal macrophages, the glucocorticoid receptor is involved in the 
inhibition of p-p38MAPK, while p-ERK and p-Akt are not affected by glucocorticoid signal-
ing 60. This suggests that the given prednisolone doses in the present study could only 
inhibit p-p38MAPK. However, the prednisolone blood concentrations were not measured 
in this study, and more research is needed to distinguish between the individual effects of 
glucocorticoids on monocyte intracellular activation pathways.
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The present study provides preliminary data on the use of phospho-specific flow 
cytometry for clinical diagnostics. More research is needed to translate the present 
findings on phosphorylation status into meaningful clinical diagnostics. For example, 
all tested proteins in the present study showed the least percentage of phosphorylation 
inhibition between day 90 and 180 after transplantation, but it is unknown whether this 
will also increase the risk of monocyte-mediated rejection. The technique is ready to be 
used for clinical diagnostics of malignancies in the field of hematology and oncology 61,62. 
However, for daily clinical TDM of immunosuppressive drugs, this technique needs more 
validation to become a standardized procedure. The labor intensity, reproducibility, and 
cost-effectiveness of the technique should be established. However, compared to western 
blotting, phospho-specific flow cytometry is cell specific and a relatively rapid method to 
measure cell signaling pathway activation. For example, the turnaround time of the test 
used in the present study is only 4 hours. The next step would be to study the correlation 
of phosphorylation profiles with pharmacokinetic parameters and to find a threshold of 
phosphorylation that indicates a risk for rejection. In a future prospective study, blood 
samples from kidney transplant patients who might develop rejection should be measured 
and the predictive value of the phosphorylation status of the different molecules in mono-
cytes, p-p38MAPK, p-ERK, and p-Akt, should be assessed. It could also be informative to 
combine phospho-specific flow cytometry with the measurement of intra-lymphocytic or 
tissue TAC concentrations. The latter directly quantifies the TAC concentration in its target 
compartment and therefore possibly relates more closely to efficacy and toxicity. Stud-
ies in intracellular TAC concentrations have hitherto been performed in lymphocytes and 
peripheral blood mononuclear cells, as well as in kidney and liver tissue, but not in purified 
monocytes 63-67. It may also be of interest to combine phospho-specific flow cytometry with 
novel biomarkers such as graft-derived cell-free DNA. Graft-derived cell-free DNA may serve 
as a “liquid biopsy” in transplantation, although this biomarker requires further validation 
and it remains to be determined whether it may aid in improving TDM of TAC and other 
immunosuppressive drugs 68,69.
Conclusion
Phospho-specific flow cytometry is a technique to measure the pharmacodynamic effects 
of immunosuppressive drug therapy on CD14+ monocytes. The use of this technique dem-
onstrated that monocyte activation pathways are only partially inhibited by TAC, MMF, and 
prednisolone combination therapy after kidney transplantation.
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Supplementary Figures and Tables
Supplementary Figure 1. Gating strategy and phosphorylation example of CD14+ monocytes. a) Gating 
strategy for CD14+ monocytes. Nucleated cells were selected from whole blood samples via a FSC/SSC dotplot. 
these cells were then gated based on their CD3 and CD14 expression. events double positive for CD14 and CD3 
were gated out to show pure populations for CD14+ monocytes. B) an example of measured median fluorescence 
intensities in CD14+ monocytes for p-p38MapK, p-erK and p-akt before and after transplantation(unstimulated 
and pMa/ionomycin stimulated) compared to their isotype control measurements. FSC) Forward scatter; SSC) 
sideward scatter.
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Supplementary Table II: Univariate analysis of the association between patient demographic char-
acteristics and signaling protein phosphorylation
	 Predictor
p-p38MAPK p-ERK p-AKT
Univariate
regression
coefficient p	value
Univariate
regression
coefficient p	value
Univariate
regression
coefficient p	value
Age	(years) -0.103 0.726 -0.357 0.210 -0.181 0.535
Gender	(male	vs.	female) -0.323 0.260 0.330 0.249 -0.212 0.467
Ethnicity	(Caucasian	vs.	non-Caucasian) -0.345 0.227 -0.261 0.367 -0.365 0.200
Before	 Renal	replacement	therapy	(no	vs.	yes) -0.075 0.799 -0.428 0.127 -0.308 0.284
Transplantation Cause	of 	ESRD:	diabetes	(no	vs.	yes) 0.030 0.918 -0.428 0.127 -0.152 0.605
Cause	of 	ESRD:	hypertension	(no	vs.	yes) 0.344 0.229 -0.343 0.231 0.317 0.270
Creatinine	Se-GFR	(mL/min) 0.044 0.880 0.131 0.655 0.272 0.348
Creatinine	(μmol/L) -0.084 0.774 -0.386 0.173 -0.305 0.289
	 Age	(years) -0.134 0.649 -0.212 0.466 -0.288 0.318
Gender	(male	vs.	female) -0.287 0.320 -0.030 0.918 -0.400 0.157
Ethnicity	(Caucasian	vs.	non-Caucasian) -0.280 0.332 -0.182 0.533 -0.343 0.230
Renal	replacement	therapy	(yes	vs.	no) 0.012 0.969 -0.476 0.085 -0.030 0.918
Day 4 Cause	of 	ESRD:	diabetes	(no	vs.	yes) 0.100 0.734 -0.467 0.092 -0.054 0.854
Cause	of 	ESRD:	hypertension	(no	vs.	yes) 0.277 0.338 -0.488 0.108 0.138 0.638
Creatinine	Se-GFR	(mL/min) 0.024 0.935 -0.024 0.934 -0.208 0.467
Creatinine	(μmol/L) -0.126 0.667 -0.053 0.858 0.046 0.875
	 Age	(years) 0.205 0.401 -0.015 0.954 0.069 0.784
Gender	(male	vs.	female) -0.081 0.741 -0.027 0.915 0.101 0.691
Ethnicity	(Caucasian	vs.	non-Caucasian) -0.006 0.982 0.261 0.295 0.416 0.086
Renal	replacement	therapy	(yes	vs.	no) -0.132 0.590 -0.170 0.500 -0.134 0.596
Day 360 Cause	of 	ESRD:	diabetes	(no	vs.	yes) -0.077 0.753 0.383 0.117 0.357 0.146
Cause	of 	ESRD:	hypertension	(no	vs.	yes) 0.337 0.158 0.087 0.732 0.011 0.965
Creatinine	Se-GFR	(mL/min) 0.590 0.034 -0.100 0.758 0.129 0.689
Creatinine	(μmol/L) -0.481 0.096 -0.017 0.959 -0.312 0.324
eSrD) end stage renal disease; GFr) Glomerular filtration rate
a two-sided p value < 0.006 was considered statistically significant after Bonferroni correction.
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Abstract
Therapeutic drug monitoring (TDM) of tacrolimus, based on blood concentrations, shows 
an imperfect correlation with the occurrence of rejection. Here, we tested whether mea-
suring NFATc1 amplification, a member of the calcineurin pathway, is suitable for TDM of 
tacrolimus.
NFATc1 amplification was monitored in T cells of kidney transplant recipients who 
received either tacrolimus- (n = 11) or belatacept-based (n = 10) therapy. Individual drug ef-
fects on NFATc1 amplification were studied in vitro, after spiking blood samples of healthy 
volunteers with either tacrolimus, belatacept or mycophenolate mofetil.
At day 30 after transplantation, in tacrolimus-treated patients, NFATc1 amplification was 
inhibited in CD4+ T cells expressing the co-stimulation receptor CD28 (mean inhibition 37%; 
p = 0.01) and in CD8+CD28+ T cells (29% inhibition; p = 0.02), while this was not observed 
in CD8+CD28- T cells or belatacept-treated patients. Tacrolimus pre-dose concentrations of 
these patients correlated inversely with NFATc1 amplification in CD28+ T cells (rs = -0.46; p < 
0.01). In vitro experiments revealed that 50 ng/ml tacrolimus affected NFATc1 amplification 
by 58% (mean; p = 0.02).
In conclusion, measuring NFATc1 amplification is a direct tool for monitoring biological 
effects of tacrolimus on T cells in whole blood samples of kidney transplant recipients. This 
technique has potential that requires further development before it can be applied in daily 
practice.
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Introduction
Therapeutic drug monitoring (TDM) is routinely used to optimize tacrolimus (TAC) dosing 
after organ transplantation 1-3. Traditionally, the TAC dose is adjusted based on whole 
blood pre-dose concentrations (C0), that have an imperfect relationship with the occur-
rence of acute rejection and adverse events, such as nephrotoxicity and infection 4-10. A 
promising strategy to overcome the limitations of traditional pharmacokinetic TDM may 
be to measure the biological effects of immunosuppressive drugs (pharmacodynamics).
The primary biological target of TAC in T cells is the calcineurin pathway, of which the 
nuclear factor of activated T cells (NFAT) is one of the most important signaling proteins 11. 
The NFAT family consists of 5 members: NFATc1 (NFAT-2), NFATc2 (NFAT-1), NFATc3 (NFAT-4), 
NFATc4 (NFAT-3) and TonEBP (NFAT-5) 12. NFAT molecules are key players in the immune 
response after transplantation and are involved in T cell development, activation, differen-
tiation, as well as in the production of cytokines like interleukin (IL)-2 11,13,14.
 Activation of the NFAT family member NFATc1 is initiated when both the T cell receptor 
(TCR) and co-stimulatory molecules, such as CD28, become activated (Figure 1). Upon 
activation, the phosphatase calcineurin is triggered, which then dephosphorylates NFATc1. 
In turn, dephosphorylated NFATc1 is translocated to the nucleus where it interacts with 
other transcription factors, such as AP-1, and induces gene transcription.
In contrast to other members of the NFAT family that are mainly known for their role 
in cytokine production, NFATc1 is also known for its strongly inducible isoform NFATc1/A. 
NFATc1/A is the only NFAT member that can be enhanced upon antigenic stimulation and 
maintained by positive autoregulation in T cells (Figure 1) 11,15-19. The calcineurin inhibitor 
(CNI) cyclosporine A is known to inhibit both the dephosphorylation of NFATc1 and the 
upregulation of NFATc1/A, but the effect of tacrolimus on NFATc1/A amplification is still 
unknown 20.
At present, clinically applicable pharmacodynamic assays to monitor the biological 
effect of TAC are in development, of which the NFAT regulate IL-2 gene expression is the 
most promising. It was recognized that measuring NFAT-regulated genes might be a good 
method to assess the risk of opportunistic infections, malignancy and acute rejection after 
transplantation 21-24. However, NFAT-regulated genes, such as IL-2, IFN-γ and GM-CSF are 
activated downstream in the calcineurin pathway. Subsequently, the activation of these 
genes can be influenced by other immunosuppressive drugs, such as glucocorticoids, 
and influenced by other signaling pathways, such as the JAK-STAT signaling pathway 25,26. 
Moreover, the measuring of NFAT-regulated gene expression is a non-validated tool to 
monitor the immunosuppressive effects in tacrolimus-treated patients. A better way for 
monitoring the direct biological effects of tacrolimus might be the measurement of the 
immunosuppressive effect on NFATc1 amplification. Flow cytometry offers the opportunity 
to quantify the amplification of NFATc1/A at the single cell level with a short turnaround 
time when blood samples were spiked with cyclosporine A 20. This technique enables the 
measurement of the immunosuppressive drug effects on the calcineurin pathway directly 
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rather than measuring the end-products of this pathway, such as IL-2. Here, the applicabil-
ity of the NFATc1 amplification assay is tested for the first time in whole-blood samples 
of TAC-treated kidney transplant recipients and we explored whether this method can 
be translated to daily clinical practice and can be an additional tool for monitoring the 
effects of TAC in different T cell subsets. Kidney transplant recipients, receiving a belata-
cept (BELA)-based maintenance therapy, served as a CNI-free control group, since BELA 
cannot directly inhibit the calcineurin/NFAT and other signaling pathways in T cells 27,28. 
In addition, NFATc1 amplification was also measured in different T cells subsets, i.e. CD4+ 
T cells, CD8+ T cells, CD28+ T cells, that need the expression of CD28 for co-stimulation 
and activation, and in the antigen experienced, potentially harmful, CD28- T cells 29,30. Here, 
the difference between these cell subsets was measured to assess their susceptibility for 
immunosuppressive drug therapy.
Material and Methods
Kidney transplant recipients
Peripheral blood samples of 21 kidney transplant recipients were analyzed for the expres-
sion of NFATc1 in T cell subsets. The current study is a substudy of a prospective, random-
ized, clinical trial of which the results were published previously 31. The study was approved 
by the Medical Ethical Committee of the Erasmus MC, University Medical Center (MEC num-
ber 2012-421, EudraCT # 2012-003269-16, registered October 17th 2013) and samples were 
collected according to the biobank protocol that was also approved by the local ethics 
committee (MEC-2010-022). The work was performed in accordance with the Declaration of 
Helsinki. All patients gave written informed consent before the start of the study.
For this study, 21 of the total of 40 kidney transplant recipients that were randomized in 
the trial were included, since these patients were also analyzed for their NFATc1 expres-
sion before transplantation 31. Of these, 11 patients received TAC-based and 10 patients 
received belatacept (BELA)-based immunosuppressive treatment. Samples from patients 
treated with BELA, that blocks the co-stimulatory CD80/86-CD28 pathway, were used as 
a control, because of the indirect effect of BELA on intracellular signaling pathways in T 
cells. Patients received a TAC starting dose (Prograf ®, Astellas Pharma Inc., Tokyo, Japan) 
based on bodyweight (0.2 mg/kg/day) in two equally divided doses starting on the day of 
transplantation. Thereafter, the TAC dose was adjusted according to whole-blood pre-dose 
concentrations: 10-15 ng/mL (week 1-2), 8-12 ng/mL (week 3-4), and 5-10 ng/mL (from 
week 5 onwards). BELA (Nulojix®, Bristol-Myers Squibb, New York, USA) was given accord-
ing to the less intensive regimen 32: a dose of 10 mg/kg administered intravenously on day 
0, 4, 15, 30, 60 and 90 after transplantation and then a reduced dose of 5 mg/kg as monthly 
intravenous infusions. All patients received an additional treatment consisting of mycophe-
nolate mofetil (MMF; Cellcept®; Roche, Basel, Switzerland), prednisolone and basiliximab 
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induction therapy (Simulect®, Novartis, Basel, Switzerland). MMF was administered at a 
starting dose of 1000 mg twice a day and then adjusted to pre-dose plasma concentrations 
between 1.5 and 3.0 mg/L. During the first three post-operative days, all patients received 
prednisolone intravenously in a dose of 100 mg/day. Thereafter, prednisolone was given 
orally in a dose of 20 mg/day and tapered to 5 mg/day by month 3 after transplantation. 
Basiliximab (20 mg) was given intravenously at day 0 and day 4 after transplantation.
Blood samples and tacrolimus pre-dose concentrations
To measure the expression of NFATc1, blood samples were collected in heparin tubes (BD 
Biosciences, San Jose, CA) by venipuncture at days 0 (pre-transplantation), 4, 30, 90, 180 
and 360 after transplantation and before anti-rejection therapy was started (in the case of 
an (suspected) acute rejection). Samples were stored at room temperature on a tube-roller 
and prepared within 2 hours after venipuncture. TAC whole-blood pre-dose concentrations 
and mycophenolic acid (MPA) plasma pre-dose concentrations were measured in EDTA 
blood at the same time points by use of the antibody-conjugated magnetic immunoassay 
on a Dimension Xpand analyzer (Siemens HealthCare Diagnostics Inc., Newark, DE) accord-
ing to the manufacturer’s instructions. The lower and upper limit of TAC detection were 1.5 
and 30 ng/mL, respectively, and the coefficient of variation was 15.0%, 8.9% and 11.2% 
for the low, middle and high control samples, respectively. For MPA, the lower and upper 
limits of detection were 0.5 μg/ml and 15 μg/ml, respectively, and the coefficient of varia-
tion was 3.9% and 3.7%, for the low and high controls, respectively. Proficiency samples 
were obtained from the UK Quality Assessment Scheme (Analytical Services International 
Ltd, London, UK). Our laboratory successfully participates in the international proficiency 
testing program.
Whole-blood intracellular staining for NFATc1
Heparinized blood samples were stimulated within 2 hours after blood collection with a 
final concentration of 0.5 μg/ml phorbol myristate acetate (PMA) and 10 μg/ml ionomycin 
for four hours at 37 °C and in the presence of Golgiplug (BD Biosciences) to maximize the 
expression of NFATc1 and to induce NFATc1 amplification intracellularly 20. Thereafter, 100 
μl 20 mM EDTA was added to remove adherent cells from the activation tube and incu-
bated for 15 minutes at room temperature. Samples were then stained with fluorescein 
isothiocyanate (FITC)-labeled mouse anti-human CD14 (clone UCHM1, Serotec, Oxford, 
UK), brilliant violet (BV) 510-labeled mouse anti-human CD3 (clone OKT3, Biolegend, San 
Diego, CA), peridinin chlorophyll (PERCP)-labeled mouse anti-human CD4 (clone SK3, 
BD Biosciences), allophycocyanin (APC)-Cy7-labeled mouse anti-human CD8 (clone SK1, 
Biolegend) and BV421-labeled mouse anti-human CD28 (clone CD28.2, BD Biosciences) 
for 30 minutes at room temperature. Subsequently, samples were lysed and fixed twice for 
10 minutes with FACS lysing solution (BD Biosciences) and treated with permeabilization 
buffer II (BD Biosciences) for 10 minutes at room temperature. Phycoerythrin (PE)-labeled 
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mouse anti-human NFATc1 (clone 7A6; Biolegend) was then added and incubated for 
30 minutes on ice to determine the intracellular expression of NFATc1 in T cell subsets. 
Samples were analyzed on a FACS Canto II flow cytometer (BD Biosciences). Unstimulated 
samples were used to calculate NFATc1 amplification. An isotype control, mouse IgG1-PE, 
was included in a separate tube to see the background effect of antibodies binding on the 
NFAT molecule. Cytocalbeads (Thermo Scientific, Fremont, CA) were used to correct for 
interday-variability of the flow cytometer according to the manufacturer’s instructions. The 
conditions and concentrations used in this assay were established after optimization of the 
intracellular staining protocol in our lab.
In vitro experiments
To measure the effect of the individual immunosuppressive drugs on NFATc1 amplifica-
tion in T cell subsets, heparinized blood samples were drawn from healthy volunteers (n 
= 5). Samples were incubated for 16 hours overnight at 37 °C with either vehicle (ethanol 
dissolved 1:8000 in distilled water), TAC (10 or 50 ng/ml), MPA (10 μg/ml; Sigma-Aldrich, 
Steinheim, Germany), prednisolone (100 ng/ml) or BELA (5 μg/ml), to be sure that the 
samples are well mixed with the immunosuppressive drug concentrations. Thereafter, 
samples were treated in the same way as the blood-samples of kidney transplant patients 
and stimulated for 4 hours with PMA/ionomycin at 37 °C. After incubation, expression of 
NFATc1 was measured according to the protocol described in section 2.3.
Statistical analysis
The median fluorescence intensity (MFI) of NFATc1 was measured and data-analysis was 
performed with Diva-version 6.0 software (BD Bioscience). MFI values were normalized us-
ing Cytocalbeads (Thermo Scientific). To calculate the total amplification of the inducible 
NFATc1/A isoform, samples were further analyzed by correcting the stimulated total expres-
sion of NFATc1 (both phosphorylated and dephosphorylated) for the MFI value in unstimu-
lated samples (also both phosphorylated and dephosphorylated). Statistical analysis was 
performed with Graph Pad Prism 5.0 (Graph Pad Software Inc., La Jolla, CA) by using paired 
and unpaired t-tests (after finding a p-value > 0.05 with the Kolmogorov-Smirnov test for 
normality of the study population). Correlations between drug concentrations and the 
expression of NFATc1 were calculated as the Spearman correlation coefficient. A two-sided 
p-value < 0.05 was considered statistically significant.
Results
Patient demographics and clinical outcomes
Supplementary Table I summarizes patient baseline characteristics, the incidence of 
rejection, and the medication of both TAC- and BELA-treated patients. In brief, the two 
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study populations did not differ in their baseline characteristics. The incidence of rejection 
was lower in the TAC-treated group than in the BELA-treated group (1 out of 11 TAC-treated 
patients versus 7 out of 10 BELA-treated patients, respectively) 31,33. In the current study, 
patients were censored from the moment of rejection onwards, since the expression of 
NFATc1 might be influenced by the anti-rejection therapy. Prednisolone doses were not 
significantly different between the two study groups, but the MPA pre-dose plasma concen-
trations were significantly lower in the TAC-treated group than in the BELA-treated group 
(p = 0.04). Further details regarding the clinical outcomes were published previously 31,33.
NFATc1 amplification in T cell subsets
The effects of immunosuppressive drug therapy were determined in CD4+CD28+, CD8+CD28+ 
and CD8+CD28- T cells. Upon stimulation, the expression of NFATc1 (expressed as MFI) 
increased compared to the unstimulated samples (Figures 2B and 3). After activation, 
no difference in the expression level of NFATc1 was found between healthy controls and 
patients before transplantation (Figure 3). Figure 2A shows the gating strategy for NFATc1 
expression in CD3+ T cells.
Before transplantation, the highest amplification of NFATc1 was found in CD4+CD28+ T 
cells, compared to CD8+CD28+ and CD8+CD28- T cells (Figure 4A). After transplantation, in 
patients receiving TAC-based therapy, NFATc1 amplification was inhibited at day 30, 180 
and day 360 in CD4+CD28+ T cells (mean inhibition of 37%, 24% and 28%; p = 0.01, p = 0.03 
and p = 0.03, respectively; Figure 4B). In comparison to pre-transplantation, CD8+CD28+ T 
cells show a lower amplification of NFATc1 at day 30 and 360 after transplantation (mean 
inhibition of 29% and 15%; p = 0.02 and p = 0.03, respectively; Figure 4C). In contrast, no 
effect of TAC-based therapy was observed in CD8+CD28- T cells (Figure 4D). T cell subsets 
of BELA-treated patients were also not affected by the immunosuppressive drug therapy 
(Figures 4B-4D). However, as depicted in Figures 4B-4D, a wide range of NFATc1 expres-
sion was observed due to the small number of patients on belatacept treatment at day 180 
and onwards.
Correlation with TAC pre-dose concentrations
To determine whether TAC pre-dose concentrations correlated with the inhibition of 
NFATc1 amplification, correlations were calculated over time. For these calculations only 
samples from TAC-treated patients were included that were taken at each tested time 
point: day 0, 4, 30, 90, 180 and 360 (n = 7). Inverse correlations were found between TAC 
pre-dose concentrations and NFATc1 amplification in both CD4+CD28+ (rs = -0.463; p < 0.01) 
and CD8+CD28+ (rs= -0.464; p < 0.01) T cells, but not in CD8+CD28- T cells (Figure 5A). No 
correlations were found between MPA pre-dose concentrations in TAC-treated patients 
and NFATc1 amplification for all three T cell subsets (Figure 5B).
113
Chapter 5  |  effect of tacroliMus on nfatc1 aMplification
Ch
ap
te
r 5
Fi
gu
re
 2
. G
at
in
g 
st
ra
te
gy
 fo
r t
he
 to
ta
l N
FA
Tc
1 
ex
pr
es
si
on
 in
 T
 ce
ll 
su
bs
et
s.
 (a
) G
at
in
g 
of
 C
D3
+  t
 ce
ll 
su
bs
et
s.
 C
el
ls
 w
er
e 
ga
te
d 
fo
r t
he
ir 
ex
pr
es
si
on
 o
f C
D1
4 
an
d 
CD
3,
 w
he
re
 
aft
er
 C
D3
+ C
D1
4-
 t
 ce
lls
 w
er
e 
ga
te
d 
fo
r t
he
ir 
ex
pr
es
si
on
 o
f C
D4
 o
r C
D8
. W
ith
in
 th
es
e 
po
pu
la
tio
ns
, t
he
 e
xp
re
ss
io
n 
of
 C
D2
8 
w
as
 d
et
er
m
in
ed
 to
 id
en
tif
y 
th
e 
CD
4+
CD
28
+ , 
CD
8+
CD
28
+  
an
d 
CD
8+
CD
28
-  t
 c
el
l s
ub
se
ts
. B
) e
xa
m
pl
e 
of
 th
e 
to
ta
l N
Fa
tc
1 
ex
pr
es
si
on
 in
 C
D3
+ C
D1
4-
 c
el
ls
, e
ith
er
 u
ns
tim
ul
at
ed
 o
r s
tim
ul
at
ed
 w
ith
 p
M
a/
io
no
m
yc
in
. F
SC
) F
or
w
ar
d 
sc
at
te
r; 
SS
C)
 si
de
w
ar
d 
sc
at
te
r
Chapter 5  |  effect of tacroliMus on nfatc1 aMplification
114
Fi
gu
re
 3
. N
FA
Tc
1 
ex
pr
es
si
on
 (M
FI
) i
n 
th
e 
to
ta
l s
tu
dy
 p
op
ul
at
io
n 
of
 T
AC
-t
re
at
ed
 p
at
ie
nt
s.
 U
ns
tim
ul
at
ed
 (g
re
y)
 a
nd
 p
M
a/
io
no
m
yc
in
 st
im
ul
at
ed
 (w
hi
te
) b
lo
od
 sa
m
pl
es
 w
er
e 
st
ai
ne
d 
fo
r t
he
 e
xp
re
ss
io
n 
of
 N
Fa
tc
1 
in
 C
D3
+  (
up
pe
r l
eft
 g
ra
ph
), 
CD
4+
 (u
pp
er
 m
id
dl
e 
gr
ap
h)
, C
D8
+  (
up
pe
r r
ig
ht
 g
ra
ph
), 
CD
4+
CD
28
+  (
lo
w
er
 le
ft 
gr
ap
h)
, C
D8
+ C
D2
8+
 (l
ow
er
 m
id
dl
e 
gr
ap
h)
 a
nd
 C
D8
+ C
D2
8-
 (l
ow
er
 ri
gh
t g
ra
ph
) t
 ce
lls
. D
at
a 
ar
e 
pl
ot
te
d 
as
 b
ox
 a
nd
 w
hi
sk
er
s (
tu
ke
y 
st
yl
e)
; n
 =
 2
3 
is
ot
yp
e 
co
nt
ro
ls
, n
 =
 1
0 
he
al
th
y 
co
nt
ro
ls
, n
 =
 1
1 
ta
C 
pa
tie
nt
s b
ef
or
e 
tr
an
sp
la
nt
at
io
n;
 *)
 p
 <
 0
.0
5,
 **
) p
 <
 0
.0
1,
 **
*)
 p
 <
 0
.0
01
115
Chapter 5  |  effect of tacroliMus on nfatc1 aMplification
Ch
ap
te
r 5
Fi
gu
re
 4
. I
m
m
un
os
up
pr
es
si
ve
 d
ru
g 
th
er
ap
y 
eff
ec
ts
 o
n 
NF
AT
c1
 a
m
pl
ifi
ca
tio
n 
in
 T
 ce
ll 
su
bs
et
s.
 (a
) N
Fa
tc
1 
am
pl
ifi
ca
tio
n 
in
 C
D4
+ C
D2
8+
, C
D8
+ C
D2
8+
 a
nd
 C
D8
+ C
D2
8-
 t
 c
el
ls
, 
be
fo
re
 tr
an
sp
la
nt
at
io
n.
 (n
 =
 2
1 
ki
dn
ey
 tr
an
sp
la
nt
 p
at
ie
nt
s)
 (B
, C
, D
) I
nh
ib
iti
on
 o
f N
Fa
tc
1 
am
pl
ifi
ca
tio
n 
(M
FI
) a
fte
r a
 t
aC
-(g
re
y)
 o
r B
eL
a-
(w
hi
te
) b
as
ed
 th
er
ap
y.
 D
el
ta
 N
Fa
tc
1 
ex
pr
es
si
on
 (a
m
pl
ifi
ca
tio
n)
 w
as
 d
et
er
m
in
ed
 a
t d
iff
er
en
t t
im
e 
po
in
ts
 a
fte
r t
ra
ns
pl
an
ta
tio
n 
an
d 
co
m
pa
re
d 
to
 th
e 
sa
m
pl
es
 b
ef
or
e 
tr
an
sp
la
nt
at
io
n 
in
 C
D4
+ C
D2
8+
 (B
), 
CD
8+
CD
28
+  
(C
) a
nd
 C
D8
+ C
D2
8-
 t
 c
el
ls
 (D
). 
th
e 
nu
m
be
r o
f p
at
ie
nt
s 
th
at
 w
er
e 
m
ea
su
re
d 
at
 e
ac
h 
tim
e 
po
in
t i
s 
sh
ow
n 
on
 th
e 
x-
ax
is
 in
 p
ar
en
th
es
es
. n
 =
 1
1 
ta
C-
tr
ea
te
d 
pa
tie
nt
s 
an
d 
n 
= 
10
 
Be
La
-t
re
at
ed
 p
at
ie
nt
s a
t d
ay
 0
. D
at
a 
ar
e 
pl
ot
te
d 
as
 b
ox
 a
nd
 w
hi
sk
er
s (
tu
ke
y 
st
yl
e)
; *
) p
 <
 0
.0
5,
 **
) p
 <
 0
.0
1 
co
m
pa
re
d 
to
 d
ay
 0
.
Chapter 5  |  effect of tacroliMus on nfatc1 aMplification
116
Fi
gu
re
 5
. S
pe
ar
m
an
 c
or
re
la
tio
ns
 o
f N
FA
Tc
1 
am
pl
ifi
ca
tio
n 
w
ith
 T
AC
 o
r M
PA
 p
re
-d
os
e 
co
nc
en
tr
at
io
ns
. (
a)
 N
Fa
tc
1 
am
pl
ifi
ca
tio
n 
in
ve
rs
el
y 
co
rr
el
at
ed
 w
ith
 t
aC
 p
re
-d
os
e 
co
nc
en
tr
at
io
ns
 in
 ti
m
e.
 t
he
 co
rr
el
at
io
n 
w
as
 o
nl
y 
se
en
 in
 C
D4
+ C
D2
8+
 (l
eft
 g
ra
ph
) a
nd
 C
D8
+ C
D2
8+
 ce
lls
 (m
id
dl
e 
gr
ap
h)
 a
nd
 n
ot
 in
 C
D8
+ C
D2
8-
 ce
lls
 (r
ig
ht
 g
ra
ph
). 
(B
) M
pa
 p
re
-d
os
e 
co
nc
en
tr
at
io
ns
 w
er
e 
no
t c
or
re
la
te
d 
to
 N
Fa
tc
1 
am
pl
ifi
ca
tio
n 
le
ve
ls
 in
 C
D4
+ C
D2
8+
 (l
eft
 g
ra
ph
) a
nd
 C
D8
+ C
D2
8+
 c
el
ls
 (m
id
dl
e 
gr
ap
h)
 n
or
 in
 C
D8
+ C
D2
8-
 c
el
ls
 (r
ig
ht
 g
ra
ph
). 
ta
C-
tr
ea
te
d 
pa
tie
nt
s w
er
e 
in
cl
ud
ed
 fo
r t
hi
s a
na
ly
si
s w
he
n 
bl
oo
d 
sa
m
pl
es
 w
er
e 
an
al
yz
ed
 fo
r N
Fa
tc
1 
am
pl
ifi
ca
tio
n 
at
 a
ll 
tim
e 
po
in
ts
: b
ef
or
e 
tr
an
sp
la
nt
at
io
n 
an
d 
da
y 
4,
 3
0,
 9
0,
 1
80
 
an
d 
36
0 
aft
er
 tr
an
sp
la
nt
at
io
n.
 n
 =
 7
; r
s,
 sp
ea
rm
an
 co
rr
el
at
io
n 
co
eff
ic
ie
nt
.
117
Chapter 5  |  effect of tacroliMus on nfatc1 aMplification
Ch
ap
te
r 5
Immunosuppressive drug effect on NFATc1 amplification: In vitro study
Next, the individual immunosuppressive drug effects on NFATc1 expression were deter-
mined in blood samples of healthy controls to define whether TAC was the responsible 
drug for the observed effects on NFATc1 amplification in the studied patient samples (who 
used a combination of immunosuppressive drugs). At a concentration of 10 ng/ml TAC, a 
small, non-significant decrease in NFATc1 expression was noted in CD4+CD28+, CD8+CD28+ 
and CD8+CD28- T cells (Figure 6). However, at a concentration of 50 ng/ml, TAC decreased 
NFATc1 expression (58%, 58% and 60% for the three T cell subsets; p = 0.02, p = 0.02 and 
p= 0.04, respectively), which is in contrast with the patient experiments which showed only 
an effect of TAC-based therapy on CD28+ T cells. MPA, prednisolone or the negative control 
BELA did not inhibit NFATc1 (Figure 6).
Discussion
TDM after transplantation is necessary to avoid problems with the small therapeutic win-
dow of TAC. To date, measuring whole-blood TAC concentrations is the method of choice 
for TDM in most clinics 2. However, these (pharmacokinetic) measurements are not ideal, 
due to their poor correlation with clinical outcomes, such as acute rejection 6. An additional 
pharmacodynamic tool for TDM is needed that measures the biological effects of TAC on 
its direct targets, such as the calcineurin pathway member NFAT. Up until now, no clini-
cally applicable pharmacodynamic assay is available to monitor the direct effect of TAC on 
NFAT expression after kidney transplantation, although several studies have attempted to 
develop such an assay that measures NFAT-regulated genes 34. For example, Maguire et al. 
studied the relation between TAC pre-dose concentrations and the translocation of NFAT 
to the nucleus 35. Other studies have tried to correlate TAC pre-dose or spiked concentra-
tions to the expression of NFAT-related genes 36-38.
This study shows that the amplification of total NFATc1 expression, measured in whole 
blood samples by means of intracellular staining, is related to the pre-dose concentration 
of TAC after transplantation. Upon stimulation of blood samples with PMA/ionomycin for 
4 hours, only the amplification of the inducible NFAT isoform, NFATc1/A, was enhanced, 
which is consistent with previous studies 20,39. Under TAC-based therapy, both CD4+CD28+ 
and CD8+CD28+ T cells, which express the CD28 molecule (needed for co-stimulation and 
proliferation), showed an inhibition of NFATc1 amplification. This was not the case when 
patients were treated with BELA-based therapy, indicating that TAC is responsible for the 
reduced NFATc1 amplification. Furthermore, the correlation between TAC pre-dose con-
centrations and the magnitude of NFATc1 amplification indicates that TAC is an important 
factor for the decreased NFATc1 amplification in kidney transplant recipients. These results 
are in line with the previous findings of the in vitro study by Brandt et al., which showed 
that the other CNI, cyclosporine A, is also responsible for the inhibition of NFATc1 amplifi-
cation 20.
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In contrast to CD28+ T cells, no effect of TAC-based therapy on NFATc1 amplification was 
noted in CD8+CD28- T cells. These cells are known to be more antigen-experienced than 
their CD28-positive counterpart and are insensitive to immunosuppressive drug therapy 
that targets co-stimulatory molecules, but up until now it has not been demonstrated 
that CD28- T cells are also less responsive to TAC-based therapy 29,30. The overall amount of 
NFATc1 amplification was also lower in CD28- T cells than in CD28+ T cells. An explanation 
could be that CD28 costimulatory signaling is needed for the inhibition of NFAT export from 
the nucleus back to the cytoplasm (deactivation) 40. In the presence of CD28, the signaling 
molecule glycogen synthase kinase 3 (GSK3) is inhibited, resulting in decreased phos-
phorylation of NFATc1 and, as a consequence, in the inhibition of nuclear export (Figure 
1). Without CD28 expression, more NFATc1 molecules become phosphorylated and will 
be retransferred to the cytoplasm, causing less amplification of NFATc1/A. However, in the 
current study, T cells were stimulated with PMA/ionomycin, which is a CD28-independent 
stimulation. This suggests that another and unknown mechanism may be responsible 
for the lower NFATc1 amplification in CD28- T cells. TAC-based therapy had no effect on 
NFATc1 amplification in CD28- T cells, confirming that these cells are indeed less sensitive 
to immunosuppressive drugs, probably due to the already low expression of NFATc1 in 
the nucleus. CD8+CD28- T cells are also known for their immunoregulatory function, next 
to their more aggressive role in autoimmune diseases and malignancies, suggesting that 
the ineffective inhibition of these cells by immunosuppressive drug therapy could have a 
positive influence on graft survival after transplantation 41,42.
In line with the results found in patient samples, individual drug experiments also 
showed a decrease in NFATc1 amplification when a high concentration of TAC was used (50 
ng/ml). However, in this setting, the high concentration of TAC also inhibited CD28- T cells, 
although the total NFATc1 amplification was again lower than in the CD28+ T cells. MPA did 
not show any significant effect on NFATc1 amplification, whereas prednisolone seemed 
to have a small effect in some individual cases. This can be explained by the inhibitory ef-
fect of glucocorticoids on the transcription factor AP-1 via the glucocorticoid receptor 43,44. 
NFATc1 and AP-1 cooperate to induce gene transcription, for example the amplification of 
NFATc1. Without the function of AP-1, NFATc1 is less effective in the transcription of genes, 
which will cause the reduced NFATc1/A production.
The present study has limitations. First, the amplification of NFATc1 is still not the most 
direct way to measure the effects of TAC, although NFATc1/A is the only NFAT member of 
which the total expression can be induced after T cell receptor activation. Other factors can 
also regulate the induction of NFATc1, including the expression of AP-1 45. The most ideal 
assay to monitor TAC exposure remains the measurement of NFAT dephosphorylation of 
all NFAT family members. However, since no such monoclonal antibody is available, the 
current assay can also provide sufficient information about TAC effects on NFAT function-
ing, since the induced NFATc1/A molecules contribute to the NFAT pathway as a positive 
feedback loop. Even more, the whole-blood assay presented here will give more sustained 
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information about TAC exposure than assays performed with isolated T cells, because 
the tacrolimus concentrations are present during the whole stimulation procedure and 
are not washed away. In blood samples of transplant patients, we here showed that it 
is possible to measure the NFATc1 amplification in the presence of tacrolimus. This has 
clear advantages over isolated T cell procedures where tacrolimus and other immunosup-
pressive drugs are washed away during the T cell isolation process. Another advantage of 
the whole-blood assay is that the impact of immunosuppression can be determined in 
different T cell subsets, such as CD4+CD28+, CD8+CD28+ and CD8+CD28- T cells. The assay 
is also drug specific, as is shown by the individual drug experiments. However, it remains 
unknown whether the other NFAT members that are present in T cells (e.g. NFATc2 and 
NFATc3) are also affected by TAC in the same way and to the same extent, since those 
NFAT members cannot be amplified 11. Secondly, the small group size of this study might 
be a restriction for implementing the technique in daily clinical routine measurements. 
This is a single-center pilot study and it can only be recommended as a new method for 
biomarker when the individual responses to immunosuppressive drugs are validated 21. 
For that a larger study population is needed to reveal the effect of baseline demographics 
on NFATc1 amplification. For the use of this assay in a clinical setting, future studies need 
to focus also on correlations between NFATc1 amplification and clinical outcomes, such as 
acute rejection 46. The present study included only one patient suffering from a rejection 
under TAC-based therapy, which makes it impossible to draw conclusions on the asso-
ciation between NFATc1 amplification and rejection risk. We feel that in order to optimize 
TDM of TAC, the pharmacodynamic measurement of NFATc1 as described here should 
be combined with classic pharmacokinetic TDM or with the alternative pharmacokinetic 
measuring of intracellular tacrolimus concentrations 47.
In conclusion, measuring NFATc1 amplification is a direct method to determine the bio-
logical effects of TAC on divers T cell subsets in whole blood samples of kidney transplant 
recipients. This technique has potential but requires further development before it can be 
applied in clinical practice.
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Supplementary Figures and Tables
Supplementary Table I. Summary of patient baseline characteristics, incidence of rejection and 
medication
Tacrolimus group
(n = 11)
Belatacept group
(n = 10)
p
Age (years) 55	(21-71) 46	(25-76) 0.46
Male / female 9	(82%)	/	2	(18%) 6	(60%)	/	4	(40%) 0.30
Ethnicity 1.00
• Caucasian 10	(91%) 9	(90%)
• African 1	(9%) 1	(10%)
Body weight (kg) 96.0	(63.3-103.0) 78.7	(56.6-111.4) 0.10
Donor age (years) 48	(22-80) 55.5	(39-70) 0.46
BPAR (median time to rejection in days) 1(152) 7(13)
TAC C0 (ng/ml ±SD)	
• Day 4 15.1	(±	4.8) -
•	 Day 30 9.9	(±	3.7) -
•	 Day 90 6.7	(±	1.7) -
•	 Day 180 6.7	(±	1.4) -
•	 Day 360 6.5	(±	2.0) -
BELA dose (mg ±SD)
• Day 4 - 798	(±	180)
•	 Day 30 - 740	(±	127)
•	 Day 90 - 780	(±	180)
•	 Day 180 - 358	(±	80)
•	 Day 360 - 379	(±	69)
MPA C0 (ng/ml ±SD) 0.04
• Day 4 3.73	(±	1.52) 3.55	(±	1.10)
•	 Day 30 2.89	(±	1.64) 3.67	(±	2.12)
•	 Day 90 2.63	(±	0.94) 4.37	(±	1.76)
•	 Day 180 2.16	(±	1.12) 2.78	(±	2.12)
•	 Day 360 2.01	(±1.00) 1.99	(±	0.89)
PRED dose (mg ±SD) 0.16
• Day 4 20.0	(±	0) 20.0	(±	0)
•	 Day 30 12.7	(±	3.4) 11.6	(±	2.6)
•	 Day 90 5.7	(±	1.6) 5.0	(±	0)
•	 Day 180 5.0	(±	0) 5.0	(±	0)
•	 Day 360 4.4	(±	1.1) 5.0	(±	0)
Continuous variables are presented as medians (plus ranges) and categorical variables as numbers (plus per-
centages), unless otherwise specified
Bpar: the incidence of the first rejection episodes is given. the highest Banff score is depicted if sequential 
biopsies were performed.
Bpar, biopsy-proven acute rejection; C0, predose concentration; Mpa, mycophenolate mofetil; preD, predniso-
lone; SD, standard deviation; taC, tacrolimus
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Abstract
Background
The once-daily formulation of tacrolimus (TACOD) has been developed to overcome adher-
ence problems. Conversion from the twice-daily TAC (TACBID) formulation to TACOD on a 
1:1 basis, however, often leads to a decrease of TAC pre-dose concentrations which aver-
ages ~15%. Switching between the two TAC formulations may thus influence drug efficacy 
and necessitates therapeutic drug monitoring. As an additional tool in transplantation 
diagnostics, phospho-specific flow cytometry was used to study the biological effects of 
conversion on p38MAPK phosphorylation, a kinase involved in T-lymphocyte activation.
Methods
Stable renal transplant recipients (n=12), at least one year after their transplantation, were 
converted from TACBID to TACOD on 1:1 mg for mg base. Co-medication consisted of myco-
phenolate mofetil (n=10) and prednisolone (n=3). TAC whole-blood pre-dose concentra-
tions were determined by immunoassay before and 3 months after conversion. P38MAPK 
phosphorylation was measured in T-lymphocytes by whole-blood phospho-specific flow 
cytometry.
Results
Three months after conversion, no significant decreases in TAC pre-dose concentrations 
(C0) were found (p = 0.54), while p38MAPK phosphorylation increased with 11.4% (p<0.05) 
in CD4+ and with 15.6% (p<0.05) in CD8+ T-lymphocytes. The TAC C0 during treatment with 
TACBID correlated inversely with p38MAPK phosphorylation in T-lymphocytes (rs= -0.638, p 
<0.05).
Conclusions
These results suggest that measurement of p38MAPK phosphorylation status in T-lym-
phocytes is a sensitive method to determine the biological effects of TAC before and after 
conversion from TACBID to TACOD. This method could be a more sensitive tool for therapeutic 
drug monitoring of TAC.
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Introduction
Therapy with the immunosuppressant tacrolimus (TAC) is routinely monitored by measur-
ing whole-blood pre-dose concentrations (C0). However, lack of efficacy (i.e. the occurrence 
of acute rejection) or toxicity does occur in solid organ transplant recipients who have TAC 
concentrations that are considered therapeutic. A better way to perform therapeutic drug 
monitoring (TDM) of TAC may be to measure the drug’s pharmacodynamic effects.
TAC inhibits the calcineurin pathway of activated T-lymphocytes resulting in decreased 
levels of de-phosphorylated Nuclear Factor of Activated T-lymphocytes (NFAT), less pro-
duction of the cytokine IL-2, and ultimately, inhibition of T-lymphocyte proliferation. Earlier 
studies demonstrated that the protein expression of IL-2 in cell samples can be used as 
a pharmacodynamic tool for TDM of TAC 1. However, this assay measures the effects of 
other immunosuppressive drugs, such as the effect of steroids, as well, and therefore is not 
specific for TAC 2. In addition, this assay is time-consuming, costly and may not reflect TAC 
toxicity 3. Thus there is an unmet need of better pharmacodynamic assays to monitor TAC 
treatment, leading to more customized immunosuppressive therapy 2.
Apart from its effects on the NFAT pathway, TAC also suppresses the phosphorylation of 
the mitogen activated protein kinase (MAPK) pathway 4. The amount of phosphorylation 
of this signaling molecule was recently found to be inversely correlated with TAC whole-
blood C0 of kidney transplant patients. Furthermore, increased p38MAPK phosphorylation 
was associated with a higher T-lymphocyte activation status, which was inhibited by TAC 
in a dose dependent manner in vitro 4,5.
Here, the effect of conversion from the standard, twice-daily TAC formulation (TACBID) to 
the once-daily, prolonged-release TAC formulation (TACOD) on p38MAPK phosphorylation 
in kidney transplant recipients is reported. The novel TACOD formulation was developed 
to overcome adherence problems. However, whole-blood TAC C0 may decrease by 9-15% 
following 1:1 conversion on a mg for mg basis 6,7. This may lead to sub-therapeutic TAC 
exposure and may put certain patients at risk for rejection. We speculated that the pres-
ent assay may be more sensitive than conventional C0 monitoring and may reveal subtle 
changes in TAC effects.
Patients and Methods
Study design and determination of tacrolimus blood concentrations
All twelve patients reported here (for their characteristics see Table I) participated in a 
substudy of a larger clinical trial that was reported previously.7 The aim of the clinical 
trial was to study the safety of conversion from TACBID (Prograf ®, Astellas Pharma, Leiden, 
the Netherlands) to TACOD (Advagraf ®, Astellas Pharma, Leiden, the Netherlands) on a 1:1 
(mg:mg) basis. The aim of the substudy, which is presented here, was to investigate the 
effects of this conversion on p38MAPK phosphorylation status. For this pilot study n = 12 
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consecutive patients visiting the outpatient clinic and meeting the following inclusion 
criteria were asked to participate: 1) >1 year after kidney transplantation; 2) stable kidney 
function; 3) proteinuria <2 g/day; 4) age >18 years; 5) equal TAC dose before and 3 months 
after conversion. 7
Table I. Patient characteristics (n=12)
Gender	(male/female): 2	(16.7%)	/	10	(83.6%)
Age	(years):	 54.7	(19.6-69.7)*
Time	from	transplantation	to	conversion	(years): 4.92	(1-12)*
Number	of 	subjects	with	concomitant	MMF	therapy: 10	(83.3%)
Number	of 	subjects	with	concomitant	steroid	therapy: 3	(17.6%)
TAC	dose	(mg/day): 4.3	(1.5-10)*
TAC	C0	before	conversion	(ng/ml): 5.6	(1.9-9.8)*
*mean (range)
Heparin blood samples for p38MAPK phosphorylation status were collected 1 day before 
(visit 1) and 3 months after conversion to TACOD (visit 2). TAC whole-blood C0 were deter-
mined in EDTA blood by using the antibody-conjugated magnetic immunoassay (ACMIA) on 
a Dimension Xpand analyzer (Siemens HealthCare Diagnostics Inc., Newark, DE) according 
to the manufacturer’s instructions. The lower and upper limits of detection were 1.5 ng/mL 
and 30 ng/mL, respectively. Proficiency samples were obtained from the United Kingdom 
Quality Assessment Scheme (Dr. Holt, St George’s Hospital Medical School, London, UK). 
The laboratory successfully participates in international proficiency testing schemes.
Whole-blood phospho-specific flowcytometry
p38MAPK phosphorylation was measured according to the manufacturer’s instructions and 
as described previously.4 In brief, 200 μl of heparinized blood was activated with PMA/Iono-
mycin (1.6 μmol/L/10 μg/mL, Sigma-Aldrich, Steinheim, Germany) and stained with APC-
labelled mouse anti-human CD3, Pacific Blue mouse anti-human CD4 and PE-Cy7 mouse 
anti-human CD8 (BD Biosciences, San Jose, CA) for 30 minutes at 37˚C. Then cells were 
fixed for 10 minutes with Lyse/fix buffer and treated with permeabilization buffer III (both 
from BD biosciences) at -20˚C. Samples were stained with the fluorochrome-conjugated 
mAb PE mouse anti-p38MAPK (clone pT180/pY182, BD Biosciences) for 30 minutes at room 
temperature and analysed on a FACS Canto II flow cytometer (BD Biosciences). Isotype 
control IgG1-PE (clone X40, BD Biosciences) tubes were included. Interday-variability of the 
flowcytometer was corrected by using Quantibrite PE beads (BD Biosciences) according to 
the manufacturer’s instructions.
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Data analysis and statistics
The p38MAPK phosphorylation was calculated as the Median Fluorescence Intensity (MFI) 
and normalized using Quantibrite-PE beads. Data and statistical analysis was performed 
with diva-version 6.0 software (BD Biosciences) and Graph Pad Prism 5.0 (Graph Pad Soft-
ware Inc., La Jolla, CA) by using paired t-test (for p38MAPK phosphorylation after perform-
ing log transformation and after finding a P-value >0.05 with an F-test). Spearman’s test 
was used to determine the correlation between TAC C0 and p38MAPK phosphorylation. A 
two-sided p-value <0.05 was considered statistically significant.
Results
Conversion from TACBID to TACOD resulted in a decrease in C0 of 6.0% (Figure 1A), which was 
not statistically significant (p= 0.54). Before conversion the median TAC C0 was 6.0 ng/ml 
(range: 1.9 - 9.8 ng/ml); after conversion the median TAC C0 was 5.4 ng/ml (range: 3 – 7.1 
ng/ml).
A typical example of induced p38MAPK phosphorylation in CD3+, CD3+CD4+ and 
CD3+CD8+ T-lymphocytes, respectively, is shown in Figure 1B. The MFI levels of p38MAPK 
increased after stimulation with PMA/Ionomycin.
After conversion to TACOD, p38MAPK phosphorylation increased significantly, both in 
CD3+CD4+ (11.4% increase, p =0.034) and CD3+CD8+ T-lymphocytes (15.6% increase, p 
=0.038, Figure 1C).
Next, the phosphorylation was correlated to corresponding TAC C0. A significant inverse 
correlation between TAC C0 and p38MAPK phosphorylation in CD3+ T-lymphocytes was 
found for TACBID (rs = -0.638, p <0.05, Figure 1D), but not for TACOD (rs = -0.375, p=0.230, 
Figure 1D).
Discussion
p38MAPK phosphorylation potential increases significantly after 1:1 conversion from TACBID 
to TACOD, despite unchanged TAC whole-blood C0. This observation suggests that measur-
ing p38MAPK phosphorylation may be a more sensitive method to measure the effects of 
TAC therapy at the single-cell level as compared with conventional pharmacokinetic TDM. 
Figure 1. Tac blood C0 after conversion from TACBID to TACOD and p38MAPK phosphorylation status. a) tac 
C0 in kidney transplant patients before and 3 months after conversion from taCBID to taCOD. B) Dot plots dem-
onstrating the selection of lymphocytes and the CD3+CD4+ and CD3+CD8+ t-lymphocytes subsets from whole 
blood samples. the histograms show the p38 phosphorylation for each subset after pMa/Ionomycin stimula-
tion of whole blood for 30 min. C) p38 phosphorylation per cell before and 3 months after conversion from 
taCBID to taCOD in CD3+CD4+ (left panel) and CD3+CD8+ (right panel) t-lymphocytes. D) Correlation between p38 
phosphorylation per cell and taCBID C0 (left panel) or taCOD C0 (right panel) in CD3+ t-lymphocytes. FSC, forward 
scatter; SSC, side scatter (n=12)
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The method may be able to provide more precise information on T-lymphocyte activa-
tion status and could thus guide TAC dosing in daily clinical practice. However, whether 
measuring p38MAPK phosphorylation status will better predict the occurrence of acute 
rejection under TAC therapy as compared to conventional TAC C0 monitoring, remains to 
be established.
In this study, whole-blood single-cell phospho-specific flowcytometry was used to mea-
sure p38MAPK phosphorylation at the single cell level. This technique was earlier used by 
Nolan et al. who investigated the consequences of growth factor treatment on the profiles 
of cancer cell signaling networks of T-lymphocytes in tumor immunology 8. Measuring the 
p38MAPK phosphorylation holds an advantage over the classic pharmacodynamic pa-
rameter IL-2 as the phosphorylation -in contrast to cytokine concentrations- corresponds 
with the upstream effects in the signaling cascade and consequently may be associated 
more strongly to clinical outcomes specific for TAC therapy. In addition, phosphorylation of 
molecules is a rapid process that can be measured with single-cell phospho-specific flow 
cytometry in whole-blood T-lymphocyte subsets within hours 4,9.
TACOD has the same safety and efficacy profile as TACBID 10-13. Furthermore, the use of TACOD 
has been associated with improved adherence, a flatter pharmacokinetic profile and bet-
ter glycemic control 14. Nonetheless, C0 may drop considerably after conversion from TACBID 
on a 1:1 basis in individual patients and close monitoring of TAC exposure after switching 
is recommended 14-16. In the conversion trial, of which the present study was a substudy, 
TAC C0 indeed decrease by an average of 12% after conversion.7 In addition, one patient 
experienced a late acute cellular rejection that was associated with a marked drop in TAC 
exposure: TAC C0 decreased from 6,9 ng/ml immediately before conversion to 3,6 ng/ml 
shortly after conversion 7.
Increased p38MAPK phosphorylation has been associated with more T-lymphocyte 
activation 17 and may theoretically result in a higher risk of acute cellular rejection for 
kidney transplant patients 18. Despite the non-significant change in TAC exposure, that was 
observed to be significant in the whole study cohort but not in the n = 12 patients partici-
pating in this substudy, a significant 11.8% increase in p38MAPK phosphorylation was ob-
served demonstrating the high sensitivity of this assay. This present finding suggests that 
conversion to TACOD alters exposure to the drug and that this may translate into a change 
in biologic effect at the single-cell level which is not detected by routine C0 monitoring us-
ing immunoassays. Possibly, this subtle change in p38MAPK phosphorylation would have 
been reflected by the total TAC exposure during the dosing interval (measured by means of 
an area under the concentration versus time-curve) rather than a mere C0. Alternatively, the 
lack of a significant change in C0 after conversion from TACBID to TACOD and of a significant 
correlation between p38 phosphorylation status and C0 during treatment with TACOD could 
also be related to the limited statistical power of this study.
In addition, a significant correlation between p38MFI and TAC C0 during treatment with 
TACBID was observed, while remarkably, this correlation was not significant during treat-
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ment with TACOD. The reason for this observation is unclear but again, it may be explained 
by small sample size.
Another limitation of this study is that TAC C0 was measured with an immunoassay, 
which not only measures the parent compound but also cross-reacts with several TAC 
metabolites. Nonetheless, although measurement of TAC concentrations by LC-MS has 
increased, many transplant centers throughout the world still rely on immunoassays. Sec-
ond, we tested only a limited number of patients. Therefore, the present findings should be 
interpreted with caution and be considered as hypothesis-generating.
In the future, it can be interesting to determine the risk of rejection during TAC therapy in 
kidney transplant patients with the help of phospho-specific flow cytometry. This pharma-
codynamical approach could detect the risk of rejection in a more sensitive way than the 
standard pharmacokinetic method.
Furthermore, the assessment of the p38MAPK phosphorylation is a rapid method for 
therapeutic drug monitoring of TAC and can be used to consider dose adjustment during 
therapy.
Furthermore, it will be essential to start a longitudinal study to investigate the long-term 
effects of TAC conversion on p38MAPK phosphorylation to assess the phosphorylation 
change over time and to define if this change is related to a higher risk for rejection 12. 
In addition, the results of the present study suggest that the increase of the p38MAPK 
phosphorylation status after conversion depends on the starting MFI of p38MAPK phos-
phorylation. It could be interesting to study intra-individual differences with the help of a 
larger study cohort.
Conclusion
Conversion from TACBID to TACOD is associated with a significant increase in p38MAPK phos-
phorylation which was not reflected by TAC whole-blood exposure as determined by C0. 
Measurement of p38MAPK phosphorylation status seems feasible and could be a sensitive 
tool to assess the biological effects of TAC at the single T-lymphocyte level.
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Abstract
Pharmacokinetic immunosuppressive drug monitoring poorly correlates with clinical 
outcomes after solid organ transplantation. A promising method for pharmacodynamic 
monitoring of tacrolimus (TAC) in T cell subsets of transplant recipients might be the mea-
surement of (phosphorylated) p38MAPK, ERK1/2 and Akt (activated downstream of the T 
cell receptor) by phospho-specific flow cytometry.
Here, blood samples from n = 40 kidney transplant recipients (treated with either TAC-
based or belatacept (BELA)-based immunosuppressive drug therapy) were monitored 
before and throughout the first year after transplantation.
After transplantation and in unstimulated samples, p-p38MAPK and p-Akt were inhibited 
in CD8+ T cells and p-ERK in CD4+ T cells but only in patients who received TAC-based 
therapy. After activation with PMA/ionomycin, p-p38MAPK and p-AKT were significantly 
inhibited in CD4+ and CD8+ T cells when TAC was given, compared to pre-transplantation. 
Eleven BELA-treated patients had a biopsy-proven acute rejection, which was associated 
with higher p-ERK levels in both CD4+ and CD8+ T cells compared to patients without rejec-
tion.
In conclusion, phospho-specific flow cytometry is a promising tool to pharmacodynami-
cally monitor TAC-based therapy. In contrast to TAC-based therapy, BELA-based immuno-
suppression does not inhibit key T cell activation pathways which may contribute to the 
high rejection incidence among BELA-treated transplant recipients.
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Introduction
Pharmacokinetic monitoring of the most frequently used immunosuppressive drug after 
solid organ transplantation, tacrolimus (TAC), is most often based on whole-blood, pre-
dose concentrations. The TAC pre-dose concentration, however, has an imperfect correla-
tion (rs ≈ 0.7) with the total exposure to TAC during a dosing interval as measured by the 
area-under the concentration versus time-curve 1-3. As a consequence, and due to a high 
intra-patient variability in TAC exposure, the occurrence of acute rejection or side effects is 
not accurately predicted by TAC pre-dose concentrations 4-7.
T cells are the main target of most immunosuppressive drugs used in transplantation. T 
cells become activated upon three separate stimulation signals: 1) antigen recognition by 
the T cell receptor (TCR) with the help of antigen presenting cells (APC); 2) co-stimulation, 
of which the interaction between CD28 molecules on T cells and CD80/86 molecules on the 
APC is the best known pathway, and 3) binding of cytokines 8. This will activate intracellular 
signaling pathways downstream of the TCR [including the calcineurin, Mitogen-Activated 
Protein Kinase (MAPK) and PI3K pathways] and initiate the activation of transcription factors 
that regulate the production of cytokines (e.g. IL-2, IFN-γ and TNF-α) 9. The activation of these 
pathways is characterized by (de-)phosphorylation of specific signaling molecules: Nuclear 
Factor of Activated T cells (NFAT), p38 MAPK, Extracellular signal-Regulated Kinases 1 and 2 
(ERK1/2) and AKT8 virus oncogene cellular homolog (Akt) (Supplementary Figure 1) 10-14.
A promising approach to determine the biological effects of immunosuppressive drugs 
may be the measurement of intracellular signaling pathway activation 4,15-19. Several 
research groups have tried to find suitable biomarkers for pharmacodynamic immunosup-
pressive drug monitoring, such as NFAT-regulated gene expression 20-22. Up until now, these 
methods have not found their way into routine clinical practice 23-26.
Phospho-specific flow cytometry of the intracellular signaling molecules p38MAPK, ERK 
and Akt is a promising technique to monitor the pharmacodynamic effects of immuno-
suppressive drugs in whole-blood of kidney transplant patients 27. Previous studies on 
phospho-specific flow cytometry have demonstrated that TAC can inhibit p38MAPK in a 
dose-dependent manner in kidney transplant patients 28. Moreover, mycophenolic acid 
(MPA) was been found to decrease the phosphorylation of p38MAPK and ERK1/2 in vitro 29. 
However, these previous studies lacked an appropriate control group that did not receive 
TAC and could therefore not exclude an effect of other, concomitantly used immunosup-
pressive drugs on T cell activation in these kidney transplant patients.
Belatacept (BELA), a fusion protein consisting of the Fc-fragment of human immuno-
globulin G1 linked to the extracellular domain of human cytotoxic T-lymphocyte antigen 
(CTLA)-4, was approved in 2011 for the prevention of acute rejection after kidney transplan-
tation 30-32. It blocks the co-stimulation signal between CD80/86 and CD28 molecules (on 
APCs and T cells, respectively) and prevents T cell activation. In contrast to TAC, BELA is not 
nephrotoxic and has less metabolic side effects, although the incidence of acute rejection 
with a BELA-based treatment is relatively high 33,34. The higher risk of acute rejection of 
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patients who receive treatment with BELA has been associated with a more aggressive T 
cell-mediated allogeneic response 33,35-37. One of the explanations for this phenomenon 
is the fact that memory CD8+ T cells lack CD28 expression and are not dependent on the 
co-stimulatory signal from CD80/86 35,38-40.
Here, we expand on our previous work and investigated the phosphorylation status of 3 
signaling proteins involved in T cell activation, namely p38MAPK, ERK and Akt, by means 
of phospho-specific flow cytometry to investigate whether this technique can be used as 
a tool for pharmacodynamic monitoring of TAC-based immunosuppression after kidney 
transplantation 28. Phosphorylation was measured in blood samples of kidney transplant 
patients treated with either a TAC-based or a BELA-based immunosuppressive regimen 
as a part of a randomized controlled clinical trial 34. Both groups received MPA and pred-
nisolone. Because BELA only indirectly inhibits T cell activation, the BELA-treated group 
served as a control group in this study, circumventing a limitation of previous studies 28,29. 
In contrast to previous studies, the effect of TAC and BELA was also determined in different 
CD3+ T cell subsets and at multiple time points after transplantation.
Material and Methods
Kidney transplant patients
Between January 21th, 2014 and February 19th, 2016 peripheral blood samples were col-
lected from renal transplant recipients to determine the effect of a TAC- or BELA-based 
treatment on CD3+ T cell subset activation. This study was part of a randomized-controlled 
clinical trial that was approved by the Medical Ethical Committee of the Erasmus MC, 
University Medical Center Rotterdam (MEC-2012-421, EudraCT # 2012-003169-16, http://
www.trialregister.nl/trialreg/index.asp number NTR4242, registered October 17th 2013)  34. 
Detailed information about study design, interventions, outcomes, sample size and ran-
domization was previously reported by de Graav et al. 34. All patients (≥ 18 years) described 
in this single center study received a kidney from a living donor at our institution (Erasmus 
MC, Department of Internal Medicine, Rotterdam, the Netherlands) 34. Kidneys were either 
allocated directly or as part of the Dutch national kidney exchange program 41. Recipients 
of a deceased donor kidney were not included in this study and no organs were procured 
from (executed) prisoners. All experiments were performed in accordance with relevant 
guidelines and regulations. Forty renal transplant patients were included and random-
ized to receive a BELA-based treatment (n = 20) or TAC-based treatment (n = 20). In- and 
exclusion criteria were described previously 34. All participants gave written informed 
consent for participation in this study and for collecting their blood samples. On the day 
of transplantation and on day 4 after transplantation, patients were treated with 20 mg 
basiliximab intravenously (Simulect®, Novartis, Basel, Switzerland). During the first three 
post-operative days prednisolone was administered intravenously in a dosage of 100 mg/
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day. Afterwards, prednisolone was given orally in a dose of 20 mg and tapered to 5 mg/
day by month 3 and was then continued throughout the first post-transplant year. Myco-
phenolate mofetil (MMF; Cellcept®; Roche, Basel, Switzerland) was given in a starting dose 
of 2000 mg/day equally divided in two doses, and then adjusted to pre-dose concentra-
tions (target 1.5 – 3.0 mg/L). Patients received TAC (Prograf ®, Astellas Pharma Inc., Tokyo, 
Japan) twice a day from the day of transplantation with a starting dose of 0.2 mg/kg/day. 
Thereafter, TAC was adjusted to pre-dose concentrations: 10-15 ng/mL (week 1-2), 8-12 ng/
mL (week 3-4), and 5-10 ng/mL (from week 5 onwards). BELA-treated patients received 10 
mg/kg/day BELA (Nulojix®, Bristol-Myers Squibb, New York, USA) intravenously on the day 
of transplantation and on days 4, 15, 30, 60, and 90 after transplantation. From month 4 
onwards, patients received monthly infusions of 5 mg/kg BELA (according to the so-called 
less intensive regimen) 33. Heparinized blood samples were collected pre-transplantation 
and 4, 30, 90, 180 and 360 days post-transplantation or before anti-rejection therapy was 
started when an acute rejection was suspected (usually on the day of the kidney biopsy).
Immunosuppressive drug whole-blood pre-dose concentrations
TAC and MPA whole-blood or plasma pre-dose concentrations, respectively, were deter-
mined in EDTA blood using the antibody-conjugated magnetic immunoassay on a Dimen-
sion Xpand analyzer (Siemens HealthCare Diagnostics Inc., Newark, DE) according to the 
manufacturer’s instructions. The lower and upper limits of detection of TAC were 1.5 and 
30 ng/mL and for MPA 0.5 μg/ml and 15 μg/ml, respectively. For TAC, the coefficient of 
variations (CV) was 15.0%, 8.9% and 11.2% for the low, middle and high control samples, 
respectively. For MPA, the CV was 3.9% and 3.7%, for the low and high controls, respectively. 
Proficiency samples were obtained from the UK Quality Assessment Scheme (Analytical 
Services International Ltd, London, UK) and the laboratory successfully participates in 
international proficiency testing schemes.
Whole-blood phospho-specific flow cytometry
Whole-blood samples were monitored for the expression of phosphorylated (p-) p38MAPK, 
ERK and Akt according to the manufacturer’s instructions for phospho-protein analysis (BD 
Biosciences, San Jose, CA) and as described previously.42 The CV for phospho-specific flow 
cytometry was 5.6%.43 In short, 200 μl heparinized blood was stained with Brilliant Violet 
(BV) 510-labeled mouse anti-human CD3 (Biolegend, San Diego, CA), peridinin chlorophyll 
(PERCP)-labeled mouse anti-human CD4 (BD Biosciences), allophycocyanin(APC)-Cy7-
labeled mouse anti-human CD8 (Biolegend), BV421-labeled mouse anti-human CD28 
(BD Biosciences) and Fluorescein Isothiocyanate (FITC)-labeled mouse anti-human CD14 
(Serotec, Oxford, UK) for 30 minutes at 37˚C. After 15 minutes of staining, PMA/ionomycin 
(Sigma-Aldrich, Steinheim, Germany) was added to activate T cells in the remaining 15 
minutes. A final optimized concentration of 500 ng/ml and 5 μg/ml of PMA and ionomycin, 
respectively was used for samples stained for p38MAPK and Akt. 100 ng/ml PMA and 1 
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μg/ml ionomycin was used for ERK. From here, unstimulated and stimulated cells with 
PMA/ionomycin were considered as two different samples and analyzed separately. 
Cells were then fixed and lysed for 10 minutes with Lyse/Fix buffer (BD Biosciences) and 
permeabilized with 90% methanol for 30 minutes at -20˚C. Phycoerythrin (PE)-labeled 
mouse anti-p-p38MAPK (clone pT180/pY182), PE-labeled mouse anti-p-Akt (clone pS473) 
or AlexaFluor647 (AF647)-labeled mouse anti-p-ERK1/2 (pT202/pY204) mAB (all from BD 
Biosciences) were used for 30 minutes at room temperature to stain for the intracellular 
signaling pathway activation. Samples were analyzed on a FACS Canto II flow cytometer 
(BD Biosciences). Isotype controls; mouse IgG1-PE (p38MAPK and Akt, Biolegend) and 
mouse IgG1-AF647 (ERK; Biolegend); served as negative controls and were included in 
separated tubes. Cytocalbeads (Thermo Scientific, Fremont, CA) were used to correct for 
interday-variability of the flow cytometer according to the manufacturer’s instructions. 
Absolute numbers of CD3+, CD4+ and CD8+ cells were measured with BD multi-test 6-colour 
in BD TruCount Tubes (BD Biosciences, San Jose, CA).
Cytokine production
Heparinized blood samples were activated with a final concentration of 0.5 μg/ml PMA 
and 10 μg/ml ionomycin for four hours at 37°C. Golgiplug (BD Biosciences) was added 
during this incubation to accumulate cytokines intracellularly. Subsequently, EDTA was 
added for 15 minutes. Cells were then stained with BV510-labeled mouse anti-human CD3 
(Biolegend), BV421-labeled mouse anti-human CD4 (Biolegend), APC-Cy7-labeled mouse 
anti-human CD8 (Biolegend) and PERCP-Cy5-labeled mouse anti-human CD28 (BD Biosci-
ences) for 30 minutes at room temperature, fixed twice for 10 minutes with FACS lysing 
solution (BD Biosciences) and treated with permeabilization buffer II (BD Biosciences) for 
10 min. FITC-labeled mouse anti-human IFN-γ (BD Biosciences) was used for intracellular 
cytokine staining for 30 minutes at room temperature.
Statistical Analysis
The Median Fluorescence Intensity (MFI) was measured for the phosphorylation of 
p38MAPK, ERK and Akt and data-analysis was performed with Diva-version 6.0 software 
(BD Bioscience). Negative values measured with flow cytometry can be explained by the 
compensation settings of the FACS and are displayed via hyperlog transformation.44 MFI 
values were normalized using Cytocalbeads (Thermo Scientific). Statistical analysis was 
performed with Graph Pad Prism 5.0 (Graph Pad Software Inc., La Jolla, CA) by using paired 
and unpaired t-tests (after finding a p-value > 0.05 with the Kolmogorov-Smirnov test for 
normality for the study population). Correlations between drug concentrations and phos-
phorylation were calculated as the Pearson correlation coefficient. Associations between 
phosphorylation levels and co-variates were tested by linear regression with IBM SPSS 
statistics software (version 21; IBM Analytics, Chicago, Illinois, USA). Bonferroni correction 
was used to correct for multiple testing. A two-sided p-value < 0.05 was considered statisti-
145
Chapter 7  |  iMMunosuppressive druG MonitorinG in t cell subsets
Ch
ap
te
r 7
cally significant and for the association calculations, two-sided p-values of < 0.0042 were 
considered statistically significant after Bonferroni correction.
Results
Patient demographics and graft survival
Baseline patient characteristics and information regarding patient and graft survival are 
shown in Supplementary Tables I and II 34. In summary, three patients in the BELA group 
lost their graft at day 12 (Banff type IIB acute rejection), day 59 (Banff type III acute rejec-
tion) and day 161 (Banff type IIB acute rejection) after transplantation. The total incidence 
of biopsy-proven acute rejection (BPAR) in this group was 55% (n = 11, median time to 
rejection 81 days). The incidence of BPAR was lower in the TAC-treated group (n = 2, 10%, 
median time to rejection 56 days). In the TAC group, one patient died 294 days after trans-
plantation, due to a traumatic head injury. For the present study, patients with a BPAR were 
censored from the moment of rejection onwards, because measurements of intracellular 
signaling pathways after the occurrence of rejection were likely to be heavily influenced by 
the anti-rejection therapy.
T cell subset counts and immunosuppressive drug pre-dose concentrations
Figure 1A represents a gating strategy example of the phospho-specific flow cytometry 
measurements and the selection of the CD3+ T cell subsets. Absolute numbers of CD3+, 
CD4+, CD8+, CD4+CD28+, CD4+CD28-, CD8+CD28+ and CD8+CD28- T cells were constant over 
time after transplantation (Figure 1B). There were no differences between the absolute T 
cell counts of TAC- and BELA-treated patients (Figure 1B).
TAC pre-dose concentrations decreased over time and followed the targeted pre-dose 
concentration range (Supplementary Table III). Likewise, MPA pre-dose concentrations 
and prednisolone doses were in the range specified by the protocol. BELA was adminis-
tered according to the less-intensive regimen (10 mg/kg at days 0, 4, 30 and 90 and 5 mg/
kg at days 180 and 360.34 CD86 saturation of monocytes was complete at all time points of 
all BELA-treated patients. 34
Whole blood phospho-specific flow cytometry of p38MAPK, ERK and Akt
Phosphorylation of intracellular signaling molecules was measured with or without PMA/
ionomycin stimulation to monitor the effects of the immunosuppressive drug combination 
therapy, consisting of either TAC or BELA in combination with prednisolone and MMF. An 
example of the phosphorylation measurements is depicted in Figure 2A. In the total CD3+ 
T cell population, p-p38MAPK, p-ERK and p-Akt showed significantly higher MFI values after 
stimulation (before transplantation; mean MFI: 1308, 718 and 813, respectively) compared 
to the isotype controls (mean MFI: 394, 177 and 387, respectively; p < 0.001) and unstimu-
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Figure 2. Phosphorylation of p38MAPK, ERK and Akt in CD3+ T cells. a) example of measured median fluores-
cence intensities in CD3+ t cells for p-p38MapK, p-erK and p-akt before and after transplantation (in both un-
stimulated and pMa/ionomycin stimulated samples) compared to their isotype control measurements. Negative 
values measured with flow cytometry can be explained by the compensation settings of the FaCS. B) total phos-
phorylation (after stimulation with pMa/ionomycin) of p38MapK (upper left), erK (right) and akt (lower left) before 
and after transplantation compared to isotype controls, unstimulated samples and stimulated samples of healthy 
controls. Data are plotted as box and whiskers indicating total range. In contrast to p-erK and p-akt, p-p38MapK is 
inhibited in CD3+ t cells at all time points after transplantation (n=40); *) p < 0.05, **) p < 0.01, ***) p < 0.001
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lated samples (mean MFI: 466, 222 and 458, respectively; p < 0.001) (Figure 2B). Expression 
of p-p38MAPK was higher in patients before transplantation than in healthy controls (mean 
MFI: 1308 vs. 916; p < 0.01). P-p38MAPK expression in CD3+ cells significantly decreased 
in the total study population and at all measured time points after transplantation, in 
contrast to p-ERK and p-Akt.
Signaling protein phosphorylation in T cell subsets of TAC- and BELA-treated kidney 
transplant patients
To assess the effect of TAC on T cell subset activation, phosphorylation of p38MAPK, 
ERK and Akt was measured before and throughout the first year after transplantation in 
CD4+CD28+, CD8+CD28+ and CD8+CD28- T cell subsets of TAC-treated patients (Figure 3 and 
S5 Figure). Samples of BELA-treated patients were included as controls.
In unstimulated blood samples, p-ERK was significantly inhibited in CD4+CD28+ T cells 
when TAC was given, but not in the presence of BELA (p < 0.01) (Supplementary Figure 
2). This phenomenon was not observed in CD8+CD28+ and CD28- cells (Supplementary 
Figure 2).
After PMA/ionomycin stimulation, inhibition of signaling protein phosphorylation was 
found for p-p38MAPK and p-Akt, but not for p-ERK and only during TAC-based treatment 
(Figure 3). In CD4+CD28+ cells, TAC-based treatment showed a decreased expression of 
p-p38MAPK at all time points (p < 0.05) and a reduced p-Akt expression at most tested time 
points (p < 0.01) (Figure 3A). In the presence of BELA, reduced expression of p-p38MAPK 
in CD4+CD28+ was measured only at day 90 (p < 0.05). A comparable effect of a TAC-based 
immunosuppressive regimen was seen in CD8+CD28+ and CD8+CD28- T cells, although p-
p38MAPK and p-Akt were not inhibited at day 90 and 180, respectively (Figure 3B and 3C). 
Notably, at day 360, BELA-based treatment increased the expression of p-ERK in CD8+CD28+ 
T cells (Figure 3B).
Pharmacodynamic-pharmacokinetic interrelationship between immunosuppressive 
drug concentrations, clinical outcomes and signaling protein phosphorylation
After stimulation with PMA/ionomycin, no correlations were found between TAC pre-dose 
concentrations or MPA pre-dose concentrations and the phosphorylation of intracellular 
signaling proteins (Table I). Also no associations were found between the phosphorylation 
of p38MAPK, ERK and Akt and patient characteristics pre-, 4 and 360 days after transplanta-
tion (Supplementary Table IV).
Association between phosphorylation patterns and acute rejection episodes of BELA-
treated patients
The association between TAC-based therapy and the incidence of BPAR could not be 
analyzed since only two out of 20 TAC-treated patients suffered from an acute rejection. 
These patients suffered from a Banff type 1 and 2 rejection, respectively 34. To investigate 
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whether a rejection episode was associated with a change in phosphorylation status, 
blood samples of BELA-treated patients suffering from BPAR were compared with those 
who remained rejection-free. Eleven out of 20 BELA-treated patients experienced BPAR 34. 
Of these, 1 patient was graded Banff type 1, 8 patients were graded Banff type 2, 1 patient 
was graded Banff type 3, and 1 patient suffered from a mixed type rejection. Both CD4+ and 
CD8+ T cells of these patients revealed an increase in p-ERK expression at day 4 and day 
90, respectively, after stimulation with PMA/ionomycin (p < 0.05) (Figure 4, middle). In ad-
dition, p-ERK expression at the time of rejection was high compared to patients without a 
Figure 4. Signaling protein phosphorylation in BELA-treated patients with and without BPAR. phosphory-
lation of p38MapK (upper graphs), erK (middle graphs) and akt (lower graphs) in CD4+ cells (left) and CD8+ cells 
(right) after stimulation with pMa/ionomycin is shown. BeLa-treated patients suffering from an acute rejection 
(grey) episode showed a significantly higher expression of p-erK before their rejection time point compared to 
patients without a rejection within 90 days after transplantation (black). (Data are plotted as mean ±SD; n=11 
rejectors and n=9 non-rejectors) *) p < 0.05
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rejection. There was no difference in p38MAPK and Akt phosphorylation between rejectors 
and non-rejectors in both cell subsets.
Cytokine production and phosphorylation of p38MAPK
To determine whether the pharmacodynamic drug effects also correlated with T cell subset 
function, correlations were calculated between p-p38MAPK expression and the production 
of IFN-γ. Before transplantation, no correlation existed between p-p38MAPK expression 
and IFN-γ production in all tested T cell subsets. At day 90 after transplantation, a signifi-
cant positive correlation was found between p-p38MAPK expression and IFN-γ production 
in both CD4+CD28+ and CD8+CD28+ T cells (Figure 5).
Discussion
Pharmacokinetic monitoring of immunosuppressive drug therapy is routinely performed 
in most transplant centers. However, the TAC pre-dose concentration does not accurately 
predict the occurrence of acute rejection after kidney transplantation 2,6. Here, phospho-
specific flow cytometry, a promising technique with a short turnaround time for the phar-
macodynamic measurement of immunosuppressive drug effects, was investigated 15,16,45. 
The technique has been used previously for testing immunosuppressive drug responses 
in patients with rheumatoid arthritis and for the monitoring of mTOR inhibitor therapy. 
This technique was also studied with regard to TDM of TAC by our group 28. However, and 
in contrast to the present work, in that study, only p38MAPK was investigated and only 
in CD4+ and CD8+ T cells of patients treated with TAC-based immunosuppression. Here, 
three major signaling molecules involved in T cell activation, p38MAPK, ERK and Akt, were 
tested as potential biomarkers for detecting biological drug effects of TAC in different T cell 
subsets and compared to a group of patients treated with BELA-based treatment.
Table I. Correlation between signaling molecule phosphorylation (stimulated) and immunosup-
pressive drug pre-dose blood concentrations at day 4 after transplantation
T cell subset
p-p38MAPK p-ERK p-Akt
rp p-value rp p-value rp p-value
TAC CD4+CD28+ -0.09 0.79 0.11 0.73 -0.08 0.82
CD8+CD28+ 0.09 0.78 -0.14 0.66 0.20 0.54
CD8+CD28- -0.02 0.96 -0.15 0.64 0.20 0.53
MPA (TAC-
group)
CD4+CD28+ -0.40 0.20 0.46 0.13 0.31 0.33
CD8+CD28+ -0.37 0.24 0.32 0.31 0.37 0.23
CD8+CD28- -0.26 0.41 0.31 0.32 0.36 0.25
MPA 
(BELA-
group)
CD4+CD28+ -0.51 0.16 -0.38 0.32 -0.28 0.47
CD8+CD28+ -0.60 0.09 -0.17 0.66 -0.32 0.39
CD8+CD28- -0.29 0.44 -0.08 0.85 -0.35 0.35
rp) pearson correlation coefficient
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In directly measured blood samples of patients treated with a TAC-based immunosup-
pressive regimen, expression of p-ERK in CD4+ T cells was decreased at almost all mea-
sured time points after transplantation, whereas no effect was found on p38MAPK and 
Akt phosphorylation. In contrast, CD8+ T cells showed no decrease in p-ERK but showed a 
lower expression of p-p38MAPK and p-Akt at day 30.
There was no decrease in p-ERK induced by TAC-based treatment after stimulation with 
PMA/ionomycin, suggesting that the ERK pathway can still be activated after transplanta-
tion, despite the inhibited expression in unstimulated samples. A TAC-based-treatment 
also affected the expression of p-p38MAPK and p-Akt in stimulated CD4+CD28+, CD8+CD28+ 
and CD8+CD28- cells, but not to the same extent. For example, CD8+ cells did not show 
an inhibition of p38MAPK at day 90, while this molecule was significantly inhibited at all 
measured time points in CD4+ cells. P-Akt showed no significant inhibition at day 180 in all 
T cells subsets.
BELA blocks the co-stimulation signal between the CD80/86 molecule on APC’s and the 
CD28 molecule on T cells. This indicates that BELA only indirect affects the phosphoryla-
tion of signaling pathways in T cells. Indeed, no effects of BELA on signaling protein phos-
phorylation were noticed in both unstimulated and stimulated samples. Only at day 90, 
when blood samples were stimulated with PMA/ionomycin, a decrease of p-p38MAPK was 
found in CD28+ cells after treatment with BELA. This effect was not noticed in CD8+CD28- 
cells, indicating that BELA did not affect these cells. However, this effect was not observed 
at other time points, indicating that any difference between the effect of BELA on CD28+ 
and on the more aggressive CD28- T cells could not be detected with phospho-specific 
flow cytometry. Notably and in contrast to the TAC-treated study population, expression 
of p-ERK was increased at day 360 in the presence of BELA, reflecting immune activation.
The absence of decreased signaling protein phosphorylation during BELA-based therapy 
also suggests that p-p38MAPK and p-Akt are mainly affected by TAC. However, the signifi-
cant reductions that were found during TAC-based treatment were small and no correla-
tions were found between TAC pre-dose concentrations and p-p38MAPK. However, there 
could be a correlation between phosphorylation expression and peak drug concentrations 
or area under the concentration-versus time curve, but these were not measured in this 
study. No other patient baseline characteristic showed an association with the expression 
of p-p38MAPK, p-ERK or p-Akt, suggesting that the decrease in phosphorylation was not 
influenced by these parameters. Downstream of the MAPK pathway, p-p38MAPK will initi-
ate the transcription of the IFNG gene, which in turn will lead to the production of IFN-γ 
by T cells 46,47. Here, the expression of p-p38MAPK, measured by phospho-specific flow 
cytometry, significantly correlated with IFN-γ production in CD8+CD28+ T cells but only after 
transplantation when there is less variation in p-p38MAPK expression due to the presence 
of immunosuppressive drugs. Unfortunately, IFN-γ production was not measured at day 4 
and 30 after transplantation, but the immunosuppressive drug concentrations were higher 
at day 90 compared to day 180 and 360 after transplantation suggesting that a TAC-based 
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immunosuppressive drug therapy is involved in the regulation of p38MAPK phosphoryla-
tion. Altogether, the correlation between p-p38MAPK and the production of IFN-γ suggests 
that measuring phosphorylation of p38MAPK could be an effective manner to monitor 
CD8+CD28+ T cell function after transplantation.
Eleven out of 20 BELA-treated patients in this study suffered from an acute rejection 34. 
BELA-treated patients suffering from a BPAR showed an increased phosphorylation of ERK 
after stimulation with PMA/ionomycin in both CD4+ and CD8+ T cells, in contrast to patients 
without an acute rejection episode. This observation was made at day 4 in CD4+ and at day 
90 in CD8+ cells before the rejection episode was detected. p-ERK could be inhibited in the 
presence of a TAC-based regimen, as was measured in unstimulated samples. In contrast, a 
BELA-based treatment even increased the expression of p-ERK at day 360 after stimulation 
of the samples. Previously, a weak correlation was also found between the expression of 
p-ERK and antibody-mediated rejection biopsies of heart transplant patients 48. Moreover, 
graft survival could be prolonged by the use of an ERK1/2 inhibitor as was shown in a mouse 
model 49. Altogether, these results indicate an important role for ERK in both CD4+ and CD8+ 
T cells before an acute rejection episode is diagnosed clinically. Unfortunately, it could not 
be verified in this study whether the expression of p-ERK during a rejection episode was 
also increased in the presence of a TAC-based treatment, since only two patients in this 
treatment group suffered from acute rejection.
This study has other limitations, such as the small sample size and the lack of correla-
tions between the expression of p-p38MAPK, p-ERK and p-Akt and clinical outcomes. 
Larger prospective cohort studies should focus on the phosphorylation of ERK in CD4+ and 
CD8+ T cells after transplantation to prove that p-ERK is a reliable biomarker for rejection 
in the presence of either a BELA- or TAC-based therapy. Such a study should also measure 
the total expression of ERK to ensure that any effects are due to the phosphorylation in-
hibition and not to the changed expression of the total protein. Moreover, in order to use 
phospho-specific flow cytometry for daily clinical diagnostics, the technique should be 
validated by using area-under the concentration versus time-curve values instead of pre-
dose concentrations. These values could also give an explanation for the low inhibitory 
effects on signaling molecule phosphorylation at specific time points and the increase in 
p-ERK in BELA-treated patients suffering from a rejection.
In conclusion, phospho-specific flow cytometry is a promising technique to monitor the 
pharmacodynamic effects of a TAC, but not BELA, -based immunosuppressive therapy af-
ter transplantation. In contrast to TAC-based treatment, BELA-based immunosuppression 
does not inhibit key T cell activation pathways, despite the expression of CD28, which may 
contribute to the high rejection incidence observed among BELA-treated kidney transplant 
recipients.
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Supplementary Table I: Baseline characteristics at time of transplantation
Belatacept group
(n	= 20)
Tacrolimus group
(n	= 20) p
Age	(years) 57	(25-76) 55	(21-76) 0.88
Male	/	female 14	(70%)	/	6	(30%) 16	(80%)	/	4	(20%) 0.72
Ethnicity 1.00
•	 Caucasian 17	(85%) 16	(80%)
•	 African 2	(10%) 2	(10%)
•	 Asian 1	(5%) 2	(10%)
Body	weight	(kg) 79.0	(56.6-111.4) 93.6	(51.4-120.0) 0.06
HLA	A	mismatch	(mean	±	SD) 1.1	(±	0.7) 1.4	(±	0.5) 0.13
HLA	B	mismatch	(mean	±	SD) 1.3	(±	0.5) 1.5	(±	0.5) 0.51
HLA	DR	mismatch	(mean	±	SD) 1.1	(±	0.4) 1.3	(±	0.4) 0.70
Current	PRA	(%) 0	(0-5) 0	(0-17) 0.30
Peak	PRA	(%) 4	(0-6) 4	(0-21) 0.78
CMV	status	 0.80
•	 Donor	+	/	Recipient	- 3	(15%) 2	(10%)
•	 Donor	+	/	Recipient	+ 4	(20%) 7	(35%)
•	 Donor	-	/	Recipient	- 7	(35%) 6	(30%)
•	 Donor	-	/	Recipient	+ 6	(30%) 5	(25%)
Donor	age	(years) 59	(24-71) 51	(22-80) 0.18
Related	/	unrelated	donor	 6	(30%)	/	14	(70%) 5	(25%)	/	15	(75%) 1.00
Cause	of 	end-stage	renal	disease	 0.09
•	 Diabetes	mellitus 3	(15%) 7	(35%)
•	 Hypertension 2	(10%) 5	(25%)
•	 IgA	nephropathy 1	(5%) 3	(15%)
•	 Polycystic	kidney	disease 3	(15%) 3	(15%)
•	 Obstructive	nephropathy 3	(15%) 1	(5%)
•	 Unknown 5	(25%) 0	(0%)
•	 Other 3	(15%) 1	(5%)
Renal	replacement	therapy	 0.91
•	 None	(pre-emptive) 10	(50%) 12	(60%)
•	 Hemodialysis 7	(35%) 6	(30%)
•	 Peritoneal	dialysis 3	(15%) 2	(10%)
Time	on	dialysis	(days) 425	(123-2782) 605	(465-1519) 0.41
Number	of 	kidney	transplantation 1.00
•	 First	 19	(95%) 20	(100%) 1.00
•	 Second	 1	(5%) -
Continuous variables are presented as medians (plus ranges) and categorical variables as numbers (plus per-
centages), unless otherwise specified
Bpar, biopsy-proven acute rejection; CMV, cytomegalovirus; hLa, human leukocyte antigen; pra, panel reactive 
antibodies (current = pra at time of transplantation, peak = historically highest measured pra); SD, standard 
deviation.
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Supplementary Table II: Incidence of rejection according to the treatment group
Belatacept group
(n = 20)
Tacrolimus group
(n = 20) p
Borderline 0	(0%) 0	(0%) -
Type	1 1.00
•	 1A 0	(0%) 0	(0%)
•	 1B 1	(5%) 1	(5%)
Type	2 0.004
•	 2A 2	(10%) 1	(5%)
•	 2B 6	(30%) 0	(0%)
Type	3 1	(5%) 0	(0%) 1.00
Mixed	 1	(5%) 0	(0%) 1.00
Total	BPAR 11	(55%) 2	(10%) 0.006
the incidence of the first rejection episodes is given. the highest Banff score is depicted if sequential biopsies 
were performed.
Bpar, Biopsy-proven acute rejection
Supplementary Table III: Immunosuppressive drugs dose and pre-dose concentrations
TAC-treated patients BELA-treated patients
TAC dose
(mg)
TAC C0
(ng/ml)
MMF dose	
(mg)
MPA C0
(μg/ml)
PRED dose
(mg)
BELA dose
(mg)
MMF dose
(mg)
MPA C0
(μg/ml)
PRED 
dose	(mg)
Day 4 16.7	(±	2.5) 16.8	(±	6.2) 2000	(±	0) 3.35	(±	1.59) 20.0	(±	0) 792	(±	153) 2000	(±	0) 3.85	(±	1.55) 20.0	(±	0)
Day 30 8.9	(±	4.6) 9.8	(±	3.3) 1750	(±	546) 2.69	(±	1.57) 12.5	(±	3.3) 767	(±	106) 1682	(±	603) 3.39	(±	1.74) 10.5	(±	2.7)
Day 90 4.7	(±	1.4) 6.8	(±	1.7) 1342	(±	473) 2.83	(±	1.62) 5.4	(±	1.3) 774	(±	130) 1364	(±	393) 3.27	(±	1.57) 5.0	(±	0)
Day 180 4.3	(±	1.1) 6.3	(±	1.5) 1181	(±	499) 2.17	(±	0.98) 4.7	(±	1.2) 383	(±	63) 1222	(±	441) 2.15	(±	1.34) 5.0	(±	0)
Day 360 4.2	(±	1.3) 7.0	(±	2.3) 1103	(±	493) 2.02	(±	0.92) 4.3	(±	1.5) 382	(±	58) 1139	(±	377) 1.99	(±	0.63) 5.0	(±	0)
mean (±SD)
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Supplementary Table IV. Univariate regression analysis between patient demographic characteris-
tics and signaling protein phosphorylation
Predictor
p-p38MAPK p-ERK p-Akt
β p value β p value β p value
Before
transplantation
Age	(years) 0.381 0.045 -0.175 0.374 0.126 0.523
Gender	(male	vs	female) -0.267 0.169 0.267 0.169 -0.273 0.160
Ethnicity	(non	caucasian	vs	caucasian) -0.370 0.053 -0.016 0.934 -0.324 0.092
Bodyweight	before	transplantation	(kg) 0.222 0.257 0.321 0.096 0.210 0.284
Highest	PRA	(%) 0.068 0.730 0.049 0.805 0.069 0.727
HLA	total	mismatches	(4	or	more	vs	3	or	less) -0.046 0.815 0.102 0.607 -0.075 0.704
HLA	DR	mismatches	(2	vs	1) -0.228 0.243 0.197 0.315 0.147 0.457
CMV	(negative	vs	positive) 0.234 0.230 -0.363 0.058 0.142 0.470
Renal	replacement	therapy	(no	vs	yes) -0.067 0.735 -0.023 0.906 -0.099 0.616
CD86	molecules/monocyte	pre-transplantation -0.065 0.741 -0.038 0.847 -0.101 0.607
Donor	age	(years) 0.217 0.267 -0.100 0.613 0.044 0.823
Donor	gender	(male	vs	female) -0.032 0.873 -0.072 0.715 -0.029 0.884
Day 4
Age	(years) 0.423 0.031 0.049 0.806 -0.252 0.205
Gender	(m	vs	f) -0.346 0.084 0.021 0.915 -0.033 0.872
Ethnicity	(non	caucasian	vs	caucasian) -0.285 0.159 -0.006 0.975 -0.152 0.448
treatment	group	(tacrolimus	vs	belatacept 0.118 0.566 -0.134 0.505 0.242 0.225
Bodyweight	before	transplantation	(kg) -0.026 0.900 0.253 0.203 0.087 0.667
Highest	PRA	(%) 0.029 0.890 -0.203 0.310 0.231 0.246
HLA	total	mismatches	(4	or	more	vs	3	or	less) -0.084 0.689 -0.261 0.188 -0.247 0.214
HLA	DR	mismatches	(2	vs	1) -0.349 0.087 -0.054 0.789 -0.430 0.025
CMV	(negative	vs	positive) 0.270 0.191 0.112 0.577 0.054 0.788
Renal	replacement	therapy	(no	vs	yes) 0.087 0.681 -0.081 0.686 0.057 0.779
CD86	molecules/monocyte	pre-transplantation -0.061 0.771 -0.027 0.895 -0.144 0.473
Donor	age	(years) 0.442 0.027 -0.239 0.230 0.133 0.510
Donor	gender	(male	vs	female) -0.047 0.823 -0.092 0.649 0.112 0.577
Day 360
Age	(years) 0.388 0.055 0.213 0.307 0.049 0.816
Gender	(m	vs	f) -0.213 0.307 -0.090 0.669 -0.115 0.586
Ethnicity	(non	caucasian	vs	caucasian) -0.007 0.974 -0.211 0.312 -0.054 0.797
treatment	group	(tacrolimus	vs	belatacept 0.180 0.389 -0.099 0.639 -0.092 0.662
Bodyweight	before	transplantation	(kg) -0.162 0.438 0.161 0.442 -0.045 0.829
Highest	PRA	(%) -0.131 0.533 -0.157 0.453 -0.148 0.481
HLA	total	mismatches	(4	or	more	vs	3	or	less) -0.148 0.481 -0.136 0.518 -0.281 0.173
HLA	DR	mismatches	(2	vs	1) 0.020 0.923 -0.106 0.613 0.154 0.462
CMV	(negative	vs	positive) 0.285 0.167 0.316 0.124 0.346 0.090
Renal	replacement	therapy	(no	vs	yes) 0.080 0.705 0.198 0.344 -0.046 0.828
CD86	molecules/monocyte	pre-transplantation 0.279 0.176 0.171 0.414 0.303 0.141
Donor	age	(years) 0.424 0.035 0.369 0.070 0.155 0.458
Donor	gender	(male	vs	female) -0.330 0.107 0.060 0.774 -0.275 0.184

 8
Targeting JAK/STAT Signaling to Prevent Rejection After 
Kidney Transplantation: A Reappraisal
Carla C. Baan1; Nynke M. Kannegieter1; Claudia rosso Felipe2; helio tedesco Silva, Jr2
1 Department of Internal Medicine—Nephrology and Transplantation, Erasmus MC, 
University Medical Center Rotterdam, The Netherlands.
2 Division of Nephrology, Hospital do Rim-UNIFESP, Sao Paulo, Brazil
Transplantation. 2016;100(9):1833-1839
Chapter 8  |  tarGetinG JaK/stat siGnalinG after Kidney transplantation
166
Abstract
The profound involvement of cytokines in allograft rejection makes the molecules that 
control their actions, members of the Jak-Stat pathway, ideal targets for pharmacological 
intervention. Numerous studies have demonstrated that Jak3 is widely involved in the 
activation cascade and function of most immune cells. Tofacitinib, an oral Janus kinase 
inhibitor that targets Jak1/Jak3 dependent Stat activation, has been assessed as a substi-
tute for calcineurin inhibitor therapy after low-to-moderate risk kidney transplantation in 3 
randomized trials. Results using fixed-dose regimens showed a low incidence of rejection 
and better renal function with less interstitial fibrosis/tubular atrophy versus calcineurin 
inhibitor therapy. However, the safety profile of tofacitinib was poor, including increased 
incidences of cytomegalovirus disease, herpes zoster, BK virus, and nephropathy, which 
led to the discontinuation of its development for transplantation. High tofacitinib con-
centrations were independently associated with serious infection. Dosing according to 
exposure levels, coupled with pharmacodynamic monitoring based on phosphorylation 
of Stat5, could improve safety compared to the early fixed-dose regimens. Future studies 
could assess individualized dosing based on pharmacokinetic and pharmacodynamic 
monitoring. Additionally, because the increase of viral infections under tofacitinib may 
have been influenced by overlapping toxicity with concomitant mycophenolic acid, 
exploration of alternative adjunctive therapies (e.g., a mammalian target of rapamycin 
inhibitor or belatacept) may demonstrate a better efficacy/safety profile. We believe that 
Jak inhibitors are a good and useful addition to the immunosuppressive armentarium for 
kidney transplant patients, and that new studies with personalized drug dosing, improved 
immune monitoring, and better patient selection should be performed.
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Introduction
Drugs that target protein kinases have become popular. The benefit of treatment with this 
class of therapeutics is clear: a high level of selectivity. The Food and Drug Administration 
has now approved several agents that inhibit cellular signaling of pathways activated by 
receptors of the platelet-derived growth factor, epidermal growth factor, vascular endo-
thelial growth factor, hepatocyte growth factor pathway, and cytokines of the IL-2 fam-
ily 1-5. These agents are given for the treatment of a wide range of diseases, that is, cancer, 
macular degeneration, auto immune diseases and for the prevention of allograft rejection 
after organ transplantation.
Allograft rejection is characterized by the production of a wide variety of cytokines in-
cluding members of the IL-2, IL-12, IL-27 families, interferons, and growth factors. These 
soluble factors exert their biological functions through janus tyrosine kinases (Jaks) and 
signal transduction and activators of transcription (Stats), which enable direct commu-
nication from the transmembrane cytokine receptor to the nucleus to interact with regu-
latory elements for gene expression (Figure 1) 6.  In human cells, 4 different cytoplasmic 
tyrosine kinases have been identified: Jak1, Jak2, Jak3 and Tyk2, and 7 Stat proteins: Stat1, 
Stat2, Stat3, Stat4, Stat5a, Stat5b, and Stat6 7. The profound involvement of cytokines in 
allograft rejection makes the molecules that control their actions, members of the Jak-
Stat pathway, ideal targets for pharmacological intervention. In vitro studies using human 
cells and cell lines have been performed with the small drug molecule named tofacitinib, 
an oral Janus kinase inhibitor (formerly known as tasocitinib and CP-690,550) 3.  These 
have demonstrated that this agent targets Jak1/Jak3-dependent Stat activation and can 
be used as a substitute for toxic calcineurin inhibitors (CNIs) in a murine model of heart 
transplantation and in cynomolgus monkeys receiving kidney transplants 3,8-10.
For organ transplant patients in whom alloreactivity must be controlled by immuno-
suppressive medication, blockade of Jak3 signaling has a huge therapeutic potential as 
it inhibits allogeneic T, B, and natural killer (NK) cell–mediated antidonor responses in a 
nonredundant way. In this overview article, we will discuss the outcomes of clinical trials of 
tofacitinib in kidney transplantation, and put these data in a broader context to understand 
why these studies were relatively unsuccessful and had to be discontinued. In addition, we 
will discuss what we have learned from our mistakes, what immune monitoring has shown, 
and how a new trial in kidney transplantation could be planned because we believe this 
class of immunosuppressive drugs deserves a second chance using an improved trial 
design guided by immune monitoring.
JAK3 Signaling
Numerous studies have investigated the role of Jak3 in immune cell development and 
function, demonstrating that it is widely involved in the activation cascade and func-
tion of most immune cells 11.  These studies demonstrate that the biology of Jak3 is not 
restricted to T, B, and NK cells and that Jak3 plays a functional role in the activation of 
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all hematopoietic cells including cells of the myeloid lineage. Jak3 is expressed at low 
levels in resting monocytes and can be induced by lipopolysaccharide and in response 
to [gamma]c  cytokines  12 and during granulocytic differentiation Jak3 is phosphorylated 
as it is a response gene for granulocyte colony-stimulating factor 13,14. A mouse study by 
Ghoreschi et al. 15 reported that blocking Jak 3 phosphorylation also modulates the innate 
immune responses. The IL-2/IL-2receptor-triggered Jak1/Jak3/Stat5 signaling pattern in 
both conventional and regulatory T cells has been characterized 16,17 and involvement of 
the Jak1/Jak3/Stat5 signaling pathway in B cell development has also been firmly estab-
lished 18,19. Binding of IL-7 to its receptor activates this signaling pathway, which interacts 
with the regulatory elements of genes essential for B-cell development. Typical examples 
of the key role of Jak3 function in B cells are the reports showing that mutations in the Jak3 
gene result in abnormal B-cell numbers and B-cell function 18,19. Recently, the role of Jak3 
was further acknowledged by the work of Cattaneo et al. 19 who demonstrated abolished 
B-cell differentiation to plasmablasts in response to the CD40 ligand and IL-21.
Experience With Jak3 Inhibitors in Kidney Transplant Patients
Tofacitinib is licensed by the Food and Drug Administration as a disease-modifying treat-
ment for rheumatoid arthritis, and has been assessed in a placebo-controlled random-
ized trial for the management of moderate-to-severe psoriasis 20.  Clinical trials are also 
exploring the use of tofacitinib in psoriatic arthritis 21, inflammatory bowel disease (Crohn 
disease and ulcerative colitis) 22, ankylosing spondylitis 23. In kidney transplantation, 3 ran-
domized trials have been undertaken in progressively larger populations, between 2005 
and 2012.The first study was performed in 28 stable kidney transplant recipients, evaluat-
ing the pharmacokinetics, pharmacodynamics, safety and tolerability of 3 dose levels of 
tofacitinib (5, 15 and 30 mg, twice a day [BID]) 3.  It was a double-blind study comprising 
28 days of treatment with a subsequent 28-day follow up period. Patients between 1.1 
and 11.7 years after transplantation were included but there was no mention of baseline 
renal function or any exclusion criteria. Patients were randomized (3:1) to tofacitinib or 
placebo in 4 sequential dose escalation cohorts. Compared with first dose, measures of 
drug exposure (Cmax, area under the curve [AUC]0–12, C12) remained at steady state after 
28 days for the 5- and 15-mg doses but not for 30-mg BID. Higher mean dose-normalized 
AUC0–12values were observed after 5 mg BID (15%) and 15 mg BID (54%), groups in that all 
but 1 patient was receiving CNI therapy, compared with the 30 mg BID group in that all 
patients were CNI-free. The lack of dose linearity suggests that coadministration with CNIs 
may moderately increase tofacitinib exposure. Importantly, although good correlations 
were observed between early time points (1, 2, and 4 hours) after drug administration and 
AUC0–12, the correlation with trough concentrations was poor, limiting its utility for thera-
peutic drug monitoring.
There were no deaths, malignancies, systemic opportunistic infections or acute rejection 
episodes during the study. No consistent changes were observed in vital signs, including 
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electrocardiogram evaluations. Infections and gastrointestinal disorders were the most 
frequent adverse events reported. A dose-dependent reversible reduction in hemoglobin 
and reticulocyte counts was observed primarily after the administration of 15 mg BID and 
30 mg BID. No significant changes in CD3, CD4, and CD8 lymphocytes were observed, but 
a mean 50% decrease in absolute NK cell counts (CD16 and CD56) were observed after the 
administration of 15 or 30 mg BID. A mean 130% increase in absolute CD19+ B lymphocytes 
was observed after the administration of 30 mg BID 3.
Subsequently, a randomized 2-stage 6-month study comparing the efficacy of tofacitinib 
with tacrolimus in de novo kidney allograft recipients receiving IL-2 receptor antagonist 
induction, mycophenolate mofetil and corticosteroids was undertaken 24. In stage 1 (pilot 
trial), 61 patients were randomized to receive tofacitinib 15 mg BID (n = 20) or 30 mg BID (n 
= 20), or tacrolimus (n = 21). Patients completing 6 months of treatment were enrolled in an 
extension study to month 12 and doses of tofacitinib were reduced to 10 mg BID and 15 mg 
BID, respectively. The numbers of biopsy proven acute rejection (BPAR) at 6 months were 1, 
4 and 1, respectively with no further episodes by month 12. At 12 months’ mean estimated 
glomerular filtration rates (GFRs) were 83.6, 77.6 and 73.3 mL/min, respectively. Patients 
receiving tofacitinib presented higher incidences of serious adverse events and clinically 
significant infections including cytomegalovirus (CMV) disease, herpes zoster, and BK vi-
remia and nephropathy (Table I). Due to a high incidence of BK virus nephropathy only 
in patients receiving tofacitinib 30 mg BID, mycophenolate mofetil was discontinued in 
this group. In addition, patients receiving tofacitinib showed modest lipid elevations and 
a trend toward more frequent anemia and neutropenia during the first 6 months. Again, 
NK cells were reduced by 77% or less in tofacitinib-treated patients. Altogether these data 
indicated that tofacitinib at 15 mg BID showed an efficacy/safety profile that was compa-
rable to the tacrolimus control group, except for a higher rate of viral infection. Stage 2, 
anticipating enrollment of an additional 195 patients, was not implemented due to signs 
of overimmunosuppression in the 30-mg BID dose group 24.
Based on the results of this pilot study, a phase 2b prospective study was conducted, 
enrolling 331 low-to-moderate risk de novo kidney transplant patients 25.  Patients were 
randomized to receive tofacitinib 15 mg BID from months 1 to 6, reduced to 10 mg BID 
(more intensive [MI] regimen, n = 110), or 15 mg BID from months 1 to 3, reduced to 10 mg 
BID (less intensive (LI) regimen, n = 111) or cyclosporine (CsA) (n = 110). All patients received 
basiliximab induction, mycophenolic acid (MPA) and corticosteroids (Table I). There were 
no differences in the incidences of first clinical BPAR at 6 or 12 months (Table I). African 
American patients receiving tofacitinib showed a higher incidence of acute rejection 
compared to CsA (30.2%, 29.5%, and 8.3%). Patients receiving the LI regimen showed only 
vascular rejection (>IIA) and 2 of these patients eventually lost their graft. More patients in 
the CsA group were diagnosed with antibody mediated rejection (1.9%, 0.9%, and 4.6%).
At month 12, iohexol-measured GFRs were higher for MI and LI versus CsA and fewer 
patients in the MI or LI groups developed chronic allograft lesions (Table I). Drug discon-
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tinuations, serious infections, CMV disease, anemia, neutropenia, and posttransplant lym-
phoproliferative disease (PTLD) occurred more frequently in the MI and LI groups compared 
with CsA. A lower frequency of posttransplant diabetes mellitus or impaired glucose fasting 
glucose was observed in patients receiving tofacitinib compared to CsA (24.2%, 17.8%, and 
38%) 25.  It was also noted that in patients receiving tofacitinib, MPA exposure was 37.4% 
higher compared with patients receiving CsA 25.
When patients were analyzed according to tofacitinib plasma concentrations, those 
below the median level of the whole group showed a similar incidence of serious infection 
or CMV disease compared to CsA. Univariate analysis showed that tofacitinib exposure, 
as measured by C0 and C2, donor and recipient age, and use of CMV prophylaxis were as-
sociated with occurrence of serious infection 26.  Using multiple regression analysis, only 
tofacitinib C2 concentrations were independently associated with serious infection (C0 was 
not entered into the multiple regression analysis). Interestingly, MPA C0  concentrations 
were not associated with serious infections. Serious infections occurred more frequently 
in patients with tofacitinib exposure above median (AME, 53.0%) than below median 
exposure (BME, 28.4%) or in those given cyclosporine (25.5%). PTLD only occurred in the 
AME subgroup. In terms of efficacy, no differences were observed in the incidence of first 
BPAR at 6 and 12 months comparing BME and CsA groups, but patients in the AME group 
tended to show lower rates compared to the BME and CsA groups. Among black patients, 
first BPAR was observed more frequently in the BME group compared to the AME and CsA 
groups (0%, 30.6%, and 8.3%), respectively. Measured GFR was higher in both the AME 
and BME groups versus CsA (61.2 and 67.9 vs 53.9 mL/min) at month 12. Fewer patients 
developed interstitial fibrosis and tubular atrophy at month 12 in the AME (20.5%) and 
BME (27.8%) groups versus CsA (48.3%). These data suggest that monitoring of plasma 
concentrations of tofacitinib may preserve the overall benefits including low rates of acute 
rejection, improved renal function, and a lower incidence of interstitial fibrosis and tubular 
atrophy with similar rates of serious infection and no PTLD 26.
Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interactions
In healthy individuals, pharmacokinetic characterization revealed that about 74% of the 
oral dose of tofacitinib is rapidly absorbed reaching peak plasma concentrations after 0.5 
to 1 hour 27. After intravenous administration, tofacitinib shows moderate tissue distribu-
tion, with a volume of distribution of 87 L. In plasma, about 70% is parent drug, and the 
protein binding is about 40%. Clearance mechanisms appear to be 70% through hepatic 
metabolism and 30% renal excretion of the parent drug. The metabolism of tofacitinib is 
mediated by CYP3A4 with a minor contribution from CYP2C19. Thus, inhibitors and inducers 
of CYP3A4 are likely to alter the disposition of tofacitinib. Steady-state pharmacokinetics in 
healthy subjects are predictable from single-dose data, with no evidence of accumulation. 
The elimination half-life (t½) is about 3 hours 28.
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Due to inter-individual variability, it is difficult to determine the optimal therapeutic 
regimen for each patient. Individual variations in drug sensitivity can be determined by 
pharmacodynamic monitoring, which focuses on measuring the biological effects of a 
drug. For tofacitinib monitoring, the phosphorylation of Stat5 can be used as a measure 
guiding dosing 29. IL-2–induced pStat5, the key substrate of Jak3, was reduced in the pres-
ence of serum collected from 8 patients receiving 30 mg BID of tofacitinib for 29 days, an 
effect observed in both CD4 and CD8 T cells. This effect was associated with the plasma 
concentration of tofacitinib and with reduced expression of several Stat5 target genes, 
including FoxP3, granzyme B, FAS ligand, and IFN-[gamma]. IL-2–induced pStat5 predomi-
nated in regulatory CD4 T cells (71%) compared with effector T cells (42%). Ex vivo addition 
of tofacitinib blocked the IL-2 induced pStat5, while the pStat5 of regulatory T cells was 
barely inhibited. In addition, tofacitinib preserved the suppressive activity of these patient-
derived regulatory T cells 17.
 It is possible that drug-drug interactions between tofacitinib and MPA may have con-
tributed to the relatively high incidence of infections and malignancies observed in clinical 
studies. Therefore, the pharmacokinetics of MPA were evaluated in patients receiving 
tofacitinib or tacrolimus. Plasma MPA concentrations were obtained from 17 adult patients 
who received either 15 mg or 30 mg tofacitinib BID (8 patients) or tacrolimus (9 patients) 
after kidney transplantation. All patients also received concomitant mycophenolate 
mofetil, prednisone, and basiliximab induction. The median mycophenolate mofetil dose 
was 1000 mg BID. Based on individual estimates, oral clearance from the population phar-
macokinetic model, mean steady-state area under the concentration-time curve values for 
a mycophenolate mofetil dose of 1000 mg BID were 63 mg/h per liter (22%) and 59 mg/h 
per liter (36%) for the tofacitinib and tacrolimus groups, respectively, that is, tofacitinib 
does not influence systemic MPA exposure 30.
It is well recognized that pharmacokinetic and pharmacodynamic characteristics are 
influenced by other drugs, such as antibiotics and cardiovascular drugs, factors related 
to the underlying disease, and age of the recipient. These factors, combined with a highly 
complex immune system that is specific to each patient, makes it extremely difficult to 
predict the efficacy and safety of immunosuppressive drugs, such as tofacitinib. Ide-
ally, the effects of Jak3 blockade should be studied on graft-infiltrating cells attacking the 
transplant by single-cell analysis. Apart from the limited availability of tissue, this is techni-
cally challenging and currently cannot be used for diagnostic purposes. The ultimate goal 
would be to have a set of pharmacodynamic and immunological parameters to establish 
an immunological and safety risk profile. This would be a valuable pharmacodynamic tool 
kit for clinicians to help with transplantation-related risk assessment and tailoring of im-
munosuppressive medication, for example, in vulnerable groups of patients such as the 
frail and older adults because aging and immune senescence have an impact on treatment 
and outcomes 31.
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JAK 3 Inhibitors
Initial studies suggested that tofacitinib was a selective inhibitor of JAK3 kinase 8. Subse-
quent studies showed that tofacitinib also inhibits JAK1, JAK2 and Tyk2 kinases at nano-
molar concentrations 32.  This finding may account for the occurrence of adverse events 
observed in clinical studies beyond those which would be anticipated based on selective 
inhibition of [gamma]c/Jak3-dependent cytokines. Selective JAK3 inhibitors could improve 
the safety profile of tofacitinib. Several compounds were tested but none showed sufficient 
selectivity in in vitro kinase and cellular assays 33. Nevertheless, a series of elegant studies 
has indicated that Jak1 has a dominant role over Jak3 in [gamma]c-dependent signal trans-
duction. This suggests that selective pharmacological inhibition of the catalytic activity of 
Jak3 is not enough to achieve efficient immunosuppression, as demonstrated in severe 
combined immunodeficiency patients with Jak3 mutations 41.  These observations show 
that Jak1 activation by the IL-2 family of cytokines, or other Jak1-dependent cytokines like 
IL-6, can compensate for the impaired Jak3 responsiveness that results in the activation 
of immune competent cells. Cytokines also have the ability to activate multiple signaling 
pathways which contribute to cellular functions. These “backup” elements of the immune 
system make it impossible for immunosuppressive drugs to provide complete suppression 
of immune competent cells.
Future Investigation in Kidney Transplantation
Studies conducted thus far in kidney transplant recipients and in patients with autoim-
mune diseases have confirmed that Jak3 inhibition is a good target for immunosuppres-
sion and that tofacitinib is a potent inhibitor of Jak3 20,28,34. Tofacitinib, in combination with 
mycophenolate, is efficacious for the prevention of acute rejection after kidney transplan-
tation 24,25. Various questions, however, remained unexplored.
First, combination of tofacitinib with mycophenolate has been associated with higher in-
cidence of viral infections and perhaps viral-associated malignancies. Whether this safety 
profile is due to the drug combination or tofacitinib alone is not known. Mycophenolate 
has been associated with a higher incidence of viral infection 35. Tofacitinib possibly shares 
the same characteristic 36. Although no rigorous studies have been done so far, the consis-
tent and reproducible reduction in NK cells under tofacitinib may be associated with this 
observation. On the other hand, the effect of tofacitinib on NK, T, and B cells may reduce 
the incidence of chronic antibody mediated rejection 37. Also, 1 experimental study in mice 
demonstrated that JAK3/Stat6 stimulates bone marrow-derived fibroblast activation in re-
nal fibrosis. Treatment with tofacitinib significantly reduced myofibroblast transformation, 
matrix protein expression, interstitial fibrosis development, and apoptosis 38. Follow-up of 
patients in both phase 2 trials may also provide important information on the long-term 
efficacy/safety profile of tofacitinib.
Second, the pharmacokinetics of tofacitinib based on serum concentration, together 
with pharmacodynamic monitoring, provide tools for the optimization of this compound 
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in individual transplant patients. It is unfortunate that due to the adverse event profile 
under a fixed dosing regimen, tofacitinib clinical development for transplantation was 
prematurely terminated. Tofacitinib has a narrow therapeutic index, with a 5- to 6-fold 
intersubject variability in drug exposure among patients receiving the same dose, and 
efficacy/safety appear to be associated with plasma concentration rather than with oral 
dose.26 The relatively short half-life may hamper trough plasma concentration monitor-
ing, suggesting that an earlier time point (C2) may be preferable. Also, because tofacitinib 
is metabolized by CYP3A4 and CYP2C19, there is potential for drug-to-drug interaction with 
drugs commonly used to treat comorbidities. As for sirolimus 39, everolimus 40, and belata-
cept 41,  the chosen higher-dose groups tested in clinical trials were not associated with 
increased efficacy but did incur increased toxicity. Therefore, concentration-controlled 
studies are needed to evaluate the efficacy/safety profile of tofacitinib, and it could be 
anticipated that therapeutic drug monitoring—possibly with reduced exposure over time 
posttransplant—may improve outcomes and reduce serious infections and PTLD.
Third, as has been observed previously in CNI-free immunosuppressive regimens using 
mammalian target of rapamycin (mTOR) inhibitors 42, the combination of tofacitinib with 
mycophenolate has been challenging due to overlapping toxicities, primarily infections 
and bone marrow toxicities. Whether a combination with an mTOR inhibitor or belatacept 
would result in a better efficacy/safety profile is not known.
Proposed Study Designs
Considering the rational for use to tofacitinib and the studies performed to date, the 
next trial would compare tofacitinib, using concentration-controlled dosing based on C2 
monitoring versus tacrolimus. All patients would receive induction with basiliximab, and 
maintenance therapy with mycophenolate and steroids. Two target tofacitinib concen-
tration ranges would be tested, with minimal overlap between them, to further explore 
concentration-effect relationships. Prophylaxis for viral infections would be mandatory for 
at least 6 months. Serial measurements of viral replication, including Ebstein-Barr Virus 
and polyomavirus viremia, would also assist dose adjustments as indicators of over im-
munosuppression. After determination of the therapeutic concentrations of tofacitinib, 
early conversion trials could be explored, whereby patients receiving tacrolimus would be 
converted to tofacitinib at 3 to 6 months after transplantation, a period when the risk of 
acute rejection and viral infections is lower.
Another possible study design would combine tofacitinib and an mTOR inhibitor. This 
approach offers 2 advantages. First, it has been demonstrated that patients receiving 
mTOR inhibitors have a lower incidence of viral infections. Second, based on in vitro and 
ex vivo studies, this combination could enhance the number and function of regulatory 
T cells. However, the trial would require therapeutic drug monitoring of 2 drugs and the 
concerns associated with de novo use of mTOR inhibitors regarding wound healing and 
recovery of renal function would have to be taken into account.
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Summary
The introduction of calcineurin inhibitors (CNIs) and mycophenolic acid (MPA) to the trans-
plantation clinic improved the outcomes of kidney transplantation 1-3. Unfortunately, the 
use of the CNI tacrolimus is associated with side effects such as nephrotoxicity, diabetes 
mellitus, neurotoxicity and dyslipidemia and there is thus an unmet need for an alternative 
drug with comparable efficacy yet less side effects 4. The most recently approved immuno-
suppressive drug belatacept, a co-stimulation blocker, is non-nephrotoxic and more selec-
tive than tacrolimus, but its use is associated with an increased incidence of rejection 5-7.
Therapeutic drug monitoring (TDM) of tacrolimus is based on a pharmacokinetic (PK) 
method that measures whole-blood (pre-dose) concentrations. Unfortunately, this method 
has a limited predictive power with regard to the occurrence of acute rejection episodes 
or toxicity. One explanation for this observation may be that whole-blood concentrations 
do not correlate with the amount of drug acting on its receptor. Furthermore, tacrolimus 
displays considerable intra-patient variability limiting the predictive power of a drug con-
centration measurement at a single time point 8-11. A better or complementary approach 
to traditional PK TDM may be the measurement of the biological effects of tacrolimus, also 
called pharmacodynamic (PD) monitoring 12-15. In our studies, we aimed to assess novel 
assays for PD monitoring of immunosuppressive drugs within their main target: the T cell. 
Additionally, we have investigated the efficacy of currently prescribed immunosuppressive 
drugs to inhibit monocyte activation, a cell type that also plays an important role in rejec-
tion processes after kidney transplantation 16-18.
The role of cells from the monocyte-macrophage cell lineage in acute and chronic rejec-
tion processes after SOT has been increasingly recognized but the knowledge of the effect 
of currently prescribed immunosuppressive drugs on monocyte activation is relatively 
limited. In chapter 2, we reviewed the effects that are currently known and discussed 
the potential use of other available immunosuppressive drugs in- and outside the field 
of transplantation. We conclude that tacrolimus, MPA and mTOR inhibitors have limited 
inhibitory effects on monocyte functions, including the inhibition of cytokine production, 
co-stimulation blockade and the inhibition of monocyte migration to the allograft. Mono-
clonal antibodies, such as canakinumab (interleukin-1β inhibitor), tocilizumab (interleu-
kin-6 receptor blocker) and infliximab (tumor necrosis factor-α inhibitor) are effective in 
inhibiting monocyte functions in autoimmune diseases. We speculated that after organ 
transplantation new immunosuppressive therapies, possibly including these monoclonal 
antibodies, should also target cells of the monocyte-macrophage lineage to prevent acti-
vation and inhibit the function of these cells.
Because of the limited knowledge about biological effects of the currently prescribed im-
munosuppressive drugs on other signal transduction pathways besides nuclear factor of 
activated T cells (NFAT) in monocytes, the individual drug effects of tacrolimus and MPA on 
monocyte intracellular activation pathways were studied (chapter 3). By use of phospho-
specific flow cytometry, the phosphorylation patterns of three signaling proteins involved 
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in monocyte activation, i.e. p38MAPK, ERK and Akt, were measured in blood samples of 
healthy volunteers spiked with therapeutic concentrations of either tacrolimus or MPA. A 
limited effect of both drugs on monocyte signaling pathway activation and the functions of 
monocytes, such as cytokine production and phagocytosis, was found.
In chapter 4, we further investigated the PD effects of tacrolimus-based immunosup-
pression on monocyte activation. In contrast to the previous chapter, where we studied 
the individual drug effects, we determined the inhibition of monocyte activation in the 
presence of combination immunosuppressive drug therapy in blood samples of kidney 
transplant patients. Phospho-specific flow cytometry analysis of p38MAPK, ERK and Akt 
phosphorylation not only revealed that this technique is a potential tool for measuring the 
biological drug effect of tacrolimus-based immunosuppression, but also showed that even 
combination therapy only partially inhibited monocyte activation in vivo.
In the second part of the thesis, we investigated potential PD assays for improving 
TDM of tacrolimus after transplantation. The main target of tacrolimus in T cells is the 
calcineurin pathway, of which NFAT is an important signaling molecule. In chapter 5, we 
determined the PD effects of tacrolimus and other immunosuppressive drugs by measur-
ing the expression of the inducible isoform of NFAT, NFATc1, in T cells, as no tools are 
available to measure dephosphorylation of NFAT. The study described here showed that 
the amplification of NFATc1 is reduced in CD4+CD28+ and CD8+CD28+ T cells upon treat-
ment with tacrolimus-based immunosuppression. Belatacept-based treatment was used 
as a negative control. We confirmed that belatacept-based immunosuppression does not 
inhibit NFATc1 amplification. Furthermore, tacrolimus-based immunosuppression had 
no effect on NFATc1 amplification in CD8+CD28- T cells, indicating that measuring NFATc1 
amplification is a promising tool for PD monitoring of tacrolimus in CD28+ T cells.
Another intracellular pathway in T cells which is inhibited by tacrolimus is the MAPK 
pathway. Measuring p-p38MAPK, a member of this pathway, with phospho-specific flow 
cytometry can be a promising tool to monitor the effects of conversion from the twice-
daily tacrolimus formulation to the once-daily, prolonged-release tacrolimus formulation, 
as is described in chapter 6. Once-daily tacrolimus has been developed to overcome 
adherence problems associated with the use of twice-daily tacrolimus but blood pre-dose 
concentrations of this formulation may decrease on average by 15% after 1:1 (mg for mg 
basis) conversion. We showed that after conversion no difference was measured in the pre-
dose concentrations of tacrolimus, whereas the p38MAPK phosphorylation significantly 
increased in CD4+ T cells and CD8+ T cells, indicating T cell activation. Therefore, phospho-
specific flow cytometry analysis of p38MAPK phosphorylation may be a more sensitive 
tool for monitoring subtle changes in tacrolimus exposure after conversion and should be 
assessed for its suitability as an additional tool in transplantation diagnostics.
In chapter 7, we determined the PD drug effects of a tacrolimus-based therapy com-
pared to belatacept-based therapy (which served as a negative control) in T cells of kidney 
transplant recipients. Before and during the first year after transplantation, blood samples 
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of kidney transplant recipients were measured for their phosphorylation of p38MAPK, ERK 
and Akt in T cell subsets to see whether phospho-specific flow cytometry can be used for 
TDM of tacrolimus-based immunosuppression. Phosphorylation of p38MAPK and Akt, 
but not ERK, was inhibited in CD4+ and CD8+ T cells during tacrolimus-based treatment. 
Moreover, in belatacept-treated patients suffering from an acute rejection episode, ERK 
phosphorylation was higher immediately prior to the diagnosis of rejection compared to 
patients without rejection. This suggests that p-ERK is involved in rejection processes and 
that belatacept-based immunosuppression does not inhibit key T cell activation pathways, 
which may contribute to the high rejection incidence observed among belatacept-treated 
kidney transplant recipients. These findings suggest also that phospho-specific flow cy-
tometry is a promising tool to PD monitor tacrolimus-based therapy in kidney transplant 
recipients.
Rejection of the transplant is characterized by the production of a wide variety of cyto-
kines that activate Janus tyrosine kinases (JAKs) and signal transduction and activators 
of transcription (STATs) intracellularly within T cells to induce the immune response. In 
chapter 8, we reviewed the use of the JAK inhibitor tofacitinib as an immunosuppressive 
drug in kidney transplantation. The outcomes of several clinical trials where this drug was 
assessed as a substitute for CNI therapy were discussed. Although the results were promis-
ing, the high fixed-dose regimens of tofacitinib caused an increase in infections and, as a 
consequence, the discontinuation of the development of the drug for transplantation. PD 
monitoring in combination with PK monitoring for dose adjustment could improve the 
safety profile of tofacitinib. Therefore, new studies should be performed that focus on per-
sonalized tofacitinib dosing, improved immune monitoring and a better patient selection.
General Discussion
TDM of tacrolimus is currently based on a PK approach that measures whole-blood (pre-
dose) drug concentrations. Unfortunately, these measurements cannot accurately predict 
clinical outcomes after transplantation, such as rejection, and have a poor correlation with 
long-term outcomes after transplantation. PD monitoring is an alternative and possibly 
complimentary way for TDM that measures the biological effects of the drug at its target 
site. The research described in this thesis assessed novel techniques for PD monitoring of 
immunosuppressive therapy after transplantation.
New strategies for pharmacodynamic therapeutic drug monitoring of tacrolimus
Two promising methods for the optimization of TDM are the phospho-specific flow cytom-
etry assay and the intracellular monitoring of NFATc1 amplification. Phospho-specific flow 
cytometry measures the phosphorylation of molecules involved in T cell activation, such 
as p-p38MAPK and p-ERK (both members of the MAPK pathway) and p-Akt (a member of 
the PI3k/Akt/mTOR pathway). Advantages of this assay are the short turn-around time, its 
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sensitivity, the material that can be used (small volume whole-blood samples) and the 
detection at the single-cell level 12,19. The assay can be applied to monitor therapeutic drug 
effects on T cells (chapter 6 and 7) and monocytes (chapter 3 and 4). Phospho-specific 
flow cytometry is a promising tool for TDM as it measures drug-related effects upstream 
in the T cell signaling cascade. This assay can be done in several hours which makes it an 
appropriate tool for clinical purposes. In T cells, phospho-specific flow cytometry analysis 
shows a clear inhibition of p38MAPK and Akt phosphorylation during tacrolimus-based 
therapy, while no effect was measured on the phosphorylation of ERK (chapter 6 and 
7). Moreover, the phosphorylation of p38MAPK correlated significantly with the pre-dose 
concentrations of the twice-daily formulation of tacrolimus in T cells 20.
Next, we studied whether immunosuppressive drugs inhibited the expression of the acti-
vation molecules p-p38MAPK, p-ERK and p-Akt in monocytes, because up until now little is 
known about the effects of immunosuppressive drug therapy on monocyte function. From 
our studies described in this thesis it is clear that the currently prescribed immunosuppres-
sive drugs also inhibit monocyte function but only to a limited extent and that new thera-
pies are needed for targeting monocytes (chapter 2, 3 and 4). Furthermore, these studies 
show that the phospho-specific flow cytometry assay is not only suitable for monitoring 
the direct biological effects of tacrolimus on cells of the adaptive immune system, but that 
it can also be used to study effects on the intracellular signaling pathway activation in cells 
of the innate immune system. In addition, our studies show for the first time that immu-
nosuppressive effects of tacrolimus can be routinely monitored in whole-blood samples of 
transplant patients. A combination between PK and PD monitoring of immunosuppressive 
drugs will give additional information about the drug’s effects on monocyte activation. At 
the same time, it is clear that validation of our findings is warranted. Phospho-specific flow 
cytometry might be a useful tool to further optimize immunosuppression and to achieve 
optimal clinical outcome in the future 21.
Another promising method for PD monitoring of tacrolimus in T cells is the analysis of 
NFATc1 amplification (chapter 5). This assay does not measure dephosphorylation of 
NFAT but measures the production of NFATc1 after T cell activation. NFATc1 is the only 
NFAT member that can be enhanced upon antigenic stimulation and maintained by posi-
tive autoregulation in T cells and its expression is regulated by the calcineurin pathway. 
As a consequence, its amplification will be directly affected by tacrolimus. Like phospho-
specific flow cytometry, this assay can also detect the amplification of NFATc1 in differ-
ent T cell subsets each with its own specific role in the rejection process. For example, 
CD8+CD28- T cells are known to be potentially more harmful than CD8+CD28+ T cells and 
it is important to monitor this CD8+CD28- T cell subset intensively to determine whether 
these cells can still contribute to rejection after transplantation. NFATc1 analysis might be 
helpful to determine the immunosuppressive effects of tacrolimus and other agents on this 
T cell population 22-24. Our data suggest that CD8+CD28- T cells might be less sensitive to im-
munosuppressive drug therapy than the other T cell subsets, which was not known before 
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(chapter 5). In addition, we showed that this PD assay can be measured in whole blood 
samples of kidney transplant patients. However, measuring NFATc1 amplification includes 
a 7h procedure, which requires further optimization to use it for monitoring patients in 
routine clinical practice. We here present the first data and in line with our phosphorylation 
studies, this assay also needs validation in other cohorts to prove its robustness for routine 
use.
Measuring NFATc1 amplification has not yet been validated for monitoring monocyte 
activity, although these cells also express this molecule 25. Future studies should also 
determine whether this assay can be used to monitor the immunosuppressive effects of 
tacrolimus on NFATc1 amplification of monocytes. A first approach would be to spike blood 
samples of healthy volunteers with different immunosuppressive drugs and to test for the 
amplification of NFATc1. Thereafter, samples of a large group of kidney transplant patients 
should be tested before and after transplantation in order to get more sustained informa-
tion about the effects of a combined immunosuppressive drug therapy on monocytes.
In addition to the above described assays, other PD assays have also been developed, 
such as the measurement of calcineurin phosphatase activity, IL-2 production, and NFAT-
regulated gene expression. Evaluation of all these read-outs and parameters is performed 
in mostly small patient cohorts and it is clear that more and larger patient numbers are 
needed to demonstrate if these tools are sensitive and accurate enough to contribute to 
better diagnostics of tacrolimus therapy 26-28.
A way to move forward with the PD measuring of tacrolimus is standardization of the as-
says, such as the cytokine production assay 21,29,30. Currently, no threshold level of cytokine 
production for adjusting drug doses exist and the assay is still being evaluated in ongo-
ing multicenter clinical trials 29. Moreover, this method has a lack of specificity, since the 
production of cytokines may also be influenced by other factors, such as infection, which 
affects the interpretation of the cytokine measurements 27.
Analyzing NFAT-regulated gene expression for PD monitoring of CNI’s is under investiga-
tion in ongoing multicenter clinical trials and the benefit of the method for monitoring 
tacrolimus-treated patients will be evaluated in these studies. These studies show that 
monitoring residual NFAT-regulated gene expression may be helpful to identify transplant 
recipients at higher risk of rejection or infection. Hopefully these studies will also reveal the 
additive contribution of the assay in TDM 27. For the interpretation of the data it is of course 
important to realize that, apart from tacrolimus, also other immunosuppressive drugs can 
influence the expression of NFAT-regulated genes. For example, NFAT molecules are known 
to cooperate with the AP-1 proteins that are regulated by prednisolone 31,32.
Lessons learned and the road ahead
Although the results are promising, both the phospho-specific flow cytometry and NFATc1 
amplification assay are not yet ready for routine clinical use. Both assays were tested in a 
single center study and in a small patient cohort. A next step is to perform larger (multi-
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center) studies aiming to confirm our findings. Such studies should also determine the 
phosphorylation threshold associated with drug-related complications of under- and 
overdosing 33. The threshold will be helpful for standardized clinical protocols for TDM of 
tacrolimus.
For the validation of phospho-specific flow cytometry and the NFATc1 amplification 
assay, a correlation between the outcomes of those assays and pre-dose tacrolimus con-
centrations is required. On top of that, validation of both assays can also be done by the 
calculation of the area-under the concentration versus time-curve values. These values 
give a better reflection of tacrolimus exposure than pre-dose concentrations. Eventually, 
the validation will most likely lead to a complementary tool that supports conventional 
TDM of immunosuppressive drugs. Phospho-specific flow cytometry can also be combined 
with other PK approaches, such as measuring the intra-cellular immunosuppressive drug 
levels in the target cell, which might give a better reflection of drug efficacy 34-36. Recent 
studies showed that intra-lymphocytic concentrations of tacrolimus are better correlated 
to drug efficacy and toxicity than pre-dose whole-blood concentrations and would there-
fore be a better form of PK monitoring of CNIs. 
Next to their role in optimizing TDM of tacrolimus, PD assays may be also useful in pre-
dicting clinical outcomes after transplantation, such as acute rejection 37,38. However, we 
were not able to associate the phosphorylation profiles of p38MAPK, ERK and Akt with the 
occurrence of acute rejection, one reason being the low number of patients suffering from 
a rejection episode in our study population. The use of a larger study population will reveal 
the power of the assay to determine if p-p38MAPK, p-Akt or p-ERK levels are associated 
with rejection responses and perhaps also with other clinical outcomes. Our first studies 
suggest that p-ERK might be a good marker to identify patients at risk for acute rejection 
(Chapter 7). In monocytes, we showed that phosphorylation of ERK was only limited af-
fected by immunosuppressive drugs (Chapter 3 and 4). This observation shows that these 
cells are still active and can contribute to rejection processes. The important role of ERK 
phosphorylation was also noticed by other research groups, describing the association 
between p-ERK and the occurrence of antibody-mediated rejection in heart allografts and 
the relation between targeting p-ERK and the suppression of allo-immune responses in a 
cardiac allograft mouse model 39,40.
Future perspectives and recommendations
In the future, when phospho-specific flow cytometry is ready for routine use we recommend 
that the assay should be used in combination with PK measurements. In our view, this 
will improve TDM and will lead to improved dosing of immunosuppressive drugs for organ 
transplant patients. For this, multiple signaling proteins should be monitored, because 
measuring a single biomarker will not reflect the wide range of complications and events 
patients are suffering from. In addition, in monocytes, tacrolimus inhibits p-p38MAPK, 
while mycophenolate mofetil (MMF) shows the strongest effect on p-Akt (chapter 3). 
189
Chapter 9  |  suMMary and General discussion
Ch
ap
te
r 9
Thus, for a more specific monitoring of tacrolimus both p-p38MAPK and p-Akt should be 
measured in monocytes and T cells, while p-ERK should be monitored in T cells to assess 
the risk for rejection.
Both the phospho-specific flow cytometry assay and the measurement of NFATc1 ampli-
fication are specific for tacrolimus and are not influenced by the use of MMF or prednisone 
in T cells. This was found since in belatacept-based therapy, no effect on any of the studied 
parameters was found. Therefore, we recommend the assay only for TDM of tacrolimus or 
a tacrolimus-based therapy and not for the monitoring of other immunosuppressive drug 
effects.
Conclusions
•	 The	currently	prescribed	 immunosuppressive	drugs	have	only	a	 limited	effect	on	 in-
tracellular monocyte activation pathways, demonstrating the need for new drugs that 
target monocytes after solid organ transplantation.
•	 Phospho-specific	 flow	 cytometry	 is	 a	 potential	 pharmacodynamic	 tool	 for	 TDM	 of	
tacrolimus in kidney transplant recipients.
•	 Measuring	NFATc1	amplification	is	a	specific	whole-blood	test	to	monitor	the	biological	
effects of tacrolimus in T cells of kidney transplant recipients.
•	 Phosphorylation	of	ERK	in	both	monocytes	and	T	cells	is	a	promising	parameter	for	risk	
assessment of acute rejection.
•	 Conventional	pharmacokinetic	measurements	should	be	combined	with	the	pharma-
codynamic phospho-specific flow cytometry assay to optimize TDM of tacrolimus.
•	 Both	 the	 phospho-specific	 flow	 cytometry	 assay	 and	 the	 NFATc1	 amplification	 as-
say can measure the activation of signaling molecules in the different CD4+CD28+, 
CD8+CD28+ and CD8+CD28- T cell subsets.
•	 Phospho-specific	flow	cytometry	after	transplantation	is	a	relatively	new	tool	to	assess	
the efficacy and safety of the once-daily formulation of tacrolimus and JAK inhibitors.
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Nederlandse samenvatting
Niertransplantatie is voor veel patiënten met nierfalen de beste behandeling. In de eerste 
plaats, omdat de kwaliteit van leven sterk verbetert na een succesvolle transplantatie. 
Daarnaast stijgt de levensverwachting na niertransplantatie met drie tot vijftien jaar, 
waarbij zelfs oudere niertransplantatiepatiënten tot wel 5 jaar levensverlenging kunnen 
behalen 1-3. Sinds de eerste succesvolle niertransplantatie in 1954 zijn de uitkomsten na 
niertransplantatie sterk verbeterd. Dit is mede te danken aan de ontwikkeling van afweer-
remmende geneesmiddelen waardoor ook transplantatie met niet-verwante donoren 
of een transplantatie door de bloedgroep- of HLA barrière mogelijk zijn geworden. Deze 
geneesmiddelen zorgen ervoor dat de donornier niet wordt afgestoten en worden ook wel 
immunosuppressiva genoemd.
Afstoting kent vele vormen en pathofysiologische mechanismen. Al voor de transplanta-
tie zelf kan er schade in de donornier ontstaan doordat de donor hersendood is en door 
de onderbreking van de circulatie (bloeddoorstroming) van de nier na de uitname. Als 
gevolg van deze schade, de zogenaamde ischemie-reperfusie schade, zal het aangeboren 
afweersysteem van de ontvanger reageren waarbij verschillende soorten immuun cellen 
geactiveerd raken. Hieronder vallen dendritische cellen, natural killer cellen en monocy-
ten  4-6. Deze cellen raken geactiveerd door signaalmoleculen die worden uitgescheiden 
door de apoptotische cellen in de donornier. Daarnaast herkennen de cellen van het 
aangeboren afweersysteem de lichaamsvreemde eiwitten (antigenen) die behoren tot het 
witte bloedgroepensysteem (Humane Leukocyten Antigenen-systeem, HLA) en voorkomen 
op het oppervlak van cellen van de donornier. De activatie van het aangeboren immuun-
systeem draagt bij aan het ontstaan van een ontstekings- en afstotingsreactie. Deze reactie 
leidt vervolgens tot activatie van de cellen van het verworven immuunsysteem, waartoe 
T en B lymfocyten worden gerekend. Antigeen-presenterende cellen van het aangeboren 
immuunsysteem presenteren antigenen gebonden aan een HLA molecuul aan de T cel re-
ceptor (TCR; signaal-ontvangend molecuul) die aanwezig is op het oppervlak van iedere T 
cel (Figuur 1). Dit gebeurt in zogenaamde secundaire lymfoïde organen, zoals lymfeklieren 
en de milt. Wanneer een T cel een TCR op zijn oppervlakte heeft die in staat is te binden aan 
het antigeen-HLA complex, zal de T cel geactiveerd raken, zich gaan delen en vermenigvul-
digen en migreren naar het niertransplantaat. Daar aangekomen, veroorzaken T cellen een 
ontstekingsreactie waarbij zij direct via een mechanisme genaamd cytotoxie, cellen van 
het transplantaat vernietigen. Dit staat bekend als de klassieke, acute T cel-gemedieerde 
afstoting.7 Daarnaast kunnen T cellen ook de productie van antilichamen door B cellen 
activeren. Deze antilichamen binden eveneens aan cellen van het transplantaat en kunnen 
via verschillende mechanismen cellen van de donornier vernietigen. Dit proces staat be-
kend als antilichaam-gemedieerde afstoting, en kan zowel chronisch als acuut optreden. 
Chronische, antilichaam-gemedieerde rejectie is een van de belangrijkste oorzaken van 
laat transplantaat verlies 7-9.
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T cellen worden geactiveerd door 3 verschillende signalen (Figuur 1): het eerste signaal, 
het zogenaamde signaal 1, is de hierboven genoemde presentatie van een lichaamsvreemd 
antigeen in een HLA molecuul door een antigeen-presenterende cel (APC); Het tweede of 
co-stimulatoire signaal is eveneens noodzakelijk en bestaat uit de interactie tussen diverse 
receptoren op het oppervlak van de APC en de T cel. Tot slot zorgt het derde signaal er voor 
dat de activatie van T cellen versterkt wordt. Dit signaal wordt gevormd door de binding 
van diverse signaalstoffen (cytokines) aan receptoren op het T cel oppervlak 10,11. Zodra 
een T cel deze signalen heeft ontvangen, zullen er binnenin de cel verschillende signaal-
transductieroutes worden aangezet. Deze signaaltransductieroutes bestaan uit allerlei 
soorten signaalmoleculen die elkaar kunnen activeren. Zo wordt het signaal versterkt en 
doorgegeven tot aan het DNA in de celkern. Deze signaaltransductieroutes beheersen de 
functie van de T cel en zorgen ervoor dat er uiteindelijk cytokines worden geproduceerd. Er 
bestaan verschillende soorten T cellen. Elke groep T cellen heeft een aantal karakteristieke 
signaalmoleculen (bijvoorbeeld CD4, CD8 en CD28) op het cel oppervlak, waardoor hun 
functie kan worden herkend. Het bekendste onderscheid is dat tussen cytotoxische T cel-
len (CD8) en T helper cellen (CD4).
Monocyten (cellen van het aangeboren immuunsysteem) kunnen, zodra zij geactiveerd 
zijn, antigenen presenteren aan T cellen. Monocyten worden geactiveerd via verschillende 
moleculen op hun oppervlakte, zoals de CCR2 en de Fc-γ receptor, waarna zij differenti-
eren in macrofagen of dendritische cellen 12,13. Monocyten spelen een belangrijke rol in 
het afstotingsproces maar er is weinig bekend over de effecten van immunosuppressieve 
geneesmiddelen op deze cellen 14-16. Vanwege de centrale rol van monocyten in het afsto-
tingsproces, is dieper inzicht in de effecten van immunosuppressiva op deze cellen van 
belang.
Met de huidige immunosuppressieve therapie is het aantal acute afstotingen in het 
eerste jaar na niertransplantatie teruggebracht tot zo’n 20% 17. De meest voorgeschreven 
immunosuppressieve geneesmiddelen na niertransplantatie zijn tacrolimus, mycofeno-
laat mofetil (MMF) en prednison. Deze geneesmiddelen worden meestal in combinatie 
voorgeschreven 18. Tacrolimus is een calcineurine-remmer en blokkeert de calcineurine 
signaaltransductieroute in T cellen (Figuur 1) 19. Hierdoor wordt het T cel-activatie sig-
naal geblokkeerd en wordt de vermeerdering van T cellen en de productie van cytokines 
geremd.
Er kleven echter ook nadelen aan het gebruik van tacrolimus. Zo moeten patiënten dit 
geneesmiddel iedere dag gebruiken en bovendien is het therapeutisch venster van tacro-
limus is erg smal 20. Dit laatste betekent dat het verschil tussen de minimale effectieve 
dosering en de dosering waarbij bijwerkingen (toxiciteit) ontstaan, klein is. Daarnaast 
zal eenzelfde dosering tacrolimus bij verschillende patiënten leiden tot sterk verschil-
lende concentraties in het bloed. Dit staat bekend als de inter-patiënt variabiliteit 21. Het 
is daarom essentieel dat de tacrolimus dosering wordt bijgesteld op geleide van de (vol)
bloed concentraties.
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Een alternatief immunosuppressief geneesmiddel voor tacrolimus is belatacept, wat in 
2012 is geregistreerd voor het gebruik bij niertransplantatie patiënten. Belatacept blok-
keert het co-stimulatie signaal tussen een APC en een T cel, waardoor de activatie van T 
cellen wordt geremd (Figuur 1) 22. Belatacept heeft minder bijwerkingen dan tacrolimus 
maar het gebruik van dit geneesmiddel is ook geassocieerd met het optreden van meer en 
ernstiger afstotingen in de eerste maanden na niertransplantatie.
Het is essentieel dat de huidige immunosuppressieve therapie wordt verbeterd. Aange-
zien er de laatste jaren weinig nieuwe immunosuppressieve geneesmiddelen voor trans-
plantatie-doeleinden op de markt zijn gekomen, moet de huidige standaardbehandeling 
na niertransplantatie worden verbeterd. In de meeste transplantatie-klinieken wordt de 
dosering van tacrolimus bijgesteld op geleide van de gemeten concentraties tacrolimus 
in het bloed. Dit staat ook bekend als farmacokinetisch therapeutic drug monitoring 23. 
Helaas is er slechts een beperkte correlatie tussen deze volbloed concentraties en het 
optreden van een afstoting of het optreden van bijwerkingen zoals bijvoorbeeld een hoge 
bloeddruk en het ontstaan van een maligniteit, een infectie of diabetes mellitus 24-26. Wel-
licht is het beter om de biologische effecten (farmacodynamiek) van tacrolimus te meten 
en hier de dosering op aan te passen 27-29. Hierbij valt te denken aan het monitoren van de T 
cel activatie en het meten van ontstekingseiwitten in het bloed. In verschillende onderzoe-
ken werden dergelijke farmacodynamische methodes ontwikkeld en getoetst maar tot op 
heden is geen een van deze methoden goed genoeg gebleken om in de kliniek te worden 
toegepast.
In dit proefschrift worden twee nieuwe farmacodynamische methodes getest voor het 
monitoren van immunosuppressiva bij niertransplantatie patiënten, namelijk I) de fosfo-
specifieke flowcytometrie assay en II) het meten van NFATc1 amplificatie. Het doel van dit 
onderzoek was om deze relatief nieuwe farmacodynamische methodes te testen en te 
bestuderen of deze potentie hebben voor het doseren van tacrolimus en eventuele andere 
immunosuppressiva. Daarnaast hebben we onderzocht of deze nieuwe testen gebruikt 
kunnen worden voor het monitoren van de effecten van immunosuppressieve geneesmid-
delen op zowel cellen van het verworven immuunsysteem (T cellen en de verschillende 
subgroepen) als ook op cellen van het aangeboren immuunsysteem (monocyten).
Fosfo-specifieke flowcytometrie meet de fosforylering (activatie) van signaalmoleculen 
in een cel die een rol spelen bij het overbrengen van activatie signalen naar het DNA 28,30-32. 
Immunosuppressiva zullen deze fosforylering beïnvloeden en met behulp van de assay kan 
worden bepaald in welke mate dit gebeurt 33. Naast fosfo-specifieke flowcytometrie kan 
ook het meten van de hoeveelheid NFATc1, een signaalmolecuul uit de calcineurine route, 
een indicatie geven over de biologische effecten van tacrolimus. Tacrolimus remt deze 
route en de hypothese was dat de productie van NFATc1 in de celkern door dit geneesmid-
del wordt geremd 34. Deze en andere onderzoeksvragen zijn in de volgende hoofdstukken 
bestudeerd:
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In hoofdstuk 2 wordt de rol beschreven van monocyten in de afweerreactie na transplan-
tatie, alsmede wat de effecten zijn van de meest voorgeschreven immunosuppressiva op 
deze cellen. Daarnaast wordt er een overzicht gegeven van de effecten van andere immu-
nosuppressiva die (nog) niet worden gebruikt in de transplantatie-kliniek. Literatuuronder-
zoek laat zien dat tacrolimus, MMF en mTOR remmers slechts een beperkt effect hebben op 
de functie van monocyten, terwijl medicaties zoals canakinumab, tocilizimab en infliximab 
wel in staat zijn om de functies van monocyten effectief te remmen. Desondanks worden 
deze medicijnen nog niet gebruikt na transplantatie. Het is daarom belangrijk dat in nieuw 
pre-klinisch onderzoek wordt onderzocht of deze afweerremmende geneesmiddelen ook 
transplantaat-afstoting kunnen tegen gaan. Daarnaast is het belangrijk dat eventuele 
nieuwe afweerremmende therapieën ook een remmend effect hebben op monocyten.
In hoofdstuk 3 hebben we bestudeerd wat de individuele effecten zijn van tacrolimus 
en MMF op activering van verschillende signaalmoleculen in de monocyt. Met behulp van 
fosfo-specifieke flowcytometrie en bloedmonsters van gezonde vrijwilligers werd de fos-
forylering van de signaalmoleculen p38MAPK, ERK en Akt bestudeerd. Beide geneesmid-
delen blijken slechts een beperkt effect te hebben op de fosforylering (activatie) van deze 
moleculen. Daarnaast werden ook de functies van monocyten, zoals cytokineproductie en 
fagocytose, nauwelijks geremd.
In hoofdstuk 4 hebben we verder onderzocht wat de farmacodynamische effecten zijn 
van een op tacrolimus gebaseerde immunosuppressieve combinatie-therapie op monocyt 
activatie. Fosfo-specifieke flowcytometrie werd gebruikt om de fosforylering van p38MAPK, 
ERK en Akt te meten in bloedmonsters van niertransplantatiepatiënten. Dit liet niet alleen 
zien dat de techniek een grote potentie heeft om gebruikt te worden voor het meten van de 
biologische effecten van een op tacrolimus gebaseerde therapie op monocyten, maar ook 
dat deze therapie slechts ten dele de activatie van monocyten in patiënten remt.
In hoofdstuk 5 hebben we de farmacodynamische effecten van tacrolimus en andere 
immunosuppressiva getest door middel van het meten van NFATc1 amplificatie in T cel-
len. Tacrolimus kan deze amplificatie remmen, maar niet in alle T cel typen. Alleen CD4+ 
en CD8+ T cellen die het co-stimulatie molecuul CD28 op hun celoppervlak tot expressie 
brengen toonden een afgenomen amplificatie van NFATc1. Als negatieve controle werden 
bloedmonsters gebruikt van patiënten die behandeld werden met belatacept, het genees-
middel dat geen direct effect heeft op signaaltransductieroutes in T cellen. Zoals verwacht, 
liet belatacept geen effect zien op NFATc1 amplificatie. De gevonden effecten berusten dus 
op de werking van tacrolimus en niet zozeer op die van de andere geneesmiddelen die met 
tacrolimus werden gecombineerd (MMF en prednisolon).
In hoofdstuk 6 hebben we de fosfo-specifieke flowcytometrie assay verder uitgetest 
in T cellen en bestudeerd of de assay een verschil kon detecteren in de mate van im-
munosuppressie in patiënten die werden behandeld met de tweemaal-daagse of de 
eenmaal-daagse formulering van tacrolimus. De eenmaal-daagse tacrolimus formulering 
is ontwikkeld om de therapietrouw van patiënten te vergroten. Echter, wanneer een pati-
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ent 1:1 wordt geconverteerd van de tweemaal-daagse naar de eenmaal-daagse variant zal 
dit gemiddeld leiden tot een daling van de tacrolimus dal-concentratie van zo’n 15%. Uit 
de studie blijkt dat, ondanks dat er geen significant verschil werd gevonden in tacrolimus 
dal-concentratie voor en na conversie, de fosforylering van p38MAPK was verhoogd in T 
cellen tijdens het gebruik van de eenmaal-daagse tacrolimus formulering. Dit betekent dat 
T cellen meer geactiveerd zijn tijdens het gebruik van de eenmaal-daagse formulering dan 
bij de tweemaal-daagse en dat dit waarschijnlijk berust op een verminderde blootstelling 
aan tacrolimus die niet wordt gedetecteerd met behulp van een dal-concentratie. Dit sug-
gereert dat fosfo-specifieke flowcytometrie een gevoelige methode is voor het monitoren 
van minimale verschillen in de blootstelling aan tacrolimus. Wij zijn van mening dat er 
verder moet worden onderzocht of de assay een toegevoegde waarde heeft in de trans-
plantatie diagnostiek.
In hoofdstuk 7 hebben we met behulp van de fosfo-specifieke flowcytometrie assay 
de farmacodynamische effecten in T cellen vergeleken tussen een op tacrolimus geba-
seerde en een op belatacept gebaseerde (negatieve controle) therapie. Bloedmonsters 
van niertransplantatie-patiënten werden afgenomen voor en gedurende het eerste jaar na 
transplantatie. De expressie van gefosforyleerd p38MAPK, ERK en Akt in verschillende T cel 
populaties werd vervolgens gemeten. De fosforylering van p38MAPK en Akt was geremd 
in zowel CD4+ als in CD8+ T cellen wanneer patiënten werden behandeld met een op ta-
crolimus gebaseerde therapie. Deze verschillen werden niet gevonden wanneer patiënten 
werden behandeld met een op belatacept gebaseerde therapie, hetgeen suggereert dat 
de gevonden effecten veroorzaakt werden door het gebruik van tacrolimus. Ook hadden 
beide therapieën geen effect op de fosforylering van ERK, wat erop duidt dat de T cellen 
nog steeds geactiveerd kunnen worden via dit signaalmolecuul. Tot slot bleek de fosfo-
rylering van dit molecuul verhoogd in patiënten die, ondanks dat zij belatacept kregen, 
een afstotingsreactie doormaakten. Dit alles bij elkaar toont aan dat de fosfo-specifieke 
flowcytometrie assay een veelbelovende methode is voor het monitoren van tacrolimus.
In hoofdstuk 8 wordt het gebruik van het immunosuppressivum tofacitinib na niertrans-
plantatie besproken. Dit is een afweerremmend medicijn dat de JAK-STAT signaaltrans-
ductieroute in T cellen remt. Deze signaaltransductieroute is vooral belangrijk voor het 
doorgeven van het derde T cel activatie-signaal: het binden van cytokines (ontstekingsei-
witten) aan de oppervlakte-receptoren op T cellen. Tofacitinib is getest als vervanging voor 
calcineurine-remmers in verschillende klinische studies. Het gebruik van tofacitinib werd 
geassocieerd met een verhoogde incidentie van virale infecties. Dit wordt waarschijnlijk 
verklaard door het feit dat de patiënten in deze studies relatief hoge doseringen tofaci-
tinib kregen voorgeschreven. Desondanks werd besloten om tofacitinib niet verder voor 
transplantatie doeleinden te ontwikkelen. Het gebruik van tofacitinib zou mogelijk veiliger 
kunnen worden wanneer een combinatie van farmacodynamische en farmacokinetische 
assays zou worden gebruikt om dit geneesmiddel te monitoren. Er zullen daarom nieuwe 
studies moeten worden opgezet met tofacitinib waarbij rekening wordt gehouden met 
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gepersonaliseerde medicijndosering, een verbeterde immuun monitoring en een betere 
selectie van patiënten.
Uit het onderzoek zoals beschreven in dit proefschrift blijkt dat het meten van de fosforyle-
ring van intracellulaire signaalmoleculen veel voordelen met zich meebrengt. Zo is de tijd 
die nodig is voor deze meting relatief kort, kan de assay worden uitgevoerd in volbloed-
monsters van patiënten en kan de fosforylering van signaalmoleculen per individueel cel 
type worden bepaald 28,35. Ook kunnen de biologische effecten van immunosuppressiva op 
zowel het verworven immuunsysteem (T cellen, hoofdstuk 6 en 7) als op het aangeboren 
immuunsysteem (monocyten, hoofdstuk 3 en 4) worden onderzocht. De fosfo-specifieke 
flowcytometrie assay laat een duidelijke remming zien van p38MAPK en Akt fosforylering in 
T cellen wanneer deze met tacrolimus zijn behandeld. Ook laat deze assay de remmende 
effecten van tacrolimus in verschillende T cel typen zien. CD8+CD28- T cellen staan er be-
kend om dat zij snel en agressief op een lichaamsvreemd antigeen kunnen reageren 36. 
Deze cellen spelen waarschijnlijk een sleutelrol in het ontstaan van afstoting na transplan-
tatie, doordat de signaaltransductieroutes in deze cellen nog steeds actief zijn ondanks 
een behandeling met tacrolimus of belatacept. Het is daarom van belang dat de eventuele 
activatie van deze cellen na transplantatie goed wordt vervolgd. Van eventuele nieuwe im-
munosuppressieve therapieën zal moeten worden onderzocht of deze ook een voldoende 
remmende werking hebben op CD8+CD28- T cellen.
Het gebruik van tacrolimus leidt ook tot een remming van zowel p38MAPK als Akt fosfo-
rylering in monocyten. Dit effect van tacrolimus is echter niet volledig en de signaaltrans-
ductieroutes worden niet volledig geremd in monocyten. Ook de functies van monocyten 
wordt niet volledig geremd. Hierdoor bestaat de kans dat monocyten, ondanks het gebruik 
van immunosuppressiva, nog steeds verantwoordelijk kunnen zijn voor een afweerreactie 
na transplantatie. Ons onderzoek toont ook aan dat de assay gebruikt kan worden voor 
het meten van de biologische effecten van tacrolimus op zowel het verworven immuun-
systeem (T cellen) als op het aangeboren immuunsysteem (monocyten). Een assay die dit 
kan meten bestond tot op heden nog niet, maar is wel nodig om de klinische resultaten na 
transplantatie te verbeteren 37. Daarnaast is fosfo-specifieke flowcytometrie zeer geschikt 
als methode voor geneesmiddelenbewaking, omdat het de biologische effecten van im-
munosuppressiva op de signaaltransductieroutes meer proximaal detecteert dan wanneer 
eindproducten, zoals cytokines, worden gemeten.
Het meten van NFATc1 amplificatie is een tweede methode die geschikt lijkt te zijn voor 
het monitoren van de biologische effecten van tacrolimus op verschillende T cel popu-
laties (hoofdstuk 5). Deze assay is nog niet getest voor het monitoren van de effecten 
van immunosuppressieve therapie op monocyten, ook al brengen deze cellen NFATc1 tot 
expressie 38. De assay vertoont een correlatie met de bloedconcentraties van tacrolimus en 
kan, net als fosfo-specifieke flowcytometrie, ook gemeten worden in bloedmonsters van 
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patiënten. Het kost alleen wel 7 uur om de test procedure te doorlopen en bovendien is de 
techniek nog niet gevalideerd voor het gebruik in de kliniek.
Andere farmacodynamische assays die de afgelopen jaren zijn bestudeerd, hebben voor-
alsnog geen toepassing in de kliniek gevonden 39. Voorbeelden hiervan zijn het meten van 
de calcineurine activiteit, interleukine-2 productie en NFAT-gereguleerde gen expressie. 
Tot nu toe zijn er voor deze assays nog geen sterke correlaties gevonden met de bloedcon-
centraties van de gebruikte calcineurine-remmers 40. Ook ontbreekt er een gestandaardi-
seerd protocol voor deze assays, waardoor resultaten uit verschillende medische centra 
lastig vergeleken kunnen worden. De uitslagen van deze assays kunnen bovendien worden 
beïnvloed door andere factoren, zoals infecties en het gebruik van andere immunosup-
pressiva 41. De fosfo-specifieke flowcytometrie en NFATc1 amplificatie assay laten wel een 
correlatie zien met tacrolimus bloedconcentraties en lijken dus meer potentie te hebben 
om in de kliniek toepassing te vinden.
Een beperking is echter wel dat voor zowel de fosfo-specifieke flowcytometrie en NFATc1 
amplificatie assays als voor de andere farmacodynamische assays geldt dat zij tot op heden 
alleen zijn bestudeerd in kleine studiepopulaties en in individuele transplantatiecentra. 
Voor vervolgstudies is het belangrijk dat er grotere studiepopulaties worden geselecteerd, 
bij voorkeur afkomstig uit verschillende medische centra 40-42. Ook zal een dergelijk groter 
patiënt cohort gebruikt kunnen worden om drempelwaardes te bepalen voor de fosfo-
specifieke en NFATc1 amplificatie assays, zodat duidelijker wordt wanneer de dosis van 
het geneesmiddel moet worden aangepast 43. Wellicht dat de uitslagen van beide assays 
beter correleren met de klassieke farmacokinetische monitoring wanneer de expositie aan 
tacrolimus wordt gemeten middels de oppervlakte onder de concentratie-tijd-curve in 
plaats van de dal-concentratie.
Wanneer de assays gevalideerd zijn, kunnen zij als farmacodynamische test gecombi-
neerd worden met de huidige farmacokinetische methode. Meerdere signaalmoleculen 
zullen daarbij gemeten moeten worden, omdat één enkel signaalmolecuul niet alle the-
rapeutische effecten van immunosuppressiva kan weergeven. De beide assays zijn alleen 
geschikt voor het monitoren van tacrolimus, omdat er geen correlaties zijn gevonden tus-
sen de uitkomsten van deze assays en het gebruik van andere immunosuppressiva. Voor 
een optimale monitoring van geneesmiddelen zou ook een alternatieve farmacokinetische 
assay gebruikt kunnen worden, zoals het meten van de intra-lymfocytaire tacrolimus con-
centratie 44-46.
Daarnaast zou een groter patiënten-cohort een tweede toepassing van de fosfo-
specifieke en NFATc1 amplificatie assay kunnen valideren: het voorspellen van klinische 
uitkomsten na transplantatie, zoals acute afstoting 39,47. Daarbij moet vooral worden gelet 
op de fosforylering van ERK. In T cellen is de fosforylering van ERK geassocieerd met afsto-
ting na transplantatie, maar immunosuppressiva blijken weinig effect te hebben op ERK in 
monocyten.
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Conclusies en aanbevelingen
•	 De	huidige	immunosuppressiva	hebben	slechts	een	beperkt	effect	op	signaaltransduc-
tieroutes die leiden tot monocyt activatie. Er is derhalve behoefte aan nieuwe afweer-
remmende medicijnen die aangrijpen op monocyten.
•	 Fosfo-specifieke	 flowcytometrie	 is	 een	 veelbelovende	 farmacodynamische	methode	
voor het monitoren van tacrolimus therapie in niertransplantatiepatiënten en kan 
zowel voor T cellen als monocyten worden gebruikt.
•	 Het	meten	van	NFATc1	amplificatie	is	een	specifieke	volbloed	test	voor	het	monitoren	
van de biologische effecten van tacrolimus in T cellen van niertransplantatie patiënten.
•	 De	fosforylering	van	ERK	in	zowel	monocyten	als	T	cellen	is	een	veelbelovende	marker	
voor de risico-inschatting van afstoting na transplantatie.
•	 De	 gebruikelijke	 farmacokinetische	manier	 van	 tacrolimus	monitoren	 kan	 het	 beste	
worden gecombineerd met de farmacodynamische fosfo-specifieke flowcytometrie, 
zodat het aanpassen van de tacrolimus dosis kan worden geoptimaliseerd.
•	 De	 fosfo-specifieke	 flowcytometrie	 assay	 en	 de	 NFATc1	 amplificatie	 assay	 kunnen	
beiden de activatie van signaalmoleculen in de verschillende CD4+CD28+, CD8+CD28+ en 
CD8+CD28- T cel groepen meten.
•	 Het	 farmacodynamisch	monitoren	 van	 immunosuppressieve	 therapie	 na	 transplan-
tatie kan de effectiviteit en de veiligheid van (nieuwe) immunosuppressiva, zoals de 
JAK-remmer tofacitinib verbeteren.
•	 Fosfo-specifieke	flowcytometrie	is	een	relatief	nieuwe	methode	om	de	effectiviteit	en	
de veiligheid van (nieuwe) immunosuppressiva, zoals de JAK-remmer tofacitinib, te 
beoordelen.
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van mijn promotie en voor alle steun in deze lastige periode.
Linda, ik ben er trots op dat je naast mijn zusje ook mijn beste vriendin bent. Zelfs al 
gaan we nu ieder onze eigen weg, toch proberen we om zoveel mogelijk samen op te blij-
ven trekken. We maakten vaak grapjes over het feit dat jij graag dokter en ik doctor wilde 
worden. Inmiddels is jouw droom uitgekomen maar als oudere zus wil ik je toch graag nog 
één ding meegeven: Stop nooit met dromen, de wereld ligt voor je voeten.
Kitty, mijn AIO-zusje op het werk en muizen-expert van de Bela-groep. We kunnen lief en 
leed met elkaar delen en daarom voelt het voor mij als een eer dat je mijn paranimf wilde 
zijn. Ik heb respect voor hoe je elk moment van de dag op het lab bezig kunt zijn en toch 
tijd vrijmaakt om gezellig met collega’s en vrienden samen te zijn om bijvoorbeeld bij te 
kletsen met een lekkere koffie. Met al je harde werk weet ik zeker dat ook jij een prachtig 
boekje gaat vullen.
Het Bela-team, a.k.a. de Minions: samen met Kitty voelden jullie aan als een echte familie. 
Ik wil jullie enorm bedanken voor alle geweldige momenten, zowel op het lab als buiten 
werktijd om.
Marjolein, nu je tweede baby-AiO volwassen is geworden en de wijde wereld intrekt kun 
je met trots terugkijken naar wat je ons geleerd hebt. Naast dat je een zeer behulpzame 
analist bent, ben je vooral ook een hele gezellige vriendin en ik heb enorm van onze sa-
menwerking genoten. Ik denk dat het nu tijd is dat je van iemand anders pennen mag gaan 
stelen en ik ga ervan uit dat je nog heel veel nieuwe beginnende AiO’s kunt gaan helpen bij 
de eerste stapjes op het lab. Dank je wel voor alles!
Gretchen, de eerste die het veilige Bela-nest heeft verlaten. Ik heb heel veel van je mogen 
leren: van het leven als AiO, het overleven op een congres en je gedragen als een dokter 
tot aan lol maken met je collega’s (zoals Singstar avondjes en Efteling uitstapjes) en vooral 
lekker koken (vergeet vooral de kip niet). Ik wens je enorm veel succes met het voltooien 
van je opleiding ook al ben je natuurlijk nooit klaar met leren.
Rens, de enige man binnen het Bela-team. Je hebt alle tijd genomen en heel veel geduld 
gehad om mij te helpen met het opzetten van het project. Ik zal de lol en het sarcasme 
die je daar bij gebruikt hebt nooit vergeten, ook al kon je soms bloedserieus zijn als ik dat 
nodig had. Van jou leerde ik dat collega’s ook gewoon een hechte vriendengroep kunnen 
vormen. Dank je wel voor al je goed doordachte input in ons project en heel veel succes 
met je eigen PhD traject.
Marieke, de nieuwe aanwinst van het Bela-team. Vanaf het begin riepen we dat we elkaar 
toch echt ergens van moesten kennen. Al hoewel dat niet zo was, voelt het wel alsof we 
al jaren samenwerken. Door je efficiënte manier van werken ben je zelf ook al bijna op de 
helft van je promotie traject en ik heb met veel plezier meegemaakt hoe je verder gaat met 
onze Bela-studie. Dank je wel voor al je wijze raad.
Mijn lieve kamergenootjes, die ervoor hebben gezorgd dat de lange dagen achter de com-
puter toch niet zo lang meer waren.
Samantha, Sam, we zijn ongeveer tegelijk begonnen en ook weer ongeveer tegelijk 
klaar. Bovendien zat je ook nog eens naast me in het AIO hok, waardoor ik niet aan mijn 
promotietijd kan terugdenken zonder jouw aanwezigheid te herinneren. Ook zal ik nooit 
je bureaulaatje vergeten: waar andere mensen hun papieren daarin opbergen, was jouw 
laatje vooral een kluisje, apotheek en voorraadkast, die ook voor de rest van de kamer 
voordelen met zich mee bracht. Dank je wel voor al je steun en alle gezelligheid die we 
hebben gehad en veel succes met het afronden van je boekje.
Franka, ik heb veel van je mogen leren. Jouw creatieve manier van denken (en tekenen) 
heeft mij veel inspiratie opgeleverd. Ook je uitspraken zal ik nooit vergeten, zoals “ik ben 
een zelfstandige onafhankelijke vrouw” en “future Franka will deal with that” die me zowel 
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een wijze les hebben geleerd als een hele hoop lol hebben bezorgd. Ook jij heel veel succes 
met de laatste loodjes voor het afronden van je boekje.
Fleur, onze gesprekken werden vooral gevoerd over onze computerschermen heen. Als ik 
ergens tegen op zag, gaf je me op z’n minst drie goede redenen om het wel te doen. Ook 
begreep jij als geen ander dat het belangrijk is om te sporten en hebben we samen genoten 
van de aanschaf van je eigen huiskat. Dank je wel voor je daadkracht en je gezelligheid en 
ik ben benieuwd naar jouw boekje.
Jesus, the guy who still survives the stem-cell group and the only man in the room. We 
had to miss you for more than 6 months because of your time in Denmark. I’m glad that 
you have also missed our room in that period. Thanks to you I learned a lot about Spanish 
habits and that rugby will never be my cup of tea. Thank you also for your fun and your 
positive energy and I wish you good luck with your own project.
Anusha, ondanks dat je zelf altijd dacht dat je stilletjes in een hoekje kon gaan zitten, ga 
ik jou aanwezigheid echt niet vergeten. Elke uurtje dat ik langer bleef was jij er ook en er 
was een moment dat ik geloofde dat je op het werk bleef slapen. Toch heb je inmiddels 
een prachtig huis gekocht en een mooie bruiloft achter de rug waar de hele AiO kamer zich 
mee bezig heeft gehouden. Ik wil jou ook bedanken voor je gezelligheid en heel veel succes 
wensen met je eigen project.
De andere geweldige AiO’s van het transplantatie lab:
Ling, your smile and jokes are famous. I will never forget your home made noodles and the 
love that you have for your family. Together we tried to unravel the complex mechanisms 
behind signal transduction in T cells. Thank you for your support and I wish you all the best 
back in China.
Burç, de jongen die bleef publiceren. Je zag het gelijk als ik ergens mee zat en bood dan een 
luisterend oor. Van jou heb ik geleerd dat als je blijft schrijven je vanzelf een goed gevuld 
boekje krijgt. Ook de snelheid waarmee je dat deed, heb ik altijd enorm bewonderd. Het 
volleybal toernooi ga ik zeker weten nooit vergeten. Dank je wel voor de gezellige AiO tijd.
Jeroen, ondanks dat je de nieuweling onder de AiO’s was, wist je gelijk een goede indruk 
achter te laten. Weliswaar heb je het heel druk gehad om je master opleiding te combine-
ren met de start van je PhD, maar je liet gelijk al zien dat je over een grote portie creativiteit 
bezit. Succes met je project!
224
appeNDICeS  |  acKnowledGeMents (danKwoord)
Thierry, de expert op het gebied van monocyten en macrofagen. Het was fantastisch om 
samen met jou een review te mogen schrijven, maar daarnaast ook gewoon successen en 
problemen te kunnen delen. Ons review heeft zeker weten een belangrijk steentje kunnen 
bijdragen aan onze beide promoties, dank je wel.
Daarnaast wil ook alle postdocs bedanken voor hun bijdrage:
Martin, stil en zwijgzaam. Tenminste, dat dacht ik in het begin. Ik ben er al snel achter 
gekomen dat dat absoluut niet zo is. Ik heb meesmuilend gelachen wanneer jouw PhD 
studenten een plannetje voor je hadden bedacht. Maar ook kon ik altijd bij je terecht als 
ik iets wilde weten. Je kalme commentaar tijdens mijn presentaties gaf me een drive om 
weer door te gaan. Dank je wel hiervoor.
Nicolle, de Limburgse gezelligheid kent geen grenzen. Altijd in voor een praatje en abso-
luut nooit te verlegen om te zeggen wat je ergens van vond. Als een echte moeder stond je 
klaar met je hulp voor beginnende AiO’s. Dank je wel voor je tips en wijze raad.
Ana, I will never forget your smile or the jokes that you made. It was great to know that you 
loved the fish as much as I did. Now you have to look for another AiO to steel their chair. 
Take care of your vesicles and your students en blijf vooral je nederlands oefenen. Thank 
you for your positive energy and support.
Karin, allebei hebben we onze voetstappen in Leiden staan. Ik bewonder je doorzettings-
vermogen en ik vind het hartstikke leuk om te zien dat je nu je eigen AiO groep hebt die zich 
in rap tempo uitbreidt. Ik ben je dankbaar voor je steun die je met hebt gegeven tijdens de 
wat moeilijkere tijden.
Nicole, je soms kritische vragen tijdens presentaties zorgde ervoor dat ik op een nieuwe 
manier naar dingen keek en hoe ik problemen op andere manier kon oplossen. Dank je wel 
voor je tips en ik wens je veel succes met het Elispot-project.
Ook de mensen van de andere kant, de analisten, mogen natuurlijk niet vergeten worden:
Wenda, nuchter en vrolijk blijkt een perfecte combinatie te zijn. Ik werd altijd vrolijk van je 
frisse manier van praten terwijl je het absoluut ook nooit vervelend vond om me ergens bij 
te helpen. Dank je wel voor alle hulp en de gezellige tijd op het lab.
Mariska, je stond altijd klaar om mij te helpen met je kennis van de phosphoflow techniek 
en om af en toe een meting over te nemen. Zelfs een keertje bloed doneren was geen enkel 
probleem. Dank je wel voor al je kennis die je op mij heb weten over te brengen.
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Derek, als benjamin van de groep wist je je al heel snel thuis te voelen. Binnen een paar 
maanden wist je zelfs soms al meer over het lab dan ik zelf deed. Dank je wel voor je en-
thousiasme en je tips over praktische lab-vaardigheden.
Sander, ik zal nooit je hulp vergeten met de “CREB-assay”. Alhoewel de resultaten mis-
schien niet helemaal waren zoals we hoopten, liet je wel zien dat je altijd op zoek bent naar 
de meest efficiënte manier van werken. Ook de films die je voor het lab hebt gemaakt ga ik 
nooit vergeten. Dank je wel voor je hulp en je gezelligheid.
Annemiek, de PCR-expert van het lab. Hoewel we niet veel overlap hadden met onze 
experimenten of projecten, kon ik wel altijd bij je terecht om even bij te kletsen. Bedankt 
voor al je hulp.
Ronella, het is me helaas nooit gelukt om je te verslaan met wordfeud. Dank je wel voor je 
gezelligheid met name in het kweeklab.
Er zijn intussen ook een aantal collega’s geweest die een andere richting zijn ingeslagen. 
Anne, Elly, Fabiany, Frieda, Jeroen, Joke, Lin, Mandy, Marcella, Ruben, Ruud, 
Tanja, Thea and Dr. Wu, van een paar weken tot een paar jaar heeft ieder van jullie een 
enorme indruk op mij achtergelaten. Ik wil jullie allemaal bedanken voor onze geweldige 
tijd samen, de wijze adviezen maar natuurlijk ook gewoon de gezellige tijd die we met 
elkaar hadden. Thank you for all your support and the fun we had together!
Ook Monique, Marieken, Nelly, Saïda, Lenie, Carine, de nefrologen, de prikzusters 
en alle patiënten die hebben meegewerkt aan de belatacept-studie mogen natuurlijk 
niet vergeten worden. Mede dankzij jullie bestaat dit proefschrift en ik wil jullie enorm 
bedanken voor jullie inzet.
Lieve familie en vrienden: Opa Gabriël, Oma Gerry, Opa Henk, Oma Mady (in liefdevolle 
herinnering), Jarno, Mark, Jorien, Victor, Casper, Marjan, Ton (in liefdevolle herin-
nering), Sanne, Tim, Tinus, Denise, Peter, Marleen, Veronique, André, Patricia, Jef-
frey, Kelly, Stefano, Amber, Anne, Suzanne, Lauri, Hannah, Hilde, Joleen, Joanne, 
Michel, Kimberley en natuurlijk verdere (korfbal)vrienden en familie. Ik heb niet 
altijd de tijd kunnen doorbrengen met jullie die ik wilde. Maar in zowel voor- en tegenspoed 
stonden jullie klaar voor mij en ik kon altijd bij jullie terecht voor liefde, ondersteuning, 
etentjes, korfballen, skiën, vakanties, wandelen en vooral heel veel plezier. Het kan altijd 
beter en ik geloof dat dit rijtje nog lang niet af is. Dank jullie wel voor jullie energie en 
geduld waarbinnen ik dit project kon afronden.
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Lieve papa en mama, ik denk dat ik de meest onbezorgde jeugd heb gehad die een kind 
zich kan wensen en dankzij jullie ben ik altijd een stap verder gegaan dan ik eigenlijk van 
plan was. Dank jullie wel dat jullie me hebben gesteund in alles en dat ik op elk moment 
bij jullie terecht kon om uit te huilen, te lachen en gezellig uitstapjes te maken. Zelfs nu we 
elkaar niet elke dag meer zien, zijn jullie enorm betrokken bij wat ik allemaal uitspook. Ik 
ben blij dat jullie wilden luisteren naar mijn belevenissen en ben jullie dankbaar voor het 
vertrouwen in mij.
Lieve Mark, beginnen aan een promotie onderzoek in ons eerste half jaartje samen blijkt 
een goede relatie-test te zijn geweest. Ik was zeker niet altijd de gezelligste thuis, maar 
ondanks alles bleef je altijd achter me staan. Samenwonen, vakantie vieren, korfballen, 
alles zorgde ervoor dat we een hecht team zijn geworden en zullen blijven. Ik ben je dank-
baar voor al je nuchtere en slimme advies ( je hebt natuurlijk bijna altijd gelijk) maar ook 
gewoon voor het vertrouwde gevoel van samenzijn en de lol die we samen hebben. Door 
jou durf ik nu veel meer mezelf te zijn. Dit is nog maar het begin… Ik hou iedere dag meer 
van jou.
